---
document_datetime: 2023-09-21 20:36:27
document_pages: 66
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/zavicefta-h-c-4027-ii-0019-epar-assessment-report-variation_en.pdf
document_name: zavicefta-h-c-4027-ii-0019-epar-assessment-report-variation_en.pdf
version: success
processing_time: 94.0472308
conversion_datetime: 2025-12-27 20:23:39.324894
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 June 2020 EMA/437085/2020 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

Invented name: Zavicefta

International non-proprietary name: ceftazidime / avibactam

Procedure No. EMEA/H/C/004027/II/0019

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................6                         |                                                                                                 |
|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| 1.1. Type II variation........................................................................................    | 6                                                                                               |
| 1.2. Steps taken for the assessment of the product...................................................             | 7                                                                                               |
| 2. Scientific discussion................................................................................7         |                                                                                                 |
| 2.1. Introduction..............................................................................................   | 7                                                                                               |
| 2.2. Non-clinical aspects....................................................................................     | 9                                                                                               |
| 2.2.1. Ecotoxicity/environmental risk assessment.....................................................             | 9                                                                                               |
| 2.2.2. Discussion on non-clinical aspects...............................................................13        |                                                                                                 |
| 2.2.3. Conclusion on the non-clinical aspects..........................................................13         |                                                                                                 |
| 2.3. Clinical aspects.........................................................................................13  |                                                                                                 |
| 2.3.1. Introduction..........................................................................................13   |                                                                                                 |
| 2.3.2. Pharmacokinetics....................................................................................15     |                                                                                                 |
| 2.3.3. Pharmacodynamics                                                                                           | .................................................................................15             |
| 2.3.4. PK/PD modelling.....................................................................................15     |                                                                                                 |
| 2.3.5. Discussion on clinical pharmacology.............................................................18         |                                                                                                 |
| 2.3.6. Conclusions on clinical pharmacology...........................................................19          |                                                                                                 |
| 2.4. Clinical efficacy.........................................................................................19 |                                                                                                 |
| 2.4.1. Dose response study(ies)..........................................................................19       |                                                                                                 |
| 2.4.2. Main studies..........................................................................................19   |                                                                                                 |
| 2.4.3. Discussion on clinical efficacy.....................................................................35     |                                                                                                 |
| 2.4.4. Conclusions on the clinical efficacy ..............................................................38      |                                                                                                 |
| 2.5. Clinical safety...........................................................................................38 |                                                                                                 |
| 2.5.1. Discussion on clinical safety.......................................................................59     |                                                                                                 |
| 2.5.2. Conclusions on clinical safety.....................................................................61      |                                                                                                 |
| 2.5.3. PSUR cycle............................................................................................61   |                                                                                                 |
| 2.6. Update of the Product information.................................................................61         |                                                                                                 |
| 2.6.1. User consultation....................................................................................62    |                                                                                                 |
| 3. Benefit-Risk Balance.............................................................................62            |                                                                                                 |
| 3.1. Therapeutic Context...................................................................................62     |                                                                                                 |
| 3.1.1. Disease or condition................................................................................62     |                                                                                                 |
| 3.1.2. Available therapies and unmet medical need..................................................62             |                                                                                                 |
| 3.1.3. Main clinical studies.................................................................................63   |                                                                                                 |
| 3.2. Favourable effects.....................................................................................63    |                                                                                                 |
| 3.3. Uncertainties and limitations about favourable effects.........................................63            |                                                                                                 |
| 3.4. Unfavourable effects                                                                                         | ..................................................................................63            |
| 3.5. Uncertainties and limitations about unfavourable effects......................................64             |                                                                                                 |
| 3.6. Benefit-risk assessment and discussion...........................................................64          |                                                                                                 |
| 3.6.1. Importance of favourable and unfavourable effects..........................................64              |                                                                                                 |
| 3.6.2. Balance of benefits and risks                                                                              | .....................................................................65                         |
| 3.6.3. Additional considerations on the benefit-risk balance........................................65            |                                                                                                 |
| 3.7. Conclusions                                                                                                  | .............................................................................................65 |

<div style=\"page-break-after: always\"></div>

4. Recommendations.................................................................................  65

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation special term   | or   | Definition                                     |
|-----------------------------|------|------------------------------------------------|
| 50% f T                     |      | 50% of the dosing interval                     |
| ADR                         |      | Adverse drug reaction                          |
| AE                          |      | Adverse event                                  |
| APACHE                      |      | Acute Physiology and Chronic Health Evaluation |
| BAT                         |      | Best available therapy                         |
| BMI                         |      | Body mass index                                |
| CAZ-AVI                     |      | Ceftazidime-avibactam                          |
| CC                          |      | Clinical cure                                  |
| CF                          |      | Clinical failure                               |
| CFU                         |      | Colony-forming unit                            |
| CI                          |      | Confidence interval                            |
| cIAI                        |      | Complicated intra-abdominal infection          |
| CrCl 1                      |      | Creatinine clearance                           |
| CSR                         |      | Clinical Study Report                          |
| cUTI                        |      | Complicated urinary tract infection            |
| ECG                         |      | Electrocardiogram                              |
| EOT                         |      | End of treatment                               |
| ESBL                        |      | Extended spectrum β -lactamases                |
| EU                          |      | European Union                                 |
| FDA                         |      | Food and Drug Administration                   |
| FDC                         |      | Fixed dose combination                         |
| HAP                         |      | Hospital-acquired pneumonia                    |
| HLT                         |      | Higher Level Term                              |
| ICH                         |      | International Council for Harmonisation        |
| IB                          |      | Investigator's Brochure                        |
| IP                          |      | Investigational product                        |
| IV                          |      | Intravenous                                    |
| LLN                         |      | Lower limit of normal                          |
| KPC                         |      | Klebsiella pneumoniae carbapenemases           |
| MD                          |      | Multiple dose                                  |
| ME                          |      | Microbiologically evaluable                    |
| MedDRA                      |      | Medical Dictionary for Regulatory Activities   |
| MIC                         |      | Minimum inhibitory concentration               |
| mMITT                       |      | Microbiological modified intent-to-treat       |
| MTZ                         |      | Metronidazole                                  |
| NEC                         |      | Not elsewhere classified                       |

<div style=\"page-break-after: always\"></div>

| Abbreviation special term   | or   | Definition                         |
|-----------------------------|------|------------------------------------|
| NP                          |      | Nosocomial pneumonia               |
| PCS                         |      | Potentially clinically significant |
| PD                          |      | Pharmacodynamic                    |
| PK                          |      | Pharmacokinetic                    |
| PT                          |      | Preferred term                     |
| q8h                         |      | quaque octa hora (every 8 hours)   |
| RMP                         |      | Risk Management Plan               |
| SAE                         |      | Serious adverse event              |
| SCS                         |      | Summary of Clinical Safety         |
| SD                          |      | Standard deviation                 |
| SI                          |      | International System of Units      |
| SmPC                        |      | Summary of Product Characteristics |
| SOC                         |      | System organ class                 |
| STOI                        |      | Safety topic of interest           |
| TOC                         |      | Test of cure                       |
| ULN                         |      | Upper limit of normal              |
| US                          |      | United States                      |
| VAP                         |      | Ventilator-associated pneumonia    |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant  to  Article  16 of  Commission  Regulation  (EC)  No  1234/2008,  Pfizer  Ireland  Pharmaceuticals submitted to the European Medicines Agency on 13 November 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to include bacteraemia (in association with, or suspected to be associated with, the currently approved indications for complicated intra-abdominal infection (cIAI), complicated urinary tract  infection  (cUTI)  and  hospital-acquired  pneumonia,  including  ventilator-associated  pneumonia (HAP/VAP)) for Zavicefta; as a consequence, sections 4.1 and 4.2 of the SmPC are updated in order to add this indication and the posology. Furthermore, the PI is brought in line with the latest QRD template version 10.1.

The Package Leaflet is updated in accordance.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet.

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  an  EMA  Decision(s) P/0340/2018 on the agreement of a paediatric investigation plan (PIP). Although the current indication bacteraemia is not specifically mentioned in the PIP, the relevant data in this application are based on the studies in this PIP.

At the time of submission of the application, the PIP EMEA-001313-PIP01-12-M08 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the MAH did not submit a critical report addressing the possible similarity with authorised orphan  medicinal  products  because  there  is  no  authorised  orphan  medicinal  product  for a  condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Bjorg Bolstad

Co-Rapporteur:

Simona Stankeviciute

| Timetable                                            | Actual dates     |
|------------------------------------------------------|------------------|
| Submission date                                      | 13 November 2019 |
| Start of procedure:                                  | 30 November 2019 |
| CHMP Co-Rapporteur Assessment Report                 | 9 January 2020   |
| CHMP Rapporteur Assessment Report                    | 24 January 2020  |
| CHMP members comments                                | 17 February 2020 |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 20 February 2020 |
| Request for supplementary information (RSI)          | 27 February 2020 |
| CHMP Rapporteur Assessment Report                    | 2 June 2020      |
| CHMP members comments                                | 15 Jun 2020      |
| Updated CHMP Rapporteur Assessment Report            | 18 Jun 2020      |
| Opinion                                              | 25 Jun 2020      |

## 2. Scientific discussion

## 2.1. Introduction

Bacteraemia  due  to Gram-negative  pathogens  is  associated  with  significant  morbidity  and  mortality. Nearly 2 million episodes of bloodstream infection in North America and Europe annually led to ~250,000 deaths and nearly half of community-acquired and one third of healthcare associated cases were caused by Gram-negative bacteria. Infections associated with bacteraemia may  be severe, require hospitalisation and have the potential to be life-threatening. Bacteraemia due to resistant pathogens is increasing in frequency and associated with more adverse effects. Prompt administration of effective antibiotics is therefore critical for a favorable outcome.

Zavicefta -  Ceftazidime-avibactam  (CAZ-AVI)  -  is  a  fixed  dose  combination  (FDC)  that  has  been developed as an intravenously administered compound for treatment of patients with infections caused by Gram-negative pathogens, including pathogens that are resistant to ceftazidime.

Ceftazidime is a cephalosporin that has been approved for many years in several member states. As a result  from  an  Article  30  referral  procedure  (EMEA/H/A-30/001006,  EC  decision  date  13/01/2011) ceftazidime  (brand  leader  Fortum)  was  approved  for  the  following  indications:  the  treatment  of complicated  intra-abdominal  infection  (cIAI),  complicated  urinary  tract  infection  (cUTI),  nosocomial pneumonia (NP), including treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above . In addition, a range of other infections were also approved in the referral procedure, however these are not mentioned here. Ceftazidime has no noticeable antibacterial activity against Gram-positive pathogens, with the exception of  some streptococci, or anaerobes.

<div style=\"page-break-after: always\"></div>

Avibactam is a novel non-betalactam-lactamase inhibitor with a spectrum of beta-lactamases of class A and  class  C,  including  ESBLs  and  serine-based  carbapenemases  (KPCs).  It  also  inhibits  class  D beta-lactamases  (e.g.  OXA-48  type  carbapenemase).  Avibactam  has  no  inhibitory  effect  on  class  B metallo-beta-lactamases.

CAZ-AVI is currently approved for use in EU, under the trade name Zavicefta, for the treatment of adults with  cIAI,  cUTI  including  pyelonephritis,  hospital-acquired  pneumonia  (HAP)  including  ventilator associated pneumonia (VAP), and infections due to aerobic Gram-negative organisms in patients with limited treatment options. Zavicefta was first made commercially available in the EU in 2016.

Zavicefta is currently only approved for adults, however, a Type II variation to extend the indication of Zavicefta to include paediatric patients aged 3 months to less than 18 years for the treatment of cIAI and cUTI is ongoing at the time of the adoption of this assessment report (EMEA/H/C/004027/II/0015).

This Type II variation concerns an extension of the indication to include treatment of bacteraemia (in association with, or suspected to be associated with, the currently approved indications for cIAI, cUTI and HAP/VAP) in Section 4.1 of the SmPC.

The clinical development program for CAZ-AVI included patients with bacteraemia at baseline in all of the 5 completed Phase 3 studies that were conducted to support the currently approved indications of cIAI, cUTI  and  HAP/VAP  (this  includes  also  the  indication  related  to  aerobic  Gram-negative  organisms  in patients with limited treatment options). A brief overview of these studies are presented in Table 1 below. No new studies have been submitted for the current application.

This  Type  II  variation  for  the  extension  of  the  indication  to  include  treatment  of  bacteraemia  (in association with, or suspected to be associated with, the currently approved indications for cIAI, cUTI and HAP/VAP) is based on:

- Post-hoc analysis of efficacy  and safety data from the sub-group of patients who had bacteraemia at baseline across these 5 studies mentioned above.
- Relevant post-marketing (PM) safety data.

The  CHMP  acknowledged  that  this  proposed  indication  extension  for  the  addition  of  bacteraemia associated  with  the  currently  approved  indication  in  adults  is  mainly  based  on  post-hoc  analysis  of efficacy and safety data from the sub-group of patients who had bacteraemia at baseline across the previously  assessed  5  Phase  3  studies.  These  studies  (RECLAIM,  RECLAIM3,  RECAPTURE,  REPRISE, REPROVE) were conducted to support the currently approved indications of cIAI, cUTI and HAP/VAP. No new documentation to  support  the  indication  extension  to  include  bacteraemia  was  submitted.  The Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (EMA/CHMP/351889/2013) states the following regarding non-pathogen-specific bacteraemia: ' It  may  be  possible  to  accumulate  sufficient  clinical  data  to  support  an  indication  for  use  of  an antibacterial agent in the treatment of bacteraemia that is associated with specific types of infection, with or without restriction to certain pathogens. For example, in the case of agents that have been in use for many years and are indicated for use in a broad range of infections the total evidence may be considered sufficient for an indication that reads: Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above (i.e. referring to the list of indications approved). If the antibacterial agent has been evaluated in several indications and the total number of bacteraemic patients treated across these indications is deemed sufficient (e.g. ~50 or more) to support a conclusion that efficacy is comparable to that in other patients or, at least, comparable to that of other treatments, then the addition of the sentence could be considered appropriate. '

<div style=\"page-break-after: always\"></div>

The MAH's approach is therefore considered acceptable and in line with the current AB-guideline as well as in accordance with the CHMP-decisions for older antibiotics that have been going through referral harmonisations, e.g. ceftazidime (Article 30 referral procedure, EMEA/H/A-30/001006).

Of main importance when evaluating this extension of the indication for Zavicefta is the fact that during the aforementioned Article 30 procedure of ceftazidime in 2011 (EMEA/H/A-30/001006), treatment of patients with bacteraemia in association with, or suspected to be associated with, the approved adult indications for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP) was added to the EU SmPC of ceftazidime. The additional data submitted for the Fixed Dose Combination Zavicefta, which is further described below, are merely supplementary.

## 2.2. Non-clinical aspects

This Type II variation concerns an extension of the indication to include treatment of bacteraemia in adults associated with, or suspected to be associated with, the currently approved indications cIAI, cUTI and HAP/VAP. No new non-clinical data have been submitted with this application, which was considered acceptable by the CHMP. In view of that the proposed posology and route of administration in patients with bacteraemia are identical as for the approved indications, update of the initial non-clinical safety assessment is not warranted.

Non-clinical data within previous submissions of MAA for Zavicefta reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproduction toxicity or genotoxicity. Carcinogenicity studies have not been conducted with ceftazidime and avibactam, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

## Introduction

Zavicefta is indicated for the treatment of the following infections in adults;

- Complicated intra-abdominal infection (cIAI)
- Complicated urinary tract infection (cUTI), including pyelonephritis
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
- Treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.

The current indication extension seeks to include 'treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above'.

The active ingredients in Zavicefta are ceftazidime  and avibactam. The  recommended dosage of Zavicefta for patients wi th estimated creatinine clearance ≥51 mL/min is 1 vial containing 2000 mg ceftazidime and 500 mg avibactam administered by intravenous (IV) infusion. Treatment will be repeated every 8 hours, i.e. a maximum of 3 vials per 24-hour period. Hence, the maximum daily dose is 6000 mg/day and 1500 mg/day of ceftazidime and avibactam, respectively. Treatment duration is normally from 5 to 14 days. For the paediatric population, the recommended maximum dosage is similar to the adult population.

Zavicefta was first approved in Europe in 2016. In 2019, an application for extension of the indication to include paediatric use for the indications cIAI and cUTI was submitted, which was pending at the time of adoption of this AR.

<div style=\"page-break-after: always\"></div>

The environmental risk assessment (ERA) is divided into an ERA for ceftazidime (Phase I and Phase II: Tier A and Tier B) and an ERA for avibactam (Phase I and Phase II: Tier A and B).

## Ceftazidime

## PEC calculation ceftazidime

The Fpen of ceftazidime is refined by taking into account the consumption data of ceftazidime in Italy in 2016 (4268 kg), a maximum daily dose of 6000 and a population in Italy in 2016 of 59,290,969:

<!-- formula-not-decoded -->

This Fpen reflects existing approved indications, but not necessarily bacteraemia. Based on the ECDC 2016-17 point prevalence survey, approximately 5.5% of patients in the EU were diagnosed with at least one healthcare associated infection (HAI) during 2016-2017. This ECDC data estimates the total annual number of people acquiring one HAI is about 3.8 million. The same survey reported 10.8% of HAIs across the EU countries are attributed to blood stream infections or bacteraemia.

Therefore, the EU prevalence (Fpen) for bacteremia may be determined as follows:

<!-- formula-not-decoded -->

| fpen (market penetration bacteremia)          |               |
|-----------------------------------------------|---------------|
| Number of HAIin EU (2016-2017)                | 3.8 million   |
| EU population in 2016 (Eurostat)              | 511.8 million |
| HAIs associated with bloodstream (bacteremia) | 10.8%         |

<!-- formula-not-decoded -->

## Totalfpenbasedonconsumptionandbacteremia:

|                                               | Ceftazidine fpen   | Avibactam fpen   |
|-----------------------------------------------|--------------------|------------------|
| Approved indications (consumption-Appendix 1) | 3.8 x 10-5         | 2.0 x 10-6       |
| Bacteremia (prevalence)                       | 8.0 x 104          | 8.0 x 104        |
| Total fpen                                    | 8.4 x 10-4         | 8.0 x 104        |

In addition, the  MAH has used US hospital data (Optum de-identified Electronic  Health Record (EHR) dataset 2007-2019) to recalculate the daily dose consumed per inhabitant, in order to cover the possible scenario that a patient could receive more than one course of treatment per year. EHR data includes more than 700 hospitals and 7000 clinics in US and show that approximately 15% of patients receive more than

<div style=\"page-break-after: always\"></div>

one course of treatment within a 12 month period. There are no similar European data available. The revised Doseai is thus 267.7 mg/day for ceftazidime, and 66.2 mg/day for avibactam.

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

The refined PECsw value is above the threshold of 0.01 µg/L, and a Phase II assessment is provided.

## Phase II Tier A, ceftazidime

The Phase II Tier A assessment for ceftazidime was assessed during the initial marketing authorisation procedure.

Table 1: Updated Risk calculations ceftazidime

| PEC surfacewater PNEC surfacewater PEC/PNEC surfacewater       | 0.111 1.3 0.085          | µg/L µg/L     | Unlikely to represent a risk to the aquatic environment     |
|----------------------------------------------------------------|--------------------------|---------------|-------------------------------------------------------------|
| PEC groundwater PNEC groundwater PEC/PNEC g ro undwa ter       | 0.028 920 0.00003        | µg/L µg/L     | Unlikely to represent a risk to the aquatic environment     |
| PEC microorganisms PNEC microorganisms PEC/PNEC microorganisms | 0.111 32 000 3.5 x 10 -6 | µg/L µg/L     | Unlikely to represent a risk to wastewatermicro-organisms   |
| PEC sediment PNEC sediment PEC/PNEC sediment                   | 1.29 3030 0.00043        | µ g/kg µ g/kg | Unlikely to represent a risk to sediment dwelling organisms |

For the calculation of the PNEC of all three compartments, an assessment factor (AF) of 10 is used.

The risk quotient (RQ) for all compartments are under the action limit (table 1), therefore a Tier B is not triggered.  However,  in  the  water-sediment  study  greater  than  10%  of  the  applied  radioactivity  was associated  with  the  sediment  phase,  therefore  the  effect  of  ceftazidime  on  the  sediment  dwelling organism Chironomus riparius was investigated in Tier B.

## Phase II Tier B, ceftazidime

The Tier B study on sediment-water toxicity in Chironomids has been assessed previously: LOEC (28d) &gt;100 mg/kg dw, NOEC 100 mg/kg dw, recalculated to standard sediment: NOECstandard sediment 303 mg/kg, and using an AF of 10, results in a PNEC of 3030 µg/kg.

The RQsediment is 0.00043, which is under the action limit of 1 and no further testing is required.

The CHMP considered that the study on ceftazidime transformation in water/sediment systems (OECD 308) shows that both main transformation products M1 and M3 are very persistent considering the DT50 values  of  101.0  d  and  118.0  d  at  20°C  for  M1  and  M3,  respectively  in  water/sediment.  Criteria  for classification as PBT or vPvB are, however, not met (not B or T).

<div style=\"page-break-after: always\"></div>

## Avibactam

## PEC calculation avibactam

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

The refined PECsw value for avibactam is above the threshold of 0.01 µg/L, and a Phase II assessment is provided.

## Phase II Tier A, avibactam

The Phase II Tier A assessment for avibactam was assessed during the initial marketing authorisation procedure.

Table 2: Updated Risk Calculations avibactam

| PEC surfacewater PNEC surfacewater PEC/PNEC surfacewater       | 0.2027 200 0.00014      | µg/L µg/L     | Unlikely to represent a risk to the aquatic environment     |
|----------------------------------------------------------------|-------------------------|---------------|-------------------------------------------------------------|
| PEC groundwater PNEC groundwater PEC/PNEC g ro undwa ter       | 0.0068 10 000 0.0000068 | µg/L µg/L     | Unlikely to represent a risk to the aquatic environment     |
| PEC microorganisms PNEC microorganisms PEC/PNEC microorganisms | 0.027 100 0.00027       | µg/L µg/L     | Unlikely to represent a risk to wastewater micro-organisms  |
| PEC sediment PNEC sediment PEC/PNEC sediment                   | 0.14 11,110 0.000012    | µ g/kg µ g/kg | Unlikely to represent a risk to sediment dwelling organisms |

For the calculation of the PNEC of all three compartments, an assessment factor (AF) of 10 is used.

The risk quotient (RQ) for all compartments are under the action limit (table 2), therefore a Tier B is not triggered.  However,  in  the  water-sediment  study  greater  than  10%  of  the  applied  radioactivity  was associated with the sediment phase, therefore the effect of avibactam on the sediment dwelling organism Chironomus riparius was investigated in Tier B.

<div style=\"page-break-after: always\"></div>

## Phase II Tier B, avibactam

The Tier B study on sediment-water toxicity in Chironomids has been assessed previously: LOEC (28d) &gt;300 mg/kg dw, NOEC 300 mg/kg dw, recalculated to standard sediment: NOECstandard sediment  1111 mg/kg, and using an AF of 100, results in a PNEC of 11,110 µg/kg.

The RQsediment is 0.000012, which is under the action limit of 1 and no further testing is required.

Consumption based refinement of Fpen values was considered acceptable by CHMP as part of the ongoing extension of indication procedure to include the paediatric population (Zavicefta Module 1.6.1 ERA dated 23  October  2019).  In  addition,  the  MAH  refined  Doseai for  ceftazidime and  avibactam  to  reflect  the possibility of patients receiving more than one course of treatment per  year, in line with the CHMP request made during this assessment. The source for data and the estimate is considered appropriate to use for PEC calculation.

## 2.2.2. Discussion on non-clinical aspects

The MAH did not propose any changes to section 4.6 (Fertility, pregnancy and lactation) or 5.3 (Preclinical safety data) of the SmPC, or in corresponding parts of the PL. This is considered adequate and acceptable by the CHMP.

## 2.2.3. Conclusion on the non-clinical aspects

There are no objections to approval of the proposed extension of indication from a non-clinical point of view.

Ceftazidime and avibactam as combined in the product Zavicefta are not expected to pose a risk to the environment

## 2.3. Clinical aspects

## 2.3.1. Introduction

No new clinical pharmacology data was submitted for this extension of indication variation. This however was acceptable to the CHMP as a previously submitted population PK, PK/PD and PK/PD target attainment analyses report, CAZ-MS-09, was used to justify  the posology in patients with bacteraemia. Refer to Section 2.3.4 on PK/PD modelling for discussion on the topic.

· Tabular overview of the 5 completed clinical Phase 3 studies that were conducted to support the indications of cIAI, cUTI and HAP/VAP:

<div style=\"page-break-after: always\"></div>

Table  3.  Overview  of  Phase  3  Studies  by  Indication  -  (Studies  RECLAIM,  RECLAIM3, RECAPTURE, REPRISE, REPROVE)

| Study                                                                                                                                                                                                                                                                                                                                              | CAZ-AVI Dosage                                                                                                                                                                                              | Comparator Dosage                                                                                                                                                | Overall Set     | Overall Set   | BacteraemiaSubset   | BacteraemiaSubset   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------------|---------------------|---------------------|
| [Study Number] Title                                                                                                                                                                                                                                                                                                                               | regimen                                                                                                                                                                                                     | regimen                                                                                                                                                          | CAZ-AVI ±MTZ nN | Comparator N  | CAZ-AVI± MTZ n/N    | Comparator /N       |
| CIAI                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                             |                                                                                                                                                                  |                 |               |                     |                     |
| RECLAIM (Global) [D4280C00001/5] A Phase 3, randomised, multicentre, double-blind double-dummy, parallel-group, comparative study to determinetheefficacy,safety,andtolerabilityof ceftazidime-avibactam (CAZ-AVI) plus metronidazole (MTZ) vs meropenem in the treatment of complicated intra-abdominal infections (cIAIs) in hospitalised adults | CAZ-AVI (ceftazidime 2000 mg + avibactam 500 mg; 2-hour IV infusion) followed by MTZ 500 mg (1-hour IV infusion) q8h for 5 to 14 days                                                                       | Meropenem 1000 mg; 30- minute IV infusion q8h for 5 to 14 days                                                                                                   | 270/529         | 294/529       | 9/22                | 4 / 14              |
| RECLAIM3 (Asia) [D4280C00018] APhase3,randomisedmulticentre,double-blind double-dummy,parallel-group, comparative study to determinetheefficacy,safety,andtolerabilityof ceftazidime-avibactam(CAZ-AVI)plus metronidazole Vs meropenem in the treatment of complicated intra- abdominal infections (cIAIs)in hospitalised adults                   | CAZ-AVI (ceftazidime 2000 mg + avibactam 500 mg; 2-hour IV infusion) followed by MTZ 500 mg (1-hour IV infusion) q8h for 5 to 14 days                                                                       | Meropenem 1000 mg; 30- minute IV infusion q8h for 5 to 14 days                                                                                                   | 100/215         | 119/217       | 2/5                 | 6/10                |
| REPRISE/cIAI [D4280C00006] An open-label, randomised, multicentre, Phase 3 study of ceftazidime-avibactam (CAZ-AVI) and the best available therapyfor thetreatment ofinfections dueto ceftazidime-resistant Gram-negative pathogens                                                                                                                | CAZ-AVI (ceftazidime 2000 mg + avibactam 500 mg); 2-hour IV infusion q8h for 5 to 21 days Patients with cIAI also receive MTZ 500 mg 1 hr IV q8h following completion of CAZ-AVI infusion for 5 to 21 days. | Investigator's BAT choice for 5 to 21 days Preferred choices for cIAI: meropenem, imipenem, doripenem, tigecycline, and colistin with MTZ for anaerobic coverage | 8/12 378/756    | 5/15          | 0/0 11/27           | 0/0 10/24           |

Total cIAI

cUTI

RECAPTURE (Global)

[D4280C00002/4]

A Phase 3,randomised, multicentre, double-blind, double-dummy, parallel-group, comparative study to

determine the efficacy, safety, and tolerability of ceftazidime-avibactam(CAZ-AVI,formerlyCAZ104)

vs doripenem followed by appropriate oral therapy in the treatment of complicated urinary tract infections,

including acute pyelonephritis, with a Gram-negative pathogen in hospitalised adults

REPRISE/cUTI

[D4280C00006]

An open-label,randomised,multicentre,Phase3study ofceftazidime-avibactam(CAZ-AVI)and thebest

available therapyfor thetreatment of infections due to ceftazidime-resistant Gram-negative pathogens

378/756

292/511

131/152

423/663

418/761

311/509

124/153

435/662

11/27

25 /43

3/5

28/48

10/24

24/36

5/6

29/42

CAZ-AVI

(ceftazidime avibactam 500

2000 mg +

mg; 2-hour IV

infusion) q8h days

for 5 to 14

CAZ-AVI

(ceftazidime

2000 mg +

avibactam 500

mg); 2-hour IV

infusion q8h days.

for 5 to 21

Doripenem 500

mg; 1-hour IV

infusion q8h for

5 to 14 days

Investigator's

BAT choice for

5 to 21 days

Preferred choices for

cUTI:

meropenem, imipenem,

colistin doripenem and

<div style=\"page-break-after: always\"></div>

<!-- image -->

| NP                                                                                                                                                                                                                                                                                                                      | NP                                                                                   | NP                                                      | NP               | NP       | NP    | NP    | NP   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------|------------------|----------|-------|-------|------|
| REPROVE [D4281C00001] Phase3,randomised,multicentre,double-blind double-dummy,parallel-group comparative study to determinetheefficacy,safety,andtolerabilityof ceftazidime-avibactam(CAZ-AVI)vsmeropenemin thetreatmentofnosocomialpneumonia(NP)including ventilator-associated pneumonia (VAP) in hospitalised adults | CAZ-AVI (ceftazidime 2000 mg + avibactam500 mg);2-hourIV infusion q8h for7 to14 days | Meropenem 1000 mg;30 minuteIV infusionq8hfor 7to14 days | 125/436 131/ 434 |          | 15/24 | 8/18  |      |
| TotalNP                                                                                                                                                                                                                                                                                                                 | TotalNP                                                                              | TotalNP                                                 | 125/436          | 131/434  | 15/24 | 8/18  |      |
| TotalNumberofPatientsintheOverallset                                                                                                                                                                                                                                                                                    | TotalNumberofPatientsintheOverallset                                                 | TotalNumberofPatientsintheOverallset                    | 926/1855         | 984/1857 |       |       |      |
| TotalNumberofPatientsintheBacteraemiasubset                                                                                                                                                                                                                                                                             | TotalNumberofPatientsintheBacteraemiasubset                                          | TotalNumberofPatientsintheBacteraemiasubset             |                  |          | 54/99 | 47/84 |      |

BAT = best available therapy; q8h = every 8 hours; VAP = ventilator-associated pneumonia n = the number of subjects in the efficacy population i.e. the Gram-negative extended ME at TOC population N = the number of subjects in the safety population. For the Overall set this is the overall Phase 2/3 pooled safety analysis population and for the Bacteraemia subset this is the pooled safety analysis population of the patients that had bacteraemia at baseline in the 5 Phase 3 studies.

## 2.3.2. Pharmacokinetics

Reference is made to the initial MAA (EMEA/H/C/4027) and other extension of indications procedures EMEA/H/C/004027/II/0002 and EMEA/H/C/004027/II/0015 for details on pharmacokinetics.

## 2.3.3. Pharmacodynamics

Reference is made to the initial MAA (EMEA/H/C/4027) and other extension of indications procedures EMEA/H/C/004027/II/0002 and EMEA/H/C/004027/II/0015 for details on pharmacodynamics.

## 2.3.4. PK/PD modelling

- The ceftazidime (CAZ) dataset comprised 9155 observations from 1975 individuals, including 86 (4.4%)  healthy  volunteers,  696  (35.2%)  cUTI  patients,  781  (39.5%)  cIAI  patients  and  412 (20.9%) with HAP/VAP.
- The avibactam (AVI) dataset included 13735 observations from 2249 individuals, including 345 (15.3%) healthy volunteers, 705 (31.3%) cUTI patients, 786 (34.9%) cIAI patients and  413 (18.4%) with HAP/VAP.

There is a difference between the number of Phase 3 patients in the two datasets (n=1747 CAZ, n=1762 AVI) because 16 patients did not have CAZ concentrations and one did not have AVI concentrations available.

The  PK  data  for  each  analyte  were  well  described  by  2-compartment  PK  models  with  first-order disposition and elimination. Of the covariates evaluated (including CrCL, age, body weight, sex, race, indication and geographic region) only CrCL had sufficiently large effects on exposures to warrant dose adjustment and only for patients with CrCL&lt;50 mL/min. The CL of CAZ and AVI were correlated with CrCL. The relationship was close to proportional at CrCL &lt;100 mL/min. Above this level, CL was found to increase slowly with increasing CrCL, such that an increase  of 100 mL/min in CrCL led to a 27.9% increase in AVI CL and a 12.5% increase in CAZ CL.

The  final  POPPK  models  included  a  number  of  other  covariate  effects  that  did  not  warrant  dose adjustment. Typically, covariate effects were retained in the final models if the associated impact on

<div style=\"page-break-after: always\"></div>

either CL or Vc was on the order of ± 20%. However, in some instances, covariate effects with smaller magnitudes were retained for informational purposes as deemed appropriate.

Individual Etas for CL and VC, stratified by bacteraemia status, for the CAZ model are presented in Figure 1 and Figure 2, respectively. Etas for CL and Vc for the AVI model are presented in Figure 3 and Figure 4, respectively.

Figure  1.  Individual  estimates  of  ceftazidime  ETA-CL  in  individuals  with  and  without bacteraemia.  Source:  CAZ-09-MS,  Post-Text\\_Figure  8.  Parameter  shrinkage  was  11.4% (CAZ-09-MS, Table 7)

## Bacteremia

<!-- image -->

Figure  2.  Individual  estimates  of  ceftazidime  ETA-Vc  in  individuals  with  and  without bacteraemia.  Source:  CAZ-09-MS,  Post-Text\\_Figure  9.  Parameter  shrinkage  was  31.2% (CAZ-09-MS, Table 7) Bacteremia

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure  3.  Individual  estimates  of  avibactam  ETA-CL  in  individuals  with  and  without bacteraemia.  Source:  CAZ-09-MS,  Appendix  14.14.2.  Parameter  shrinkage  was  7.29% (CAZ-09-MS, Table 11)

## Bacteremia

## clAWcUTl and bacteremia

Figure  4.  Individual  estimates  of  avibactam  ETA-Vc  in  individuals  with  and  without bacteraemia. Source: CAZ-09-MS, Appendix 14.14.2. Parameter shrinkage 28.15% (CAZ-09-MS, Table 11)

<!-- image -->

## Bacteremia

<!-- image -->

## clAWcUTl and bacteremia

The final POPPK models performed well on visual predictive testing (pcVPC) in subgroups such as patients with high and low CrCL, obese patients and elderly patients (figures not shown here).

Exposure and joint probability of target attainment defined as the probability of PK/pharmacodynamic (PD) target attainment for the joint PK/PD targets of free CAZ concentrations that exceed the CAZ-AVI minimum inhibitory  concentration  (MIC)  for  50%  of  the  dosing  interval,  denoted  50% f T  &gt;  MIC,  and simultaneously, free  AVI concentrations that exceed the threshold concentration (CT) of 1 mg/L for 50%fT &gt; CT were comparable among patients with and without baseline bacteraemia. The joint probability of PK/PD target attainment at CAZ-AVI MIC=8 mg/L were &gt;98% in patients with and without concurrent bacteraemia (Table 4).

<div style=\"page-break-after: always\"></div>

Table  4.  Comparison  of geometric  mean  (CV%)  of  Cmax,ss,  AUCss,0-24  and  rates  of  the  joint target attainment in patients with- and without baseline bacteraemia for Phase III cIAI, cUTI, and NP, including VAP and non-VAP patients. Source: CAZ-MS-09, Table 13

|                      |      | Ceftazidime   | Ceftazidime      | Avibactam     | Avibactam        |                                               |
|----------------------|------|---------------|------------------|---------------|------------------|-----------------------------------------------|
| Baseline bacteraemia | N    | Cmax,ss (CV%) | AUCss,0-24 (CV%) | Cmax,ss (CV%) | AUCss,0-24 (CV%) | Probability of target attainment*, % (95% CI) |
| No                   | 1465 | 71.9 (116.1)  | 881 (126)        | 12.6 (157)    | 141 (161)        | 98.6 (98.0, 99.2)                             |
| Yes                  | 88   | 73.6 (102.8)  | 919 (120)        | 14.2 (164)    | 161 (161)        | 100 (NA)                                      |

AUCss,0-24; area under the plasma concentration versus time curve at steady state, cIAI; complicated intra-abdominal infections, Cmax,ss; maximum plasma concentration at steady state, cUTI; complicated urinary tract infections, CV%; coefficient of variation, NP; nosocomial pneumonia, VAP; ventilator associated pneumonia

*PTA was calculated for the joint PK/PD target of the free CAZ concentration above the MIC for 50% of the dosing interval (50%fT &gt; MIC) and free avibactam concentrations exceeding the threshold concentration (CT) of 1 mg/mL for (50%fT &gt; CT) at CAZ-AVI MIC of 8 mg/L.

The CHMP noted that the CAZ-MS-09 study report was submitted as part of a previous type II variation (EMEA/H/C/4027/II/002).  The presented models in the report were assessed as part of that procedure.

The PK/PD modelling presented in CAZ-09-MS report was not conducted specifically to investigate the impact  of  bacteraemia on  CAZ  and AVI exposure.  This  has  led  to  some  limitations  in  the  presented analyses:

-  Bacteraemia  status  is  not  included  in  the  tables  describing  the  baseline  demographics  in  subjects included  in  the  CAZ-  and  AVI  models  (Table  5  and  Table  9  in  CAZ-09-MS).  This  has  led  to  some uncertainty regarding the bacteraemia status in the patients included in the exposure/target attainment analyses. In Table 4, there are n=88 patients with status 'yes' and n=1465 with 'no'. Conflictingly, as shown in the Eta plots in e.g. Figure 1, there were n=65 patients with bacteraemia status 'yes', n=347 with status 'no' and n=1563 with status 'missing'. In addition, there is also a discrepancy in the number of patients with bacteraemia status 'yes', with n=88 in the exposure/target attainment analyses versus n=65/66/67 in the eta plots.

- The report did not contain diagnostic plots (pcVPCs) confirming that the models predicted exposure adequately across bacteraemia status.

The  above-mentioned  issues  were  however  not  further  pursued,  since  bacteraemia  status  had  no apparent effect on the CL or Vc for neither CAZ nor AVI, as shown in Figure 1, Figure 2, Figure 3 and Figure  4.  These  plots  are  considered  sufficiently  reliable  due  to  the  low  parameter shrinkage  for  CL (&lt;12%)  and  moderate  shrinkage  for  Vc  (28-31%).  There  was  no  apparent  difference  in  Cmax,ss  or AUCss,0-24 of CAZ and AVI between patients with and without bacteraemia. The joint target attainment of CAZ and AVI was also comparable in patients with and without bacteraemia. Finally, bacteraemia per se is not expected to influence pharmacokinetic processes.

## 2.3.5. Discussion on clinical pharmacology

No new clinical pharmacology data were submitted. This however was acceptable to the CHMP as the posology is supported by a previously submitted modelling report (CAZ-09-MS), which indicated  that

<div style=\"page-break-after: always\"></div>

patients with bacteraemia have similar pharmacokinetics and therefore similar joint target attainment of CAZ and AVI as patients without bacteraemia.

CAZ monotherapy is currently approved for the treatment of bacteraemia associated, or expected to be associated, with cUTI, cIAI and nosocomial pneumonia (HAP/VAP) (EMEA/H/A-30/1006). No CAZ dose adjustments are needed for patients with bacteraemia in comparison to non-bacteraemic patients.

## 2.3.6. Conclusions on clinical pharmacology

The pharmacokinetics and the joint target attainment for CAZ and AVI appear similar in patients with and without bacteraemia. Similar posology in these patient populations is endorsed.

## 2.4. Clinical efficacy

## 2.4.1. Dose response study(ies)

N/A

## 2.4.2. Main studies

The 5 main studies ( RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE ) were conducted to support the currently approved indications for Zavicefta. These five Phase 3 studies were used for a pooled analysis to support an extension of the adult cIAI, cUTI, and HAP/VAP indications to patients with bacteraemia associated with, or is suspected to be associated with, any of these infections. The MAH presented  post-hoc  analyses  of  results  across  these  studies  from  the  sub-group  of  patients  in  the Gram-negative extended ME at TOC population who had bacteraemia at baseline (54 patients in the CAZ-AVI +/-MTZ treatment group and 47 patients in the pooled comparator treatment group). In the analysis  performed  for  this  submission,  bacteraemia  was  defined  as any  patient  who  had  1  or  more bacteria  identified  from  a  blood culture  at  baseline  for  all  studies,  except  for  1  of  the  cUTI  studies (RECAPTURE),  which  also  required  the  same  pathogen  to  be  identified  in  a  urine  sample  at  &gt;10 5 colony-forming units (CFUs)/ml.

The CHMP considered that 5 adult Phase 3 main studies (RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE) have been presented, and assessed before,  in  connection  with  previous  applications  for Zavicefta (i.e., EMEA/H/C/004027/0000 - initial MAA and EMEA/H/C/004027II/0002 - Type II variation application to provide the results from the finalized REPROVE study). Therefore, the methods and results for these studies are only briefly described in this assessment report. The main focus will be on the post-hoc analysis of efficacy data from the sub-group of patients who had bacteraemia at baseline across these 5 studies.

A brief overview of the overall study designs for each of the 5 adult Phase 3 studies is presented below, and  in  Table  1  above.  The  primary  endpoint  results  and  analysis  populations  presented  are  those corresponding to the ROW (rest of world, including EU) analyses in each original Clinical Study Report (CSR).  Of  note,  randomisation  was  not  stratified  by  bacteraemia  status  at  baseline  in  any  of  these studies.

RECLAIM and RECLAIM3 were both prospective, randomised, multi-centre, double-blind, double-dummy, comparative studies to determine the efficacy, safety and tolerability of CAZ-AVI plus

<div style=\"page-break-after: always\"></div>

metronidazole (MTZ) versus meropenem in the treatment of hospitalised adults with cIAI. RECLAIM was conducted  in  predominantly  Western  patients  whereas  RECLAIM3  was  conducted  at  sites  in  the Asia-Pacific  region.  Patients  were  stratified  by  baseline severity  of  disease  and  region.  The  primary objective was to assess the non-inferiority of CAZ-AVI plus MTZ compared to meropenem with respect to clinical cure at the TOC visit for the modified intent-to-treat (MITT) analysis population (RECLAIM) and the clinically evaluable (CE) analysis population (both RECLAIM and RECLAIM 3):

Figure 5. RECLAIM (cIAI- Global) and RECLAIM3 (cIAI- Asia)

<!-- image -->

*FDArequiresanNI marginof 10.0%

LFU Late follow Up. NI Non-Inferiority

RECAPTURE was a prospective, randomised, multi-centre, double-blind, double-dummy, comparative study to determine  the efficacy, safety, and tolerability of CAZ-AVI compared with doripenem in the treatment of hospitalised patients with cUTIs. Patients were stratified by type of infection at baseline and region.  The  primary  objective  for  the  ROW  analysis  was  to  assess  the  non-inferiority  of  CAZ-AVI compared to doripenem with respect to the per-patient microbiological response at the TOC visit in the mMITT analysis population:

Figure 6. RECAPTURE (cUTI)

<!-- image -->

LFU Late follow Up. NI Non-Inferiority

<div style=\"page-break-after: always\"></div>

REPROVE was  a  prospective,  randomised,  multi-centre,  double-blind,  double-dummy,  comparative study designed to evaluate the efficacy, safety, and tolerability of CAZ-AVI versus meropenem in the treatment of nosocomial  pneumonia  (NP)  including ventilator-associated pneumonia  (VAP),  in hospitalised adult patients. Patients were stratified by type of infection (VAP/non-VAP) and geographical region. The primary objective was to assess the non-inferiority of CAZ-AVI compared to meropenem with respect to clinical cure at the TOC visit for the clinically modified intent-to-treat (cMITT) and clinically evaluable (CE) analysis populations:

Figure 7. REPROVE (HAP)

<!-- image -->

LFU Late follow Up. NI Non-Inferiority

REPRISE was a prospective, randomised, multi-centre, open-label, non-comparative study to evaluate the efficacy, safety, and tolerability of CAZ-AVI and Best Available Therapy (BAT) in the treatment of hospitalised adults with cIAIs and cUTIs caused by CAZ-resistant Gram-negative pathogens. Patients were stratified by entry diagnosis and region. The substantial majority (306/333 patients) had cUTI at baseline and therefore REPRISE principally provided supportive  evidence of efficacy  against CAZ-resistant pathogens in the cUTI indication. The primary objective was to estimate the per-patient overall clinical response to CAZ-AVI and BAT at TOC in the mMITT analysis population:

Figure 8. REPRISE (CAZ-Resistant Gram-Negative  Pathogens)

<!-- image -->

FU Follow Up

<div style=\"page-break-after: always\"></div>

The primary endpoint results for each of the 5 adults Phase 3 studies are presented in the table below.

Table  5.  Primary  Endpoint  Results  for  the  5  Adult  Phase  3  Studies  (RECLAIM,  RECLAIM3, RECAPTURE, REPRISE, REPROVE)

| Indication Study                                  | PrimaryEndpoint (Analysis Population)              | CAZ-AVIa n/N (%)   | Comparatorb n/N (%)   | %Difference (95% CI)   | Non-inferiority test p-value for a -12.5% margin`   |
|---------------------------------------------------|----------------------------------------------------|--------------------|-----------------------|------------------------|-----------------------------------------------------|
| cIAI RECLAIM1&2                                   | Clinical cure at TOC (MITT)                        | 429/520 (82.5)     | 444/523 (84.9)        | -2.4 (-6.9,2.10)       | <0.001                                              |
|                                                   | Clinical cure at TOC (CE)                          | 376/410 (91.7)     | 385/416 (92.5)        | -0.8 (-4.61, 2.89)     | <0.001                                              |
| cIAI RECLAIM3                                     | Clinical cure at TOC (CE)                          | 166/177 (93.8)     | 173/184 (94.0)        | -0.2 (-5.53, 4.97)     | <0.001                                              |
| cUTI RECAPTURE1&2                                 | Favourablemicrobiological responseatToC(mMITT)     | 304/393 (77.4)     | 296/417 (71.0)        | 6.4 (0.33, 12.36)      | <0.0001                                             |
| NP REPROVE                                        | Clinical response at TOC (cMITT)                   | 245/356 (68.8)     | 270/370 (73.0)        | -4.2 (-10.76, 2.46)    | 0.007                                               |
|                                                   | Clinical cure at TOC (CE)                          | 199/257 (77.4)     | 211/270 (78.1)        | -0.7 (-7.86, 6.39)     | <0.001                                              |
| Resistant pathogensd REPRISE [CAZ-R cIAI or cUT1] | Overall clinical cure at TOC (mMITT) (cIAI + cUTI) | 140/154 (90.9)     | 135/148 (91.2)        | ND                     | ND                                                  |

and Table 11.2.1.1 REPRISE CSR.

The table below presents the results observed for the primary efficacy endpoint in each study for the subset  of  patients  with  bacteraemia  at  baseline,  that  were  analysed  as  a  pre-specified  descriptive sub-group analysis in 4 of the 5 adult Phase 3 studies (RECLAIM, RECLAIM3, RECAPTURE and REPROVE). These  results  were  presented  in  the  individual  CSRs,  and  assessed  in  connection  with  previously submitted applications for Zavicefta (initial MAA and EMEA/H/C/004027/II/0002).

Table 6. Favourable Response Rates for the Bacteraemia Subsets in the Adult Phase 3 Studies (RECLAIM, RECLAIM3, RECAPTURE, REPROVE)

| Indication Study   | PrimaryEndpoint (AnalysisPopulation)                         | CAZ-AVI n/N (%)   | Comparatorb n/N (%)   | %Difference (95% C1)   |
|--------------------|--------------------------------------------------------------|-------------------|-----------------------|------------------------|
| cIAI RECLAIM1&2    | Clinical cure at TOC (MITT)                                  | 17/22 (77.3)      | 10/14 (71.4)          | 5.8 (-22.28, 36.44)    |
|                    | Clinical cure at TOC (CE) Clinical cure at TOC               | 15/17 (88.2)      | 9/10 (90.0)           | -1.8 (-27.45, 31.39)   |
| cIAI RECLAIM3 cUTI | (CE)                                                         | 4/4 (100.0)       | 7/8 (87.5)            | 12.5 (-41.70, 48.68)   |
| RECAPTURE1&2       | Per-patientmicrobiologicalfavourable response at TOC (mMITT) | 31/38 (81.6)      | 24/33 (72.7)          | 8.9 (-10.9, 28.9)      |
| cUTI REPRISE NP    | N/A                                                          | N/A               | N/A                   | N/A                    |
| REPROVE            | Clinical cure atTOC (cMITT) Clinical cure at TOC             | 13/19 (68.4)      | 9/15 (60.0)           | 8.4 (-23.35, 39.62)    |
|                    | (CE)                                                         | 12/17 (70.6)      | 7/10 (70.0)           | 0.6 (-32.38, 37.28)    |

<div style=\"page-break-after: always\"></div>

Zavicefta was  granted a marketing authorisation in adults for the treatment of complicated intra-abdominal  and  urinary  tract  infections,  hospital-acquired  pneumonia  (including  VAP)  as  well  as infections due to aerobic Gram-negative organisms where treatment options are limited, primarily based on the outcome of the main studies as show in Table 2 and Table 3 above.

The  CHMP  acknowledged  that  patients  with  bacteremia  were  included  from  five  Phase  3  studies (RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE) and the MAH submitted a pooled analysis of results across studies.

Overall features of the studies are presented below in Table 2.

| Table 2. Overview of studies included in the pooled analysis.   | Table 2. Overview of studies included in the pooled analysis.                                                                                                   | Table 2. Overview of studies included in the pooled analysis.                                                                                                             | Table 2. Overview of studies included in the pooled analysis.                                                                                                                                 | Table 2. Overview of studies included in the pooled analysis.                                                    |
|-----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
|                                                                 | RECLAIM (global) and RECLAIM3 (Asian)                                                                                                                           | RECAPTURE                                                                                                                                                                 | REPROVE                                                                                                                                                                                       | REPRISE                                                                                                          |
| Study design                                                    | Prospective, randomized, multi-centre, double-blind, double-dummy, comparative studies                                                                          | Prospective, randomized, multi-centre, double-blind, double-dummy, comparative study                                                                                      | Prospective, randomized, multi-centre, double-blind, double-dummy, comparative study                                                                                                          | Prospective, randomised, multi-centre, open-label, non-comparative study                                         |
| Study drug                                                      | CAZ AVI plus MTZ                                                                                                                                                | CAZ AVI                                                                                                                                                                   | CAZ AVI                                                                                                                                                                                       | CAZ AVI                                                                                                          |
| Comparator                                                      | Meropenem                                                                                                                                                       | Doripenem                                                                                                                                                                 | Meropenem                                                                                                                                                                                     | BAT                                                                                                              |
| Indication                                                      | The treatment of hospitalised adults with cIAI                                                                                                                  | The treatment of hospitalized patients with cUTIs                                                                                                                         | The treatment of NP (HAP) including VAP in hospitalized patients                                                                                                                              | The treatment of hospitalized adults with cIAIs and cUTIs caused by CAZ-resistant Gram-negative pathogens        |
| Primary objective/ endpoints                                    | To assess the non-inferiority of CAZ-AVI plus MTZ compared to meropenem with respect to clinical cure at the TOC visit for the MITT the CE analysis populations | To assess the non-inferiority of CAZ-AVI compared to doripenem with respect to the per-patient microbiological response at the TOC visit in the mMITT analysis population | To assess the non-inferiority of CAZ-AVI compared to meropenem with respect to clinical cure at the TOC visit for the clinically modified intent-to-treat (cMITT) and CE analysis populations | To estimate the per-patient overall clinical response to CAZ-AVI and BAT at TOC in the mMITT analysis population |
| Stratification                                                  | Patients were stratified by baseline severity of disease and                                                                                                    | Patients were stratified by type of infection at baseline and                                                                                                             | Patients were stratified by type of infection (VAP/non-VAP) and                                                                                                                               | Patients were stratified by entry diagnosis and region                                                           |

<div style=\"page-break-after: always\"></div>

|                     | region                                                                                                                                                                                                                                                                                                                                       | region                                                                                                                                                                                                     | geographical region                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis population | The MITT analysis population included all randomised patients who met the disease definition of cIAI and had at least 1 identified pathogen. The CE analysis population includes all patients who had an appropriate diagnosis of cIAI and excluded patients with a bacterial species typically not expected to respond to both study drugs. | The mMITT analysis population includes all randomised patients who received at least 1 dose of study drug and had a study qualifying pre-treatment urine culture containing ≥105 CFUs/mL of ≥1 uropathogen | The cMITT analysis population includes patients who had properly obtained baseline respiratory or blood cultures demonstrating Gram negative pathogens, with or without concomitant Gram positive pathogens, excluding patients with Gram negative pathogens not expected to respond to either study treatment (ie, patients with only the following monomicrobial Gram negative infections. The cMITT also includes patients in whom no etiologic pathogens were identified from respiratory or blood cultures at baseline. The CE analysis population is a subset of the cMITT analysis population in which patients were required to have either received therapy for ≥48 hours, with ≥80% of the scheduled drug administered over the number of days administered, or for <48 hours before discontinuing treatment due to an AE. | The mMITT analysis population includes all patients who had a diagnosis of cIAI or cUTI with a ceftazidime-resistant Gram-negative pathogen on the study-qualifying culture and who received at least 1 dose of study therapy. |
| EOT                 | The period within 24 hours following the last IV infusion                                                                                                                                                                                                                                                                                    | The period within 24 hours following the last IV infusion                                                                                                                                                  | The period within 24 hours following the last IV infusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | The period within 24 hours following the last IV infusion                                                                                                                                                                      |
| Time of TOC visit   | 28 to 35 calendar days from                                                                                                                                                                                                                                                                                                                  | 21 to 25 calendar days                                                                                                                                                                                     | 21 to 25 days from randomisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 7 to 10 days after the last infusion of therapy                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                                                                                                    | randomisation                                              | from randomisation       |                         |                        |
|----------------------------------------------------------------------------------------------------|------------------------------------------------------------|--------------------------|-------------------------|------------------------|
| Number of patients included to the pooled analysis from each study (extended ME at TOC population) | Global CAZ-AVI 9 Comparator 4 Asian CAZ-AVI 2 Comparator 6 | CAZ-AVI 25 Comparator 24 | CAZ-AVI 15 Comparator 8 | CAZ-AVI 3 Comparator 5 |

CAZ  AVI  -  ceftazidime/avibactam;  MTZ  -  metronidazole;  BAT  -  best  available  therapy;  cIAI  -  complicated intraabdominal infection; cUTI -complicated urinary tract infection;  NP -  nosocomial  pneumonia;  HAP  hospital-acquired pneumonia; VAP - ventilator-associated pneumonia; TOC - test of cure; MITT - modified intent to treat; CE - clinically evaluable; mMITT - microbilogically modified intent to treat; cMITT - clinically modified intent to treat; EOT - end of treatment

## Comparison  and  analyses  of  results  across  studies  -  pooled  analysis  of efficacy

Results for the subset of patients with bacteraemia at baseline who were enrolled in the 5 Phase 3 studies are  summarised  in  the  sections  below.  Patients  with  bacteraemia at  baseline  are  referred  to  as  the Bacteraemia subset(s) and all patients enrolled in any of the 5 Phase 3 studies are referred to as the 'Overall set'.

Summaries were presented according to the following indications:

- cIAI: includes patients enrolled from RECLAIM, RECLAIM3 and REPRISE/cIAI;
- cUTI: includes patients enrolled from RECAPTURE and REPRISE/cUTI;
- NP: includes patients enrolled from REPROVE. For this study, patients with moderate or severe renal impairment at baseline who enrolled prior to amendment 3 and who received the original dosing were excluded from the pooled efficacy analysis because they were not part of the primary efficacy analyses presented in the CSR for the REPROVE study in the initial MAA.
- All Indications (cIAI, cUTI and NP): includes patients enrolled from any of the above studies (RECLAIM, RECLAIM3, RECAPTURE, REPRISE and REPROVE).

## Methods

## Study participants - population included in the pooled analysis

A total of 101 patients in the Bacteremia subset (i.e., 54 patients in the CAZ-AVI ± MTZ treatment group and 47 patients in the pooled comparator treatment group) were included in the Gram-negative extended ME at  TOC  population.  Within  each  indication  in  total  21  patients,  57  patients  and  23  patients  were included in the following diagnosis categories cIAI, cUTI and HAP/VAP, respectively.

<div style=\"page-break-after: always\"></div>

## Treatments

A brief description of the treatments in the different treatment groups in the main studies are presented in Table 1 and under section 'Main studies' above.

The comparators used in the main studies (which also included patients with bacteraemia) were already considered appropriate by the CHMP in the context of the assessment of the initial MAA for use in the treatment  of  cIAI, cUTI  and  HAP  (including VAP)  as  well  as  infections  due  to aerobic  Gram-negative organisms where treatment options are limited (EMEA/H/C/004027/0000 and EMEA/H/C/004027II/0002). Furthermore, meropenem, the main comparator in the studies concerning cIAI and HAP/VAP, is approved in EU for treatment of bacteraemia in association with these indications. For doripenem, the main comparator in the cUTI studies, no restriction with respect to the use in patients with bacteraemia is included in its EU SmPC.

## Outcomes/endpoints

Efficacy endpoints were assessed in relation to the primary diagnosis, according to the definitions of response utilised in each of the individual studies (see above under section 'Main study', table 3). The efficacy results for each set (i.e. the Bacteraemia subset and the Overall set) were presented for CAZ-AVI ± MTZ and comparator for the following endpoints:

- Clinical response at TOC and at EOT (favourable clinical response at TOC was considered the efficacy endpoint of interest of this pooled analysis of efficacy)
- Per-pathogen microbiological response at TOC
- Per-patient microbiological response at TOC and at EOT
- Emergent infections

## Statistical methods

No formal statistical hypotheses testing was performed. Efficacy data in the Bacteraemia Subset, and Overall Set, presented for CAZ-AVI±MTZ and comparator, were summarised descriptively for the three indications (cIAI, cUTI, NP) separately and combined.

Descriptive statistics for age, sex and race for the Bacteraemia subset and Overall set were presented.

## Analysis population

The Gram-negative extended ME at TOC population (see definition of populations below) is considered the main analysis population, since, for the Bacteraemia subset, this population is limited to patients with the most relevant pathogens (i.e., aerobic Gram-negative bacteria - either Enterobacteriaceae or aerobic Gram-negative pathogens other than Enterobacteriaceae ) isolated from the blood at baseline. For the purposes of this application, data presentations are focused on the Gram-negative extended ME at TOC population.

Definitions for each of the analysis populations used for the pooled efficacy analyses are as follows:

Extended ME at TOC population . The ME and extended ME at TOC analysis sets was not included as formal analysis sets in this submission, but are defined here to aid the definition of the Gram-negative extended ME population below.

- The ME analysis set across the pivotal Phase 3 studies included patients who were compliant with

<div style=\"page-break-after: always\"></div>

the protocol (as defined in each of the individual studies), had an evaluable clinical response (i.e., not  indeterminate),  and  had  a  study-qualifying  Gram-negative  pathogen  at  baseline.  The REPRISE study did not have an ME analysis set defined.

- The definition of the extended ME analysis set was the same as the ME analysis set but without a requirement  for  susceptibility  of  the  baseline  pathogen  to  study  treatment.  For  the  REPRISE study,  the  extended  ME  analysis  set  was  a  subset  of  the  mMITT  analysis  set  and  comprised patients who also received a minimum duration of study treatment and had no major protocol deviations that would affect the assessment of efficacy.

Gram-Negative Extended ME population at TOC . For the Overall set, the Gram-negative extended ME population was defined as a subset of the extended ME population as defined in each individual study, limited to patients with aerobic Gram-negative  bacteria (either Enterobacteriaceae or aerobic Gram-negative  pathogens  other  than Enterobacteriaceae )  isolated  from  the  primary  site  of  infection and/or  blood.  For  the  Bacteraemia  subset,  this  population  was  further  limited  to  subjects  with Gram-negative pathogens isolated from the blood at baseline.

mMITT population . The mMITT population across the Phase 3 studies was defined as patients who received  1  dose of  study  drug,  met  the  protocol-specific  disease  definition,  and  who  had  at  least  1 etiologic pathogen at baseline at the primary site of infection and/or in blood, excluding those that were not  expected  to  respond  to  either  study  treatment  (i.e.,  patients  with  only  the  monomicrobial Gram-negative  infections  against  which  CAZ-AVI  has  no  activity,  such  as  any  of  the Acinetobacter species, any of the Legionella species, Stenotrophomonas maltophilia , or Elizabethkingia meningoseptica) . RECAPTURE 1 &amp; 2 also required the same pathogen to be identified in a urine sample at &gt;10 5  CFUs/ml.  For the REPRISE study, the mMITT analysis set included all patients who met the protocol-specific  disease  definition,  had  a  ceftazidime-resistant  Gram-negative  pathogen  on  the study-qualifying culture, and received at least 1 dose of study therapy.

## Results

## Baseline data

The MAH stated that compared with  the Overall set, patients in the Bacteraemia subset were slightly older, had a higher proportion of females and Asian patients and higher mean baseline APACHE II scores (Acute Physiology, Age, Chronic Health Evaluation). The mean creatinine clearance (CrCL) was lower in the Bacteraemia subset than the Overall set.

Demographic and disease characteristics for the Bacteremia subset are presented in the tables below.

<div style=\"page-break-after: always\"></div>

Table  7.  Demographic  Characteristics  (Age,  Sex,  and  Race)  for  Patients  with  Bacteraemia: Gram-Negative Extended ME at TOC Population (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                        |                           | Number (%) of Patients with Bacteraemia   | Number (%) of Patients with Bacteraemia   | Number (%) of Patients with Bacteraemia   | Number (%) of Patients with Bacteraemia   | Number (%) of Patients with Bacteraemia   | Number (%) of Patients with Bacteraemia   | Number (%) of Patients with Bacteraemia   | Number (%) of Patients with Bacteraemia   |
|------------------------|---------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|                        |                           | cIAI                                      | cIAI                                      | IN                                        | IN                                        | NP                                        | NP                                        | AllIndications                            | AllIndications                            |
|                        |                           | CAZ-AVI+MTZ (N=11)                        | Comparator (N=10)                         | CAZ-AVI (N=28)                            | Comparator (N=29)                         | CAZ-AVI (N=15)                            | Meropenem (N=8)                           | CAZ-AVI+/- MTZ (N=54)                     | Comparator (N=47)                         |
| Age (years)            | n                         | 11                                        | 10                                        | 28                                        | 29                                        | 15                                        | 8                                         | 54                                        | 47                                        |
|                        | Mean                      | 61.5                                      | 53.7                                      | 57.4                                      | 64.2                                      | 65.3                                      | 65.8                                      | 60.4                                      | 62.2                                      |
|                        | SD                        | 19.80                                     | 16.83                                     | 20.27                                     | 14.93                                     | 11.09                                     | 13.33                                     | 18.10                                     | 15.44                                     |
|                        | Median                    | 62.0                                      | 54.0                                      | 63.5                                      | 66.0                                      | 65.0                                      | 65.5                                      | 64.0                                      | 65.0                                      |
|                        | Minimum                   | 24                                        | 19                                        | 19                                        | 26                                        | 45                                        | 49                                        | 19                                        | 19                                        |
|                        | Maximum                   | 83                                        | 75                                        | 79                                        | 84                                        | 86                                        | 86                                        | 86                                        | 86                                        |
| Age group (years) n(%) | >=18 -45                  | 2 (18.2)                                  | 3 (30.0)                                  | 7 (25.0)                                  | 3 (10.3)                                  | 1 (6.7)                                   | 0 (0.0)                                   | 10 (18.5)                                 | 6 (12.8)                                  |
|                        | 46 - 64                   | 4 (36.4)                                  | 4 (40.0)                                  | 9 (32.1)                                  | 9 (31.0)                                  | 5 (33.3)                                  | 3 (37.5)                                  | 18 (33.3)                                 | 16 (34.0)                                 |
|                        | 65 - 74                   | 1 (9.1)                                   | 2 (20.0)                                  | 5 (17.9)                                  | 10 (34.5)                                 | 6 (40.0)                                  | 3 (37.5)                                  | 12 (22.2)                                 | 15 (31.9)                                 |
|                        | >=75 -<=90                | 4 (36.4)                                  | 1 (10.0)                                  | 7 (25.0)                                  | 7 (24.1)                                  | 3 (20.0)                                  | 2 (25.0)                                  | 14 (25.9)                                 | 10 (21.3)                                 |
|                        | Total                     | 11 (100)                                  | 10 (100)                                  | 28 (100)                                  | 29 (100)                                  | 15 (100)                                  | 8 (100)                                   | 54 (100)                                  | 47 (100)                                  |
| Sex n(%)               | Female                    | 7 (63.6)                                  | 4 (40.0)                                  | 25 (89.3)                                 | 23 (79.3)                                 | 6 (40.0)                                  | 2 (25.0)                                  | 38 (70.4)                                 | 29 (61.7)                                 |
|                        | Male                      | 4 (36.4)                                  | 6 (60.0)                                  | 3 (10.7)                                  | 6 (20.7)                                  | 9 (60.0)                                  | 6 (75.0)                                  | 16 (29.6)                                 | 18 (38.3)                                 |
|                        | Total                     | 11 (100)                                  | 10 (100)                                  | 28 (100)                                  | 29 (100)                                  | 15 (100)                                  | 8 (100)                                   | 54 (100)                                  | 47 (100)                                  |
| Race n(%)              | White                     | 7 (63.6)                                  | 3 (30.0)                                  | 15 (53.6)                                 | 18 (62.1)                                 | 10 (66.7)                                 | 5 (62.5)                                  | 32 (59.3)                                 | 26 (55.3)                                 |
|                        | Black or African American | 0 (0.0)                                   | 0 (0.0)                                   | 1(3.6)                                    | 1(3.4)                                    | 0 (0.0)                                   | 0 (0.0)                                   | 1 (1.9)                                   | 1 (2.1)                                   |
|                        | Asian                     | 4 (36.4)                                  | 7 (70.0)                                  | 11 (39.3)                                 | 6 (20.7)                                  | 5 (33.3)                                  | 2 (25.0)                                  | 20 (37.0)                                 | 15 (31.9)                                 |
|                        | Other                     | 0 (0.0)                                   | 0 (0.0)                                   | 1 (3.6)                                   | 4 (13.8)                                  | 0 (0.0)                                   | 1 (12.5)                                  | 1(1.9)                                    | 5 (10.6)                                  |
|                        | Total                     | 11 (100)                                  | 10 (100)                                  | 28 (100)                                  | 29 (100)                                  | 15 (100)                                  | 8 (100)                                   | 54 (100)                                  | 47 (100)                                  |

n Number of patients in category or analysis. SD Standard deviation. ME Microbiologically evaluable. TOC Test of cure. Percentages are based on the total number of patients in the treatment group (N).

<div style=\"page-break-after: always\"></div>

Table 8. Disease Characteristics (APACHE II, Prior Treatment Failure, Estimated CrCl, Renal Status)  at  Baseline  for  Patients  with  Bacteremia:  Gram-Negative  Extended  ME  at  TOC population (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                                 |                  |                    |                    | Number(%)of PatientswithBacteraemia   | Number(%)of PatientswithBacteraemia   | Number(%)of PatientswithBacteraemia   | Number(%)of PatientswithBacteraemia   |                       |                   |
|---------------------------------|------------------|--------------------|--------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-----------------------|-------------------|
|                                 |                  | cIAI               | cIAI               | IN                                    | IN                                    | NP                                    | NP                                    | All Indications       | All Indications   |
|                                 |                  | CAZ-AVI+MTZ (N=11) | Comparator' (N=10) | CAZ-AVI (N=28)                        | Comparator (N=29)                     | CAZ-AVI (N=15)                        | Meropenem (N=8)                       | CAZ-AVI+/- MTZ (N=54) | Comparator (N=47) |
| APACHE II score (from eCRF) [al |                  | 11                 | 10                 | 0                                     | 0                                     | 15                                    | 8                                     | 26                    | 18                |
|                                 | Mean             | 9.5                | 9.7                |                                       |                                       | 16.1                                  | 15.1                                  | 13.3                  | 12.1              |
|                                 | SD               | 6.06               | 6.24               |                                       |                                       | 5.03                                  | 3.76                                  | 6.31                  | 5.84              |
|                                 | Median           | 10.0               | 8.5                |                                       |                                       | 15.0                                  | 15.0                                  | 13.5                  | 11.5              |
|                                 | Minimum          | 1                  | 3                  |                                       |                                       | 10                                    | 10                                    | 1                     | 3                 |
|                                 | Maximum          | 19                 | 24                 |                                       |                                       | 29                                    | 20                                    | 29                    | 24                |
| APACHEII(from eCRF)<10 n (%)    |                  | 5 (45.5)           | 5 (50.0)           | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 5 (9.3)               | 5 (10.6)          |
|                                 | 10 -19           | 6 (54.5)           | 4 (40.0)           | 0 (0.0)                               | 0 (0.0)                               | 12 (80.0)                             | 6 (75.0)                              | 18 (33.3)             | 10 (21.3)         |
|                                 | 20 -30           | 0 (0.0)            | 1 (10.0)           | 0 (0.0)                               | 0 (0.0)                               | 3 (20.0)                              | 2 (25.0)                              | 3 (5.6)               | 3 (6.4)           |
|                                 | Missing/Not done | 0 (0.0)            | 0 (0.0)            | 28 (100)                              | 29 (100)                              | 0 (0.0)                               | 0 (0.0)                               | 28 (51.9)             | 29 (61.7)         |
|                                 | Total            | 11 (100)           | 10 (100)           | 28 (100)                              | 29 (100)                              | 15 (100)                              | 8 (100)                               | 54 (100)              | 47 (100)          |
| Prior treatment failure n (%)   | Yes              | 1 (9.1)            | 1 (10.0)           | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 1 (1.9)               | 1 (2.1)           |
|                                 | No               | 10 (90.9)          | 9 (90.0)           | 3 (10.7)                              | 5 (17.2)                              | 0 (0.0)                               | 0 (0.0)                               | 13 (24.1)             | 14 (29.8)         |
|                                 | Missing/Not done | 0 (0.0)            | 0 (0.0)            | 25 (89.3)                             | 24 (82.8)                             | 15 (100)                              | 8 (100)                               | 40 (74.1)             | 32 (68.1)         |
|                                 | Total            | 11 (100)           | 10 (100)           | 28 (100)                              | 29 (100)                              | 15 (100)                              | 8 (100)                               | 54 (100)              | 47 (100)          |
| Estimated CrC1(mL/min) n        |                  | 11                 | 10                 | 28                                    | 29                                    | 15                                    | 8                                     | 54                    | 47                |
| [b]                             | Mean             | 81.17              | 80.19              | 74.79                                 | 60.08                                 | 86.47                                 | 113.48                                | 79.33                 | 73.45             |
|                                 | SD               | 34.050             | 31.791             | 26.978                                | 22.927                                | 25.736                                | 103.558                               | 28.116                | 50.507            |
|                                 | Median           | 77.00              | 78.01              | 71.36                                 | 55.36                                 | 85.50                                 | 64.35                                 | 77.05                 | 58.00             |
|                                 | Minimum          | 31.3               | 34.0               | 22.5                                  | 26.4                                  | 50.7                                  | 41.2                                  | 22.5                  | 26.4              |
|                                 | Maximum          | 129.8              | 143.2              | 131.0                                 | 115.0                                 | 138.0                                 | 355.9                                 | 138.0                 | 355.9             |
| Renal status n (%)              | <=30             | 0 (0.0)            | 0 (0.0)            | 1 (3.6)                               | 1 (3.4)                               | 0 (0.0)                               | 0 (0.0)                               | 1(1.9)                | 1(2.1)            |
|                                 | 31-50            | 2 (18.2)           | 3 (30.0)           | 3 (10.7)                              | 7 (24.1)                              | 0 (0.0)                               | 1 (12.5)                              | 5 (9.3)               | 11 (23.4)         |
|                                 | 51-80            | 4 (36.4)           | 3 (30.0)           | 14 (50.0)                             | 17 (58.6)                             | 7 (46.7)                              | 4 (50.0)                              | 25 (46.3)             | 24 (51.1)         |
|                                 | >=81             | 5 (45.5)           | 4 (40.0)           | 10 (35.7)                             | 4 (13.8)                              | 8 (53.3)                              | 3 (37.5)                              | 23 (42.6)             | 11 (23.4)         |
|                                 | Total            | 11 (100)           | 10 (100)           | 28 (100)                              | 29 (100)                              | 15 (100)                              | 8 (100)                               | 54 (100)              | 47 (100)          |

[a] APACHE II score is calculated programmatically using data obtained at the site and reported in the eCRF. [b] As reported by the site using the Cockcroft Gault method (Cockcroft and Gault 1976) method based on local laboratory data n Number of patients in category or analysis. SD Standard deviation.

Percentages are based on the total number of patients in the treatment group (N). eCRF Electronic case report form. ME Microbiologically evaluable. TOC Test of cure.

## Prior systemic antibiotic use

In the Bacteraemia subset, for all indications combined, almost half of the subjects had prior systemic antibiotic use (42.6% for the CAZ-AVI ± MTZ treatment group and 46.8% for the comparator treatment group). Most of the prior systemic antibiotic use was reported for patients in the cIAI studies (63.6% for the CAZ-AVI + MTZ treatment group and 80.0% for the comparator treatment group) and the NP study (66.7% for the CAZ-AVI treatment group and 75.0% for the meropenem treatment group).

In the Overall set 45.4% of the CAZ-AVI ± MTZ treatment group and 45.8% of the comparator treatment group had prior systemic antibiotic use with patients in the cIAI and NP studies reporting the most prior systemic antibiotic use.

The CHMP noted that a comparison of demographic and disease characteristics for the Bacteraemia and the Overall set had not been provided by the MAH. However, according to the MAH, compared with the Overall set, patients in the Bacteraemia subset were slightly older, had a higher proportion of females and

<div style=\"page-break-after: always\"></div>

Asian patients and higher mean baseline APACHE II scores. The mean creatinine clearance (CrCL) was lower in the Bacteraemia subset than the Overall set. As illustrated in the tables above, although some differences within each indications were observed for the Bacteraemia subset, the distribution of patients according to baseline demographic and disease characteristics were largely similar between treatment groups  for  the  Bacteraemia  subset,  by  indication  and  across  all  indications.  Considering  the  small numbers in the Bacteraemia subset for each diagnosis included in these post-hoc analyses, no meaningful conclusions based on these differences can be drawn. These considerations were acceptable to the CHMP.

## Baseline microbiology

The  most  commonly  isolated  pathogens  in  CAZ-AVI  treated  patients  with  bacteremia  (Bacteraemia subset), were E. coli (68.5%), followed by P. aeruginosa (20.4%), K. pneumonia (18.5%), and E. cloacae (7.4%) (Table 9).

Table 9.  Pathogens Per Species at Baseline: Gram-Negative Extended ME at TOC Population in the Bacteraemia Subset and in the Overall Set - (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                                                       |                                                  | Nunber (%) of Patients with Bacteraemia   | Nunber (%) of Patients with Bacteraemia   | Nunber (%) of Patients with Bacteraemia   | Nunber (%) of Patients with Bacteraemia   | Nunber (%) of Patients with Bacteraemia   | Nunber (%) of Patients with Bacteraemia   | Nunber (%) of Patients with Bacteraemia   | Nunber (%) of Patients with Bacteraemia   |
|-------------------------------------------------------|--------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------------------|
|                                                       |                                                  | cIAI                                      | cIAI                                      | cUTI                                      | cUTI                                      | NP                                        | NP                                        | All Indications                           | All Indications                           |
|                                                       | Baseline pathogen                                | CAZ-AVI +MTZ (N=11)                       | Comparator (N=10)                         | CAZ-AVI (N=28)                            | Comparator (N=29)                         | CAZ-AVI (N=15)                            | Meropenem (N=8)                           | CAZ-AVI ±MTZ (N=54)                       | Comparator (N=47)                         |
| Enterobacteriaceae                                    | Enterobacter Cloacae Escherichia coli Klebsiella | 11 (100.0) 0 (0.0) 11 (100.0) 0 (0.0)     | 9 (90.0) 1 (10.0) 6 (60.0) 4 (40.0)       | 28 (100.0) 0 (0.0) 23 (82.1) 5 (17.9)     | 28 (96.6) 0 (0.0) 23 (79.3) 4 (13.8)      | 11 (73.3) 4 (26.7) 3 (20.0) 5 (33.3)      | 8 (100.0) 0 (0.0) 4 (50.0) 3 (37.5)       | 50 (92.6) 4 (7.4) 37 (68.5) 10 (18.5)     | 45 (95.7) 1 (2.1) 33 (70.2) 11 (23.4)     |
| Gram negative pathogens other than Enterobacteriaceae | Pneumoniae                                       | 4 (36.4)                                  | 2 (20.0)                                  | 0 (0.0)                                   | 1 (3.4)                                   | 9 (60.0)                                  | 3 (37.5)                                  | 13 (24.1)                                 | 6 (12.8)                                  |
|                                                       | Pseudomonas                                      | 4 (36.4)                                  | 2 (20.0)                                  | 0 (0.0)                                   | 1 (3.4)                                   | 7 (46.7)                                  | 3 (37.5)                                  | 11 (20.4)                                 | 6 (12.8)                                  |
|                                                       | aeruginosa                                       | CAZ-AVI +MTZ                              | cIAI Comparator                           | Number (%) of Patients Overall CAZ-AVI    | cUTI Comparator                           | CAZ-AVI                                   | NP Meropenem                              | CAZ-AVI ±MTZ                              | AllIndications Comparator                 |
|                                                       | pathogen                                         |                                           |                                           |                                           |                                           |                                           |                                           |                                           |                                           |
| Enterobacteriaceae                                    | Baseline                                         | (N=378)                                   | (N=418)                                   |                                           | (N=435)                                   | (N=125)                                   |                                           |                                           | (N=984)                                   |
|                                                       |                                                  | 15 (4.0)                                  |                                           | (N=423)                                   |                                           |                                           | (N=131)                                   | (N=926)                                   |                                           |
|                                                       | Enterobacter Cloacae                             | 361 (95.5)                                | 400 (95.7) 18 (4.3)                       | 399 (94.3) 14 (3.3)                       | 411 (94.5) 17 (3.9)                       | 87 (69.0) 21 (16.8)                       | 94 (71.8) 11 (8.4)                        | 847 (91.5) 50 (5.4)                       | 905 (92.0) 46 (4.7)                       |
|                                                       | Pneumoniae                                       | 57 (15.1)                                 |                                           |                                           |                                           | 57 (45.0)                                 | 54 (41.2)                                 | 141 (15.2)                                |                                           |
| Gramnegative pathogens other than Enterobacteriaceae  |                                                  |                                           | 64 (15.3)                                 | 27 (6.4)                                  | 24 (5.5)                                  |                                           |                                           |                                           | 142 (14.4)                                |
|                                                       | Pseudomonas aeruginosa                           | 46 (12.2)                                 | 49 (11.7)                                 | 26 (6.1)                                  | 23 (5.3)                                  | 42 (33.6)                                 | 35 (26.7)                                 | 114 (12.3)                                | 107 (10.9)                                |

A patient can have more than 1 pathogen. Multiple isolates of the same species from the same patient are counted only once.

Percentages are based on the total number of patients in the treatment group (N).

For  All  Enterobacteriaceae  isolated  in  the  CAZ-AVI  ±  MTZ  treatment  group  (n=38,  the  Bacteraemia subset), the CAZAVI MIC range was 0.015 to 2 μg/mL with an MIC 90 of 0.25 μg/mL.

For P. aeruginosa isolated in the CAZ-AVI ± MTZ treatment group (n=10, the Bacteraemia subset), the CAZAVI MIC range was 1 to &gt;256 μg/mL with an MIC 90 of 8 μg/mL.

The MAH stated that CAZ-AVI MICs were generally low in the Bacteraemia subset, and in general, the distribution of baseline MICs of Gram-negative pathogens were balanced across treatment arms and across all indications.

<div style=\"page-break-after: always\"></div>

For  the  Bacteraemia  subset,  CAZ-resistant  Enterobacteriaceae  pathogens  were  identified  in  18.5% (n=10) of patients in the CAZ-AVI ± MTZ group and in 38.3% (n=18) of patients in the comparator group. The number of CAZ-resistant P. aeruginosa was very limited in both treatment arms. A summary of CAZ-resistant isolates by pathogen are presented for the Gram-negative extended ME at TOC population is presented in Table 10.

Table  10.  Ceftazidime-Resistant  Gram-Negative  Pathogens  per  Species  at  Baseline  for Patients  with  Bacteraemia  -  Gram-negative  Extended  ME  at  TOC  Population  (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

| Baseline                           | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   |
|------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| pathogen                           | cIAI                                  | cIAI                                  | cUTI                                  | cUTI                                  | NP                                    | NP                                    | AllIndications                        | AllIndications                        |
|                                    | CAZ-AVI +MTZ (=11)                    | Comparator                            | CAZ-AVI                               | Comparator                            | CAZ-AVI                               | Meropenem                             | CAZ-AVI ZIINF                         | Comparator                            |
|                                    |                                       | (N=10)                                | (N=28)                                | (N=29)                                | (N=15)                                | (N=8)                                 | (N=54)                                | (N=47)                                |
| AllEnterobacteriaceae              | 2 (18.2)                              | 3 (30.0)                              | 4 (14.3)                              | 11 (37.9)                             | 4 (26.7)                              | 4 (50.0)                              | 10 (18.5)                             | 18 (38.3)                             |
| Enterobactercloacae                | 0 (0.0)                               | 1 (10.0)                              | 0 (0.0)                               | 0 (0.0)                               | 1 (6.7)                               | 0 (0.0)                               | 1 (1.9)                               | 1 (2.1)                               |
| Escherichiacoli                    | 2 (18.2)                              | 2 (20.0)                              | 1 (3.6)                               | 8 (27.6)                              | 1 (6.7)                               | 2 (25.0)                              | 4 (7.4)                               | 12 (25.5)                             |
| Klebsiellapneumoniae               | 0 (0.0)                               | 0 (0.0)                               | 3 (10.7)                              | 2 (6.9)                               | 2 (13.3)                              | 3 (37.5)                              | 5 (9.3)                               | 5 (10.6)                              |
| Morganellamorganii                 | 0 (0.0)                               | 1 (10.0)                              | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 1 (2.1)                               |
| Providenciarettgeri                | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 1 (3.4)                               | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 1 (2.1)                               |
| Gram negative pathogens other than | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 1 (6.7)                               | 1 (12.5)                              | 1 (1.9)                               | 1 (2.1)                               |
| Enterobacteriaceae                 |                                       |                                       |                                       |                                       |                                       |                                       |                                       |                                       |
| Pseudomonasaeruginosa              | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 0 (0.0)                               | 1 (6.7)                               | 1 (12.5)                              | 1 (1.9)                               | 1 (2.1)                               |

A patient can have more than 1 pathogen. Multiple isolates of the same species from the same patient are counted only once.

Percentages are based on the total number of patients in the treatment group (N).

## Comparison of efficacy results of all studies

For this submission, clinical cure (as related to the primary diagnosis) at the TOC visit was presented for each  indication  and  for  all  indications  combined  as  the  main  efficacy  analysis.  Clinical  cure  at  TOC corresponds to the primary efficacy parameter, which was assessed in the primary analysis populations for the majority of the Phase 3 studies. For the RECAPTURE study, the primary efficacy  endpoint was perpatient microbiological response  at TOC in the Gram-negative extended ME at TOC population. Therefore, this endpoint is additionally presented below for the cUTI indication in the Bacteraemia subset.

## Efficacy outcomes

## Clinical response at TOC

Table 11. Clinical Cure Rates at TOC in the Gram-Negative Extended ME at TOC Population at each Indication, for the Bacteremia Subset and the Overall Set (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                | Bacter'aemiaSubset   | Bacter'aemiaSubset   | Bacter'aemiaSubset       | OverallSet          | OverallSet         | OverallSet              |
|----------------|----------------------|----------------------|--------------------------|---------------------|--------------------|-------------------------|
| Indication     | CAZ-AVI±MTZ n/N (%)  | Comparator n/N (%)   | Difference (%)a (95% CI) | CAZ-AVI±MTZ n/N (%) | Comparator n/N (%) | Difference (%) (95% CI) |
| cIAI           | 9/11 (81.8)          | 9/10 (90.0)          | -8.2 (-41.16,27.12)      | 349/378 (92.3)      | 396/418 (94.7)     | -2.4 (-6.03, 1.02)      |
| cUTI           | 28/28 (100.0)        | 25/29 (86.2)         | 13.8 (0.71, 30.74)       | 409/423 (96.7)      | 418/435 (96.1)     | 0.6 (-2.01, 3.24)       |
| HAP            | 10/15 (66.7)         | 5/8 (62.5)           | 4.2 (-33.32,43.99)       | 96/125 (76.8)       | 103/131 (78.6)     | 1.8(-12.13,8.41)        |
| Allindications | 47/54 (87.0)         | 39/47 (83.0)         | 4.1 (-10.21, 19.09)      | 854/926 (92.2)      | 917/984 (93.2)     | -1.0 (-3.34, 1.37)      |

Source:Table3.16bandTable3.16d

CI: confidence interval

a: difference in clinical cure rates of CAZ-AVI ± MTZ treatment group minus comparator treatment group, along with 95% CI for the difference.

<div style=\"page-break-after: always\"></div>

Table 12. Clinical Cure Rates at EOT in the Gram-negative Extended ME at TOC Population at each Indication, for the Bacteremia Subset and the Overall Set (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                | Bacter'aemiaSubset   | Bacter'aemiaSubset   | Bacter'aemiaSubset       | Overall Set         | Overall Set        | Overall Set             |
|----------------|----------------------|----------------------|--------------------------|---------------------|--------------------|-------------------------|
| Indication     | CAZ-AVI±MTZ n/N (%)  | Comparator n/N (%)   | Difference (%)a (95% CI) | CAZ-AVI±MTZ n/N (%) | Comparator n/N (%) | Difference (%) (95% CI) |
| cIAI           | 9/11 (81.8)          | 9/10 (90.0)          | -8.2 (-41.16, 27.12)     | 356/378 (94.2)      | 404/418 (96.7)     | -2.5(-5.64,0.43)        |
| cUTI           | 28/28 (100.0)        | 29/29 (100.0)        | 0.0 (-12.25, 11.88)      | 421/423 (99.5)      | 434/435 (99.8)     | -0.2(-1.50,0.86)        |
| HAP            | 13/15 (86.7)         | 6/8 (75.0)           | 11.7 (-20.64, 49.42)     | 107/125 (85.6)      | 115/131 (87.8)     | -2.2(-10.82,6.28)       |
| Allindications | 50/54 (92.6)         | 44/47 (93.6)         | -1.0 (-12.26, 10.82)     | 884/926 (95.5)      | 953/984 (96.8)     | -1.4 (-3.19,0.34)       |

Source:Table 3.21b and Table 3.21d

CI: confidence interval

a: difference in clinical cure rates of CAZ-AVI ± MTZ treatment group minus comparator treatment group, along with 95% CI for the difference.

The CHMP considered that, for all indications combined, the clinical cure rate at TOC was 87.0% (47/54) for patients in  the CAZ-AVI ± MTZ treatment group vs. 83.0% (39/47) in the comparator treatment group. The difference in clinical cure rates at TOC of CAZ-AVI ± MTZ treatment group minus comparator treatment group was 4.1% (95% CI: -10.21, +19.09).

Despite the limited number of patients in each specific diagnosis category (cIAI, cUTI, HAP/VAP) included in the post-hoc analyses; generally, the presented results indicate a favourable clinical response at TOC for CAZ-AVI patients with bacteraemia at baseline. Overall, these results were comparable to those seen in the comparator group as well as in the overall population for each of the 3 indications

In total, there were no substantial differences in the mMITT analysis set (not shown) compared to the Gram-negative extended ME at TOC analysis set.

## Per-pathogen clinical response at TOC

Table 13. Clinical Response at TOC by Baseline Pathogen for the 4 most Commonly Isolated Pathogens  for  All  Indications  -  Gram-negative  Extended  ME  at  TOC  Population  for  the Bacteraemia Subset  and  Overall  Set  (Studies  RECLAIM,  RECLAIM3,  RECAPTURE,  REPRISE, REPROVE)

| Baseline pathogen                                 | CAZ-AVI±MTZ   | CAZ-AVI±MTZ   | CAZ-AVI±MTZ   | Comparator    | Comparator   | Comparator   | Comparison betveen groups   | Comparison betveen groups   |
|---------------------------------------------------|---------------|---------------|---------------|---------------|--------------|--------------|-----------------------------|-----------------------------|
|                                                   | Cure Rate (%) | 11            | N1            | Cure Rate (%) | 11           | N1           | Differencela] (%)           | 95%CIfor % difference       |
| BacteraemiaSubsetAll Indications                  |               | N=54          |               |               | N=47         |              |                             |                             |
| All                                               | 79.4          | 27            | 34            | 82.4          | 28           | 34           | -2.9                        | (-22.29, 16.45)             |
| Enterobacteriaceae                                | 81.3          | 26            | 32            | 81.3          | 26           | 32           | 0.0                         | (-19.91, 19.91)             |
| Enterobactercloacae                               | 100.0         | 4             | 4             | 100.0         | 1            | 1            | 0.0                         | (-54.55, 82.76)             |
| Escherichiacoli                                   | 81.0          | 17            | 21            | 87.0          | 20           | 23           | -6.0                        | (-29.72, 16.99)             |
| Klebsiellapneumoniae                              | 100.0         | 7             | 7             | 77.8          | 7            | 9            | 22.2                        | (-18.78, 55.74)             |
| Gram-negativepathogensotherthanEnterobacteriaceae | 72.7          | 8             | 11            | 83.3          | 5            | 6            | -10.6                       | (-46.80, 36.35)             |
| Pseudomonasaeruginosa                             | 72.7          | 8             | 11            | 83.3          | 5            | 6            | -10.6                       | (-46.80, 36.35)             |
| OverallsetAllIndications                          |               | N=926         |               |               | N=984        |              |                             |                             |
| All                                               | 88.7          | 441           | 497           | 91.1          | 499          | 548          | -2.3                        | (-6.08,1.33)                |
| Enterobacteriaceae                                | 90.0          | 412           | 458           | 91.9          | 468          | 509          | -2.0                        | (-5.72, 1.63)               |
| Enterobacter cloacae                              | 97.2          | 35            | 36            | 82.8          | 24           | 29           | 14.5                        | (0.24, 32.38)               |
| Escherichiacoli                                   | 90.9          | 280           | 308           | 94.2          | 327          | 347          | -3.3                        | (-7.60, 0.69)               |
| Klebsiellapneumoniae                              | 91.1          | 92            | 101           | 88.1          | 104          | 118          | 3.0                         | (-5.61, 11.30)              |
| GramnegativepathogensotherthanEnterobacteriaceae  | 78.0          | 71            | 91            | 87.5          | 77           | 88           | -9.5                        | (-20.69, 1.70)              |
| Pseudomonasaemuginosa                             | 77.3          | 68            | 88            | 87.1          | 74           | 85           | -9.8                        | (-21.31, 1.74)              |

[a] Difference = Difference in clinical cure rates (For All Indications, CAZ-AVI+/-MTZ treatment group minus comparator treatment group).

Apatientcanhavemore than1pathogen.Multipleisolatesofthesamespeciesinthesamepatient arecountedonlyonceusingtheisolatewith the highest MIC tostudydrugreceived.

MEMicrobiologicallyevaluable.TOCTestofcure.

N: Number of patients in treatment group. N1: number of patients with each pathogen

n:number ofpatients with clinical cure

Clinicalcurerates arebasedonthetotalnumberofpatientswitheachpathogen(i.en/N1)

<div style=\"page-break-after: always\"></div>

The CHMP considered that, for the most commonly isolated pathogens in the Bacteraemia subsets for all indications combined, the clinical cure rates by baseline pathogen for CAZ-AVI ± MTZ were supportive of the overall clinical efficacy response. For the Bacteraemia subset, clinical cure rates by baseline pathogen in the CAZ-AVI ± MTZ treatment group were: 100% for E. cloacae (4/4); 81.0% for E. coli (17/21), 100% for K. pneumoniae (7/7); and 72.7% for P. aeruginosa (8/11). The corresponding results in the Overall set were generally comparable with the results seen in the Bacteraemia subset.

## Per-patient microbiological response at TOC and at EOT

Table 14. Per-Patient Microbiological Response at EOT and TOC, All Indications: Gram-Negative Extended ME at TOC Population (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                          |                                      | Number(%)of Patients withBacteraemia   | Number(%)of Patients withBacteraemia   | Comparisonbetveengiroups     | Number(%)ofPatients Overall   | Number(%)ofPatients Overall   | Comparisonbetweengroups     |
|--------------------------|--------------------------------------|----------------------------------------|----------------------------------------|------------------------------|-------------------------------|-------------------------------|-----------------------------|
| Time point               | Per-patient microbiological response | CAZ-AVI+/- MTZ (N=63)                  | Comparator (N=54)                      | Difference[a] (%) (95% cIp]) | CAZ-AVI+/- MTZ (N=926)        | Comparator (N=984)            | Difference[a] (%) (95% CI]) |
| Endof treatmentFavorable |                                      | 53 (84.1)                              | 48 (88.9)                              | -4.8 (-17.55, 8.46)          | 865 (93.4)                    | 936 (95.1)                    | -1.7 (-3.86, 0.38)          |
|                          | Unfavorable                          | 7 (11.1)                               | 5(9.3)                                 |                              | 48 (5.2)                      | 40 ( 4.1)                     |                             |
|                          | Indeteminate                         | 3 (4.8)                                | 1(1.9)                                 |                              | 13 (1.4)                      | 8 (0.8)                       |                             |
| Test of cure             | Favorable                            | 51 (81.0)                              | 39 (72.2)                              | 8.7 (-6.66, 24.39)           | 786 (84.9)                    | 805 (81.8)                    | 3.1 (-0.28, 6.41)           |
|                          | Unfavorable                          | 12 (19.0)                              | 15 (27.8)                              |                              | 140 (15.1)                    | 179 (18.2)                    |                             |

Percentages are based on the total number of patients in the treatment group (N).ME Microbiologically evaluable.

Table  15. Per-Patient Microbiological  Response  at  TOC  for  Patients  in  cUTI  Studies: Gram-Negative Extended ME at TOC Population (RECAPTURE, REPRISE) - primary endpoint for the cUTI indication

|            |                                     | Number(%o)ofPatients withBacteraemia   | Number(%o)ofPatients withBacteraemia   | Comparisonbetveengroups      | Number(%)ofPatients Overall   | Number(%)ofPatients Overall   | Comparisonbetveengroups       |
|------------|-------------------------------------|----------------------------------------|----------------------------------------|------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Timepoint  | Per-patient microbiological respose | CAZ-AVI (N=28)                         | Comparator (N=29)                      | Difference[a] (%) (95%CI[b]) | CAZ-AVI (N=423)               | Comparator (N=435)            | Difference[a] (%) (95% CI[b]) |
| Testofcure | Favorable                           | 26 (92.9)                              | 20 (69.0)                              | 23.9 (3.58, 43.73)           | 357 (84.4)                    | 320 (73.6)                    | 10.8 (5.41, 16.24)            |
| Testofcure | Unfavorable                         | 2(7.1)                                 | 9 (31.0)                               |                              | 66 (15.6)                     | 115 (26.4)                    |                               |

Percentagesarebasedonthetotalnumberofpatientsinthetreatmentgroup().MEMicrobiologicallyevaluable.

The CHMP considered that the observed rates of favourable per-patient microbiological response at EOT and TOC for the Bacteraemia subset were similar across treatment groups. For patients in the CAZ-AVI ± MTZ treatment  group,  the  rates  between  the  Bacteraemia  subset  and  the  Overall  set  were  largely comparable.

Regarding  per-patient  microbiological  response  at  TOC  (primary  endpoint  for  the  cUTI  Indication), favourable response rate in the Bacteraemia subset for the cUTI indication was much higher (92.9%, 26/28)  in  the  CAZ-AVI  treatment  group  compared  to  for  the  comparator  treatment  group  (69.0%, 20/29). This trend was generally consistent with the results seen in the Overall set.

<div style=\"page-break-after: always\"></div>

Table 16. Favourable Per-Pathogen Microbiological Response at TOC by Baseline Pathogen for All  Indications  -  Gram  negative  Extended  ME  at  TOC  Population  (Studies  RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

| Subset/Indication Baseline pathogen                                        | CAZ-AVI±MTZ                 | CAZ-AVI±MTZ                   | CAZ-AVI±MTZ   | Comparator                  | Comparator                    | Comparator   | Comparisonbetweengroups   | Comparisonbetweengroups   |
|----------------------------------------------------------------------------|-----------------------------|-------------------------------|---------------|-----------------------------|-------------------------------|--------------|---------------------------|---------------------------|
|                                                                            | Favorable response rate (%) | Number of favorable responses | 11            | Favorable response rate (%) | Number of favorable responses | 11           | Differencela] (%)         | 95%CIfor % difference     |
| Bacteraemia/AllIndications                                                 |                             | N=54                          |               |                             | N=47                          |              |                           |                           |
| Enterobacteriaceae                                                         |                             |                               |               |                             |                               |              |                           |                           |
| Enterobactercloacae                                                        | 100.0                       | 4                             | 4             | 100.0                       | 1                             | 1            | 0.0                       | (-54.55, 82.76)           |
| Escherichiacoli                                                            | 85.7                        | 18                            | 21            | 100.0                       | 23                            | 23           | -14.3                     | (-34.91, 1.41)            |
| Klebsiella pneumoniae                                                      | 85.7                        | 6                             | 7             | 77.8                        | 7                             | 9            | 7.9                       | (-35.96, 46.13)           |
| Gramnegative pathogens other thanEnterobacteriaceae Pseudomonas aeruginosa | 54.5                        | 6                             | 11            | 50.0                        | 3                             | 6            | 4.5                       | (-40.93, 48.75)           |
| Overall/All Indications                                                    |                             | N=926                         |               |                             | N=984                         |              |                           |                           |
| Enterobacteriaceae                                                         |                             |                               |               |                             |                               |              |                           |                           |
| Enterobactercloacae                                                        | 91.7                        | 33                            | 36            | 82.8                        | 24                            | 29           | 8.9                       | (-7.82, 27.70)            |
| Escherichiacoli                                                            | 91.6                        | 282                           | 308           | 95.7                        | 332                           | 347          | -4.1                      | (-8.18, -0.41)            |
| Klebsiellapneumoniae                                                       | 89.1                        | 90                            | 101           | 88.1                        | 104                           | 118          | 1.0                       | (-7.98, 9.58)             |
| GramnegativepathogensotherthanEnterobacteriaceae Pseudomonas aeruginosa    | 67.0                        | 59                            | 88            | 71.8                        | 61                            | 85           | -4.7                      | (-18.32, 9.08)            |

[b] The confidence interval (CI) for the difference is calculated using the unstratified Miettinen &amp; Nurminen method.

[a] Difference = Difference in favorable response rates (For All Indications, CAZ-AVI+/-MTZ treatment group minus comparator treatment group).

A patient can have more than 1 pathogen. Multiple isolates of the same species from the same patient are counted only once using the isolate with the highestminimuminhibitoryconcentration(MIC)tostudydrugreceived.

N Number of patients in treatment group. ME microbiologically evaluable. TOC test of cure.

mMITT Microbiological modified intent-to-treat. TOC Test of cure.

Percentages arebased on the total number of patientswith the pathogen (n)

Source:Table 3.18bandTable3.18d.

The CHMP considered that comparisons of the per-pathogen microbiological favourable response rates in the  Bacteraemia  subset  are  limited  by  small  numbers  for  any  given  pathogen  (apart  from  E.coli). Notwithstanding this, overall, the results indicated similar favourable response rates across treatment groups, and the response trends for any given pathogen between treatment groups in the Bacteraemia set were largely comparable to the results in the Overall set. The favourable per-pathogen microbiological results were consistent with the corresponding clinical responses by baseline pathogen.

## Persistence / presumed persistence / persistence with increasing MICs

The majority of cases with persistence, presumed persistence or persistence with increasing MIC in the Bacteraemia subset were reported from the HAP study. Persistence or presumed persistence at the site of infection and/or blood was observed in 22.2% (12/54) of patients in the CAZ-AVI ± MTZ treatment group and 29.8% (14/47) of patients in the comparator treatment group of the Bacteraemia subset, regardless of indication.

The proportions of patients with persistent bacteraemia were generally low in both treatment groups; all reported cases were presumed persistent based on the clinical response, as no follow-up culture results were available at TOC for any of these cases. A total of 4 (7.4%) patients treated with CAZ-AVI ± MTZ had bacteraemia  that  was  presumed  persistent  at  the  TOC  visit  (3 E.  coli ,  and  1 Salmonella ).  In  the corresponding comparator groups, 2 patients (4.3%) had bacteraemia that was presumed persistent at the TOC visit (1 K. pneumoniae and 1 P. mirabilis ).

There were no cases of persistent bacteraemia associated with increasing MIC in the CAZ-AVI group.

## Per-pathogen microbiological response by MIC category

Per-pathogen  microbiological  response  by  MIC  category  for  each  indication  and  for  the  3  indications combined, for the Bacteraemia subset were compared to the Overall set. Due to the small numbers of bacteraemia patients in each group, it was, according to the MAH, not possible to identify any trends with respect to response by MIC.

<div style=\"page-break-after: always\"></div>

## Microbiological response at the TOC visit for patients infected with CAZ-resistant pathogens

Favourable per-patient microbiological response rates for bacteraemic patients infected with CAZ-resistant pathogens were lower than those observed in the Overall set for both treatment groups at TOC.  Similar  trends  were  observed  for  the  Bacteraemia  subset  versus  the  Overall  subset  for  each indication (cIAI, cUTI, and HAP). However, the small patient numbers (&lt;5 in each treatment group for almost all pathogens) limit interpretation.

Assessment of per-pathogen favourable microbiological response rates for bacteraemic patients infected with CAZ-resistant pathogens was similarly limited by small numbers for any given pathogen.

Emergent infections

Table 17. Emergent Infections for the Bacteraemia Subset - Gram-negative Extended ME at TOC Population (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

| Indication   | Treatment   | PatientID            | Infection Type   | Pathogen                   | Date       | CultureSource   |
|--------------|-------------|----------------------|------------------|----------------------------|------------|-----------------|
| cUTI         | CAZ-AVI     | D4280C00004/E7002006 | NewInfection     | Citrobacterfreundiicomplex | 2013-06-06 | Urine           |
| NP           | CAZ-AVI     | D4281C00001/E1902007 | NewInfection     | Klebsiellapneumoniae       | 2013-11-29 | Siteofinfection |
|              |             |                      | NewInfection     | Staphylococcusaureus       | 2013-11-29 | Siteofinfection |
|              |             | D4281C00001/E1902034 | NewInfection     | Providencia                | 2015-04-20 | Siteofinfection |
|              | Meropenem   | D4281C00001/E1902011 | Newinfection     | Klebsiellapneumoniae       | 2014-01-22 | Siteofinfection |

## 2.4.3. Discussion on clinical efficacy

The fact that during the Article 30 procedure of ceftazidime in 2011 (EMEA/H/A-30/001006), treatment of patients with bacteraemia in association with, or suspected to be associated with, the approved adult indications for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP) was added to the EU SmPC of ceftazidime (brand leader Fortum) is of critical importance for the evaluation of this Type II Variation, is. The additional data submitted for the Fixed Dose Combination Zavicefta, discussed below, are merely supplementary.

## Design and conduct of clinical studies

The proposed indication extension for the addition of bacteraemia associated with the currently approved adult indications of cIAI, cUTI and HAP/VAP is mainly based on post-hoc analysis of efficacy and safety data from the sub-group of patients who had bacteraemia at baseline across the previously assessed 5 Phase  3  studies  ( RECLAIM,  RECLAIM3,  RECAPTURE,  REPRISE,  REPROVE ).  These  studies  were conducted  to  support  the  currently  approved  indications  of  cIAI,  cUTI  and  HAP/VAP.    No  new documentation to support this indication extension has been submitted.

Main  studies: The  5  adult  Phase  3  main  studies  ( RECLAIM,  RECLAIM3,  RECAPTURE,  REPRISE, REPROVE )  have  been  presented,  and  assessed  before,  in  connection  with  previous  applications  for Zavicefta (i.e., EMEA/H/C/004027/0000 - initial MAA and EMEA/H/C/004027II/0002 - Type II variation application to provide the results from the finalized REPROVE study). Therefore, the methods and results for these studies have only been briefly described in this assessment report. The focus has been on the post-hoc analysis of efficacy data from the sub-group of patients who had bacteraemia at baseline across these 5 studies. Of note, randomization was not stratified by bacteraemia status at baseline in any of these studies.

<div style=\"page-break-after: always\"></div>

Zavicefta was granted marketing authorisation in adults for the treatment of complicated intra-abdominal and urinary tract infections, hospital-acquired pneumonia (including ventilator-associated pneumonia, VAP) as well as infections due to aerobic Gram-negative organisms where treatment options are limited, primarily based on the outcome of the above mentioned studies.

Study participants included in the pooled analysis, i.e. patients with bacteraemia at baseline: A total of 101 patients in  the Bacteraemia subset (54 patients  in the CAZ-AVI ± MTZ treatment group and 47 patients in the pooled comparator treatment group) were included in the Gram-negative extended ME at TOC population . Within each indication in total 21 patients, 57 patients and 23 patients were included in the following diagnoses categories cIAI, cUTI and HAP/VAP, respectively.

Comparators: The comparators used in the main studies (which also included patients with bacteraemia) have already been considered appropriate by the CHMP in connection with the assessment of the initial MAA for use in the treatment of cIAI, cUTI and HAP (including VAP) as well as infections due to aerobic Gram-negative organisms where treatment options are limited (EMEA/H/C/004027/0000 and EMEA/H/C/004027II/0002). Further, meropenem, the main comparator in the studies concerning cIAI and HAP/VAP, is approved in EU for treatment of bacteraemia in association with these indications. For doripenem, the main comparator in the cUTI studies, no restriction with respect to the use in patients with bacteraemia is included in its EU SmPC.

Demographic  and  disease  characteristics  for  the  Bacteraemia  and  Overall  set: A  comparison  of demographic and disease characteristics for the Bacteraemia and the Overall set was not provided by the MAH. However, the MAH explained that patients in  the Bacteraemia subset were slightly older, had a higher proportion of females and Asian patients and higher mean baseline APACHE II scores compared with the Overall set. The mean creatinine clearance (CrCL) was lower in the Bacteraemia subset than in the Overall set. Although some differences within each indications were observed for the Bacteraemia subset, the distribution of patients according to baseline demographic and disease characteristics were largely  similar  between  treatment  groups  for  the  Bacteraemia  subset,  by  indication  and  across  all indications. Considering the small numbers in the Bacteraemia subset for each diagnosis included in these post-hoc analyses, no meaningful conclusions based on these differences can be drawn.

## Efficacy data and additional analyses

## Comparison and analyses of results across studies - pooled analysis of efficacy

Clinical response at TOC and EOT: For all indications combined, the clinical cure rate at TOC was 87.0% (47/54)  for  patients  in  the  CAZ-AVI  ±  MTZ  treatment  group  vs.  83.0%  (39/47)  in  the  comparator treatment group. Despite the limited number of patients in each specific diagnosis category (cIAI, cUTI, HAP/VAP), generally the presented results indicate a favourable clinical response at TOC for CAZ-AVI patients  with  bacteraemia  at  baseline.  Overall,  these results  were  comparable  to  those  seen  in  the comparator  group as  well  as  in  the  overall  population  for  each  of  the  3  indications.  Although  some differences between Clinical response at EOT and TOC were seen, the presented results were largely comparable.  However,  the  small  numbers  included  in  these  analyses  limit  the  interpretation  of  the observed  differences.  In  total,  there  were  no  substantial  differences  in  the  mMITT analysis set  (not shown) compared to the Gram-negative extended ME at TOC analysis set.

Per-pathogen clinical response at TOC: For the most commonly isolated pathogens in the Bacteraemia subsets for all indications combined, the clinical cure rates by baseline pathogen for CAZ-AVI ± MTZ were supportive of the overall clinical efficacy response. For the Bacteraemia subset, clinical cure rates by baseline pathogen in the CAZ-AVI ± MTZ treatment group were: 100% for E. cloacae (4/4); 81.0% for E.

<div style=\"page-break-after: always\"></div>

coli (17/21), 100% for K. pneumoniae (7/7); and 72.7% for P. aeruginosa (8/11). The corresponding results in the Overall set were generally comparable with the results seen in the Bacteraemia subset.

Per-patient microbiological response at TOC and at EOT: The observed rates of favourable per-patient microbiological  response at  EOT  and  TOC for  the  Bacteraemia  subset  were  similar  across  treatment groups. For patients in the CAZ-AVI ± MTZ treatment group, the rates between the Bacteraemia subset and  the  Overall set  were  largely comparable.  Regarding  per-patient  microbiological  response at  TOC (primary endpoint for the cUTI indication), favourable response rate in the Bacteraemia subset for the cUTI indication was much higher (92.9%, 26/28) in the CAZ-AVI treatment group compared to for the comparator treatment group (69.0%, 20/29). This trend was generally consistent with the results seen in the Overall set. The comparisons of the per-pathogen microbiological favourable response rates in the Bacteraemia subset are indeed limited by small numbers for any given pathogen (apart from E.coli ). Notwithstanding  this, overall the results indicated similar favourable response rates across treatment groups, and the response trends for any given pathogen between treatment groups in the Bacteraemia set were largely comparable to the results in the Overall set. The favorable per-pathogen microbiological results were consistent with  the corresponding clinical responses by baseline pathogen. No trend for outcome by MIC could be discerned.

## Discussion

Firstly,  during  the  Article  30  procedure  of  ceftazidime  in  2011  (EMEA/H/A-30/001006),  treatment  of patients with bacteraemia in association with, or suspected to be associated with, the approved adult indications for complicated intra-abdominal infection (cIAI), complicated urinary tract infection (cUTI) and hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP) was added to the EU SmPC of ceftazidime (brand leader Fortum).

Additionally,  it  has  previously  been  demonstrated  that  ceftazidime  and  the  beta-lactamase  inhibitor avibactam penetrate into human epithelial lining fluid (ELF) to  the same extent. Overall, it has been concluded  that  the  tissue  penetration  of  avibactam  was  satisfactory  and  not  poorer  compared  to ceftazidime  alone,  thereby  ensuring  that  ceftazidime  would  be  protected  from  being  hydrolyzed  by beta-lactamases at various infection sites.

Furthermore,  according  to  the  Addendum  to  the  guideline  on  the  evaluation  of  medicinal  products indicated for treatment of bacterial infections (EMA/CHMP/351889/2013) regarding non-pathogen-specific bacteraemia 'it may be possible to accumulate sufficient clinical data to support an indication for use of an antibacterial agent in the treatment of bacteraemia that is associated with specific types of infection, with or without restriction to certain pathogens. For example, in the case of agents that have been in use for many years and are indicated for use in a broad range of infections the total evidence may be considered sufficient for an indication that reads Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above (i.e. referring to the list of indications approved). If the antibacterial agent has been evaluated in several indications  and  the  total  number  of  bacteraemic  patients  treated across  these  indications  is  deemed sufficient (e.g. ~50 or more) to support a conclusion that efficacy is comparable to that in other patients or, at least, comparable to that of other treatments, then the addition of the sentence could be considered appropriate.' The submitted data have shown that the efficacy of Zavicefta in the Bacteraemia subset, comprising 54 patients in the CAS-AVI treatment group, was comparable to the Overall set, and overall the terms as described in the Addendum are fulfilled by Zavicefta.

The additional data provided by the MAH justifies the efficacy of the standard dosing and the adequacy of the treatment duration for the HAP/VAP indication.

<div style=\"page-break-after: always\"></div>

## Additional expert consultation

N/A

## Assessment of paediatric data on clinical efficacy

A type II c.I.6a variation application, procedure number EMEA/H/C/004027/II/0015, aiming include a new indication  for  the  use  of  ceftazidime/avibactam  in  the  treatment  of  cIAI  and  cUTI  in  paediatric patien ts aged ≥3 months to &lt;18 years, is ongoing at the time of adoption of this assessment report.

## 2.4.4. Conclusions on the clinical efficacy

Ceftazidime,  the  antibacterial  component  of  this  Fixed  Dose  Combination  is  already  approved  for bacteraemia in association with, or suspected to be associated with, the currently approved indications for cIAI, cUTI and HAP/VAP through an Article 30 procedure in 2011 (EMEA/H/A-30/001006). This was of critical importance to conclude positively on this Type II Variation concerning the applied extension of the indication  to  include  bacteremia  for  Zavicefta.  The  data  based  on  the  Fixed  Dose  Combination  are considered to be supplementary and most importantly, in that respect, are the similar PK and tissue distribution of ceftazidime and avibactam.

## 2.5. Clinical safety

## Introduction

In seven Phase 2 and Phase 3 clinical trials, 2024 adult patients were treated with Zavicefta. The most common adverse reactions occurring in ≥5% of patients treated with Zavicefta were Coombs direct test positive, nausea, and diarrhoea. Nausea and diarrhoea were usually mild or moderate in intensity.

In the currently approved Summary of Product Characteristics (SmPC) for Zavicefta, there are warnings and  precautions  regarding  hypersensitivity  reactions, Clostridium  difficileassociated  diarrhoea,  renal impairment, concurrent treatment with high doses of cephalosporins and nephrotoxic medicinal products, and  direct  antiglobulin  test  (DAGT  or  Coombs  test)  seroconversion  and  potential  risk  of  haemolytic anaemia.

An overview is given on the important identified and potential risks in adults in the initial RMP submission, which were approved as part of the initial MAA for Zavicefta in 2016, see Table 18.

<div style=\"page-break-after: always\"></div>

Table 18 Listing of Important Identified and Potential Risks in the Initial RMP Submission

| Important identified risks   | Clostridium difficile-associated diarrhoea (CDAD) Anaphylaxis and other severe hypersensitivity reactions                                                                                        |
|------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Hepatotoxicity Superinfection (bacterial or fungal) Bacterial resistance development In patients with renal impairment, risk of neurological sequelae when the dose is not appropriately reduced |
| Missing information          | Pregnancy exposure Lactation exposure Pre-existing significant hepatic impairment haemodialysis/peritoneal dialysis and other renal replacement therapy Immunocompromisedpopulation exposure     |

The current Zavicefta European (EU) SmPC is based upon the safety conclusions, submitted in January 2017  as  part  of  variation  EMEA/H/C/004027/II/0002,  which  is  referred  to  as  the  2016  Summary  of Clinical Safety (SCS) within this document. The 2016 SCS includes the analysis of the overall Phase 2/3 pooled safety analysis population in complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI) and Hospital-acquired pneumonia (HAP) (5 Phase 3 studies listed above plus 2 Phase 2 studies: NXL104/2001  and NXL104/2002, 1 each in cUTI and cIAI respectively).

The  MAH  is  now  applying  for  an  extension  of  the  indication  by  a  Type II  variation  for  Zavicefta  or ceftazidime-avibactam (CAZ-AVI) to add the indication for the treatment of patients with bacteraemia in association with, or suspected to be associated with, the currently approved adult indications for cIAI, cUTI and HAP, including ventilator-associated pneumonia (HAP/VAP).

A subset of data from patients with bacteraemia at baseline was created from the overall Phase 2/3 pooled safety analysis population in cIAI, cUTI and HAP. However, the patients from the Phase 2 studies were not included because it was not possible to programmatically confirm bacteraemia at baseline due to different methods of data collection. In addition, the dose of CAZ-AVI used in Study NXL104/2001 was lower than the dose used in the Phase 3 studies.

A subset of pooled safety data in patients with bacteraemia at baseline were therefore derived from the five previously performed and assessed Phase 3 adult studies:

- RECLAIM - global, cIAI
- RECLAIM3 - Asia, cIAI
- RECAPTURE - global, cUTI
- REPRISE - global, ceftazidime-resistant pathogens in cIAI &amp; cUTI
- REPROVE - global, HAP/VAP

Bacteraemia was defined as having 1 or more bacteria identified from a blood culture at baseline for all studies, except for RECAPTURE 1 &amp; 2, which also required the same pathogen to be identified in a urine sample. The bacteraemia subset was then assessed against the known safety profile of CAZ-AVI. There were no formal statistical hypotheses for these analyses; all data were summarised descriptively.

The CHMP noted that the clinical development program for ceftazidime/avibactam for this application included patients with bacteraemia in all 5 of the completed Phase 3 clinical trials that were conducted to support  the  approved  indications  of  cIAI, cUTI  and  HAP/VAP, referred  to  as  'Bacteraemia  subset'.  A post-hoc analysis of efficacy and safety data from this sub-group of patients who had bacteraemia at baseline across these 5 studies was performed.

<div style=\"page-break-after: always\"></div>

The Bacteraemia safety subset was assessed against the known safety profile of CAZ-AVI presented in the Summary of Clinical Safety (SCS), submitted in January 2017 as part of variation EMEA/H/C/004027/II/02), referred to as the 2016 SCS. The overall Phase 2/3 pooled safety analysis population, presented within 2016 SCS, is referred to as the 'Overall safety population'.

## Patient exposure

## - Exposure to Ceftazidime-Avibactam  (CAZ-AVI)

The  evaluation  of  safety  includes  2  pooled safety  datasets  according  to  the  International  Council  for Harmonisation (ICH) M4E guideline (ICH M4E Guideline 2002):

- Overall safety population: 4050 patients in 7 completed Phase 2 (N=338) and Phase 3 (N=3712) CAZ-AVI clinical studies (2016 SCS).
- Bacteraemia subset: 183 patients with bacteraemia at baseline in 5 completed Phase 3 CAZ-AVI clinical studies.

The rationale for selecting the Phase 2/3 pool as the primary dataset for the 2016 SCS was that the patient  populations  in  the  included  studies  were  considered  representative  of  the  target  patient populations (ie, patients with serious Gram-negative infections). The Phase 2/3 pool includes all patients who received at least part of 1 dose of CAZ-AVI and may include patients that have not been included in the safety analysis set for the individual studies.

Additionally, a different Medical Dictionary for Regulatory Activities (MedDRA) version was used for the AE analyses of the Phase 2/3 pool than was used in the analyses for the individual CSRs. Thus, it is not possible to compare individual numbers of AEs noted in CSRs with the numbers reported for the Phase 2/3 pool. For the pooled AE summaries, AEs were coded using MedDRA Version 19.0.

For details of the safety variables collected and methods of evaluation refer to 2016 SCS. Safety data were  summarised  to  the  end  of  treatment  (EOT)  visit  and  were  also  summarised  to  the  end  of  the reporting period (up to and including  the  Final  Follow-up visit) in each study (up  to the 'last visit'). Discussions will focus on the last visit (ie, 'any time up to the last visit') summaries.

The CHMP noted that the pooled analysis focused on the Bacteraemia safety subset, which comprised 183 patients, of whom 99 received CAZ-AVI ± MTZ and 84 received comparator treatment (carbapenems). The safety from these patients are compared to the known safety profile of CAZ-AVI based on over 4000 patients in 7 completed Phase 2 (N=338) and Phase 3 (N=3712) CAZ-AVI clinical studies (2016 SCS), of which half of them - 2024 patients - were treated with Zavicefta.

## Overall extent  of exposure

There was a similar duration of exposure to CAZ-AVI ± MTZ in the Bacteraemia subset, with a mean of 7.7 days of exposure (Table 19) compared to 8.2 days in the Overall safety population (not shown here).

<div style=\"page-break-after: always\"></div>

Table  19. Duration  of  Exposure  on  Study  Drug,  for  Patients  with  Bacteraemia  -  (Safety Analysis Set) (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                          |         | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   | Number(%)of patients   |
|--------------------------|---------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                          |         | cIAI [a]               | cIAI [a]               | cUTI [a]               | cUTI [a]               | NP [a]                 | NP [a]                 | Total                  | Total                  |
|                          |         | CAZ-AVI+MTZ (N=27)     | Comparator (N=24)      | CAZ-AVI (N=48)         | Comparator (N=42)      | CAZ-AVI (N=24)         | Meropenem (N=18)       | CAZ-AVI+/- MTZ (N=99)  | Comparator (N=84)      |
| Exposure (days) n (%) [] |         | 0 (0.0)                | 2 (8.3)                | 2 (4.2)                | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 2 (2.0)                | 2 (2.4)                |
|                          | 2 -4    | 4 (14.8)               | 0 (0.0)                | 2 (4.2)                | 1 (2.4)                | 4 (16.7)               | 2 (11.1)               | 10 (10.1)              | 3 (3.6)                |
|                          | 5 -10   | 18 (66.7)              | 15 (62.5)              | 37 (77.1)              | 28 (66.7)              | 11 (45.8)              | 7 (38.9)               | 66 (66.7)              | 50 (59.5)              |
|                          | 11 -14  | 5 (18.5)               | 7 (29.2)               | 7 (14.6)               | 12 (28.6)              | 9 (37.5)               | 9 (50.0)               | 21 (21.2)              | 28 (33.3)              |
|                          | 15 - 21 | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 1 (2.4)                | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 1 (1.2)                |
|                          | >21     | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                | 0 (0.0)                |
| Exposure (days) [b]      | n       | 27                     | 24                     | 48                     | 42                     | 24                     | 18                     | 99                     | 84                     |
|                          | Mean    | 7.6                    | 8.8                    | 7.0                    | 9.1                    | 9.3                    | 10.2                   | 7.7                    | 9.3                    |
|                          | SD      | 3.1                    | 4.0                    | 3.0                    | 3.9                    | 4.2                    | 3.8                    | 3.5                    | 3.9                    |
|                          | Median  | 7.0                    | 9.0                    | 6.0                    | 8.0                    | 8.5                    | 11.0                   | 7.0                    | 8.5                    |
|                          | Minimum | 3                      | 1                      | 1                      | 3                      | 2                      | 2                      | 1                      | 1                      |
|                          | Maximum | 14                     | 14                     | 14                     | 21                     | 14                     | 14                     | 14                     | 21                     |

[a] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

[b] Duration of exposure is calculated as the difference between the last study therapy date and the first study therapy date converted to days plus 1 day.

Actual calculated duration could be shorter or longer than a full day.

Percentages are based on the total number of patients in the treatment group (N).

n Number of patients included in analysis. SD Standard deviation.

Table created by:

/Volumes/app/cdars/prod/prjC359/csr\\_figaro/Bacteremia\\_C359/saseng/cdisc3\\_0/macros/ex200\\_31\\_t.sas PFIZER CONFIDENTIAL Date of SDTM Dataset Creation: Date of Table Generation: 24JUN2019 (14:27) Table 4.3.2.3 is for Pfizer internal use.

The CHMP considered that the duration of exposure to CAZ-AVI ± MTZ in the Bacteraemia subset varied from  mean  of  7.0  days  in  the  cUTI  indication,  7.6  days  in  cIAI  to  9.3  days  in  pneumonia  (NP/HAP) indications, bearing in mind the limited number of patients with bacteraemia. There was, however, a similar  duration  of  exposure  to  CAZ-AVI  ±  MTZ  with  a  mean  of  7.7  days  in  the  Bacteraemia  subset compared to 8.2 days in the Overall safety population.

## Demographics of Study Population

The demographic and baseline characteristics, for the Bacteraemia subset in the safety analysis set are given.  Numerical  differences  in  the  patient  populations  which  may  impact  the  safety  analysis  and conclusions are presented below. Demographic and baseline characteristics are further described in the Clinical Efficacy section.

In the Bacteraemia subset, 62% of the patients treated with CAZ-AVI ± MTZ were female, compared with 44% in the Overall safety population treated with CAZ-AVI ± MTZ.

A larger proportion of the Bacteraemia subset treated with CAZ-AVI ± MTZ were 65 years and older compared with the Overall safety population treated with CAZ-AVI ± MTZ:

- Bacteraemia subset: 21.2% were 65 74 years; 26.3% were ≥75 -≤90 years.
- Overall safety population: 17.1% were 65 74 years; 15.5% were ≥75 -≤90 years.
- Bacteraemia subset: mean age was 60.7 years; median 64.0 years.

<div style=\"page-break-after: always\"></div>

- Overall safety population: mean age was 53.5 years; median 55.0 years.

Patients were categorised by level of renal function based on their baseline local laboratory CrCl result (calculated using CockcroftGault formula) as follows: CrCl ≥81 mL/min = normal renal function, CrCl 51 to 80 mL/min = mild renal impairment, CrCl 31 to 50 mL/min = moderate renal impairment and CrCl ≤30 mL/min = severe renal impairment

There was a higher proportion of patients with moderate to severe renal insufficiency in the Bacteraemia subset  treated  with  CAZ-AVI  ±  MTZ  compared  with  the  Overall  safety  population  treated  with CAZ-AVI ± MTZ:

- Bacteraemia subset: 14.1% moderate; 3.0% severe
- Overall safety population: 8.6% moderate; 1.1% severe
- Mean CrCl in the Bacteraemia subset: 78.2 ml/ min; median 77.0 ml/min
- Mean CrCl in the Overall safety population: 95 ml/min; median 87.5 ml/min

## Disease Characteristics

The system \"Acute Physiology, Age, Chronic Health Evaluation II\" (APACHE II) is a severity-of-disease classification system. The APACHE II scores at baseline were only captured in the study database for patients in the cIAI and NP studies - the APACHE II scores for the Bacteraemia subset are presented in Table 20. The median APACHE II scores for the Bacteraemia subset (12 for both the CAZ-AVI ± MTZ treatment group and the comparator treatment group) were higher than for the Overall safety population (9 for both the CAZ-AVI ± MTZ treatment group and the comparator treatment group).

Table 20. Disease Characteristics (APACHE  II  score) at Baseline for Patients with Bacteraemia  -  (Safety  Population)  (Studies  RECLAIM,  RECLAIM3,  RECAPTURE,  REPRISE, REPROVE)

|                              |         | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   | Nunber(%o)ofPatientswithBacteraemia   |
|------------------------------|---------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                              |         | CIAI                                  | CIAI                                  | cUTI                                  | cUTI                                  | NP                                    | NP                                    | AllIndications                        | AllIndications                        |
|                              |         | CAZ-AVI+MTZ (N=27)                    | Comparator (N=24)                     | CAZ-AVI (N=48)                        | Comparator (N=42)                     | CAZ-AVI (N=24)                        | Meropenem (N=18)                      | CAZ-AVI+/- MTZ (66=N)                 | Comparator (N=84)                     |
| APACHEIIscore(from eCRF) [a] |         | 27                                    | 23                                    | 0                                     | 0                                     | 24                                    | 18                                    | 51                                    | 41                                    |
|                              | Mean    | 8.9                                   | 10.2                                  |                                       |                                       | 15.8                                  | 16.1                                  | 12.1                                  | 12.8                                  |
|                              | SD      | 5.69                                  | 6.86                                  |                                       |                                       | 4.39                                  | 4.20                                  | 6.14                                  | 6.49                                  |
|                              | Median  | 9.0                                   | 8.0                                   |                                       |                                       | 15.0                                  | 15.5                                  | 12.0                                  | 12.0                                  |
|                              | Minimum | 0                                     | 3                                     |                                       |                                       | 10                                    | 10                                    | 0                                     | 3                                     |
|                              | Maximum | 21                                    | 27                                    |                                       |                                       | 29                                    | 24                                    | 29                                    | 27                                    |

In the CAZ-AVI-treatment group, 38 patients were from EU member states. The largest proportion of these patients (18) was recruited in the Czech Republic.

The  CHMP  considered  that  there  was  a  higher  proportion  of  patients  with  moderate  to  severe  renal insufficiency in the Bacteraemia subset treated with CAZ-AVI ± MTZ compared with the Overall safety population (14.1% moderate; 3.0% severe the Bacteraemia subset compared to 8.6% moderate; 1.1% severe Overall). This means that 17 of the  99 patients with bacteraemia dosed with Zavicefta had a moderate/severe renal insufficiency, which then according to the posology recommendation in the SmPC should have received a reduced dose of Zavicefta. However, if the dose reductions are performed as recommended according to renal status, it is not expected that patients with bacteraemia are at greater risk for adverse events than for patients without bacteraemia.

<div style=\"page-break-after: always\"></div>

The MAH suggested that the differences between patients included in Bacteremia subset and Overall safety population when evaluating demographic characteristics may be due to small number of patients included in CAZ-AVI ± MTZ group in Bacteremia subset (n=99).

The CHMP took into account  that more patients in  the CAZ-AVI group were female, older, with more severe renal impairment than in Overall patient pool. The median APACHE II scores for the Bacteraemia subset was also higher than for the Overall safety population, which is not unexpected due to the severity of bacteraemia. In conclusion, the differences  observed are compatible with the clinical appearance of the patient with blood stream infection.

## Adverse events

AEs with an onset date and time on or after the date and time of the first dose of study drug up to and including the last visit are summarised below.

## Analysis of Adverse Events

The incidence of AEs up to last visit in the Bacteraemia subset and the incidence of AEs in the Overall safety population are presented below in Table 21.

A higher rate of AEs and serious adverse events (SAEs) was reported in both treatment arms in the total Bacteraemia  subset  compared  with  the  Overall  safety  population  and  this  was  also  true  for  the bacteraemic patients with cUTI taking CAZ-AVI compared with the overall cUTI safety population. This may be explained by the difference in the underlying medical condition of the patients in the Bacteraemia subset and may be magnified by the smaller denominators of the Bacteraemia subset as compared to the Overall safety population. This higher rate was not seen with regards to the AEs of severe intensity or AEs with the outcome of death in patients taking CAZ-AVI ± MTZ.

There was a similar rate of severe events in the Bacteraemia subset compared with the Overall safety population. With regards to cUTI, a higher rate of severe events was seen in the Bacteraemia subset compared to the Overall safety population which could reflect that patients with bacteraemia may be more unwell at baseline, however this must be interpreted with caution as the number of patients (2) is very small and it may be caused by the lower denominator.

In the Bacteraemia subset, as the denominators were small in the CAZ-AVI ± MTZ and the comparator arms, and the comparator arm comprises of several different drugs, direct comparison between the two is not appropriate. However, if a difference was seen in the CAZ-AVI ± MTZ arm, the comparator arm was also assessed as to whether the same trend was observed.

<div style=\"page-break-after: always\"></div>

Table 21. Adverse Events up to Last Visit in the Bacteraemia Subset Compared to the Overall Safety Population

| AE Category                                 | Overall Safety Population n (%) [a]   | Overall Safety Population n (%) [a]   | Bacteraemia Subset n (%) [a]   | Bacteraemia Subset n (%) [a]   | Bacteraemia Subset n (%) [a]   |
|---------------------------------------------|---------------------------------------|---------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| cIAI [b]                                    | cIAI [b]                              | cIAI [b]                              | cIAI [b]                       | cIAI [b]                       | cIAI [b]                       |
| Any AE                                      | CAZ-AVI+ MIZ (N=857)                  | Comparator* (N=863)                   | CAZ-AVI+ MTZ (N=27)            | Comparator* (N=24)             |                                |
| Any AE with an outcome of death [c]         | 398 (46.4)                            | 381 (44.1) 9 (1.0)                    | 15 (55.6) 0 (0.0)              | 15 (62.5) 0 (0.0)              |                                |
| Any SAE Any AE leading to                   | 11 (1.3)                              | 67 (7.8)                              | 2 (7.4)                        |                                |                                |
| discontinuation of IP [d]                   | 62 (7.2) 26 (3.0)                     | 14 (1.6)                              | 2 (7.4)                        | 6 (25.0) 1 (4.2)               |                                |
| Any AE of severe intensity                  | 41 (4.8)                              |                                       |                                |                                |                                |
|                                             |                                       | 54 (6.3)                              | 1 (3.7)                        | 4 (16.7)                       |                                |
|                                             |                                       | cUTI [b] Comparator*                  | CAZ-AVI                        | Comparator*                    |                                |
|                                             | CAZ-AVI (IN=731)                      | (N=729)                               | (N=48) 35 (72.9)               | (N=42) 22 (52.4)               |                                |
| Any AE Any AE with an outcome of death [c]  | 275 (37.6) 3 (0.4)                    | 263 (36.1) 4 (0.5)                    | 1 (2.1)                        | 0 (0.0)                        |                                |
| Any SAE Any AE leading to                   | 35 (4.8) 10 (1.4)                     | 19 (2.6) 7 (1.0)                      | 6 (12.5) 3 (6.3)               | 0 (0.0) 0 (0.0)                |                                |
| discontinuation of IP [d]                   | 16 (2.2)                              | 18 (2.5)                              | 2 (4.2)                        | 0 (0.0)                        |                                |
| Any AE of severe intensity                  |                                       | NP#[b]                                |                                |                                |                                |
|                                             | (N=430)                               | (N=434)                               | (N=24)                         | (N=18)                         |                                |
|                                             | CAZ-AVI                               | Meropenam                             | CAZ-AVI                        | Meropenam 14 (77.8)            |                                |
| Any AE                                      |                                       |                                       |                                |                                |                                |
| Any AE with an outcome of death [c]         | 323 (74.1) 27 (6.2)                   | 321 (74.0) 24 (5.5)                   | 19 (79.2)                      | 1 (5.6)                        |                                |
| Any SAE                                     | 79 (18.1)                             |                                       | 1 (4.2)                        | 2 (11.1) 2 (11.1)              |                                |
| Any AE leading to discontinuation of IP [d] | 16 (3.7)                              | 59 (13.6) 13 (3.0)                    | 4 (16.7) 1 (4.2)               | 2 (11.1)                       |                                |
| Any AE of severe intensity                  | 68 (15.6)                             | 55 (12.7) Total#                      | 3 (12.5)                       |                                |                                |
|                                             | CAZ-AVI± MIZ                          | (N=2026)                              |                                |                                |                                |
|                                             | (N=2024)                              | Comparator*                           | CAZ-AVI± MIZ                   | Comparator*                    |                                |
| Any AE                                      | 996 (49.2)                            |                                       | (N=99) 69 (69.7)               | (N=84) 51 (60.7)               |                                |
| Any AE with an outcome of death [c]         | 41 (2.0)                              | 965 (47.6) 37 (1.8)                   | 2 (2.0)                        | 1 (1.2)                        |                                |
| Any SAE                                     |                                       |                                       |                                |                                |                                |
| Any AE leading to                           | 176 (8.7)                             | 145 (7.2)                             | 12 (12.1)                      | 3 (3.6)                        |                                |
|                                             | 125 (6.2)                             |                                       |                                |                                |                                |
|                                             |                                       |                                       |                                | 6 (7.1)                        |                                |
|                                             |                                       |                                       | 6 (6.1)                        |                                |                                |
|                                             |                                       | 127 (6.3)                             |                                |                                |                                |
| Any AE of severe intensity                  |                                       |                                       |                                |                                |                                |
| discontinuation of IP [d]                   |                                       |                                       |                                |                                |                                |
|                                             |                                       | 34 (1.7)                              |                                |                                |                                |
|                                             | 52 (2.6)                              |                                       |                                |                                |                                |
|                                             |                                       |                                       | 6 (6.1)                        |                                |                                |
|                                             |                                       |                                       |                                | 8 (9.5)                        |                                |

Includes AEs and SAEs with an onset date and time on or after the date and time of first dose and up to and including the last visit.

*comparator was meropenem in pivotal cIAI; doripenam in pivotal cUTI studies and best supportive care in supportive resistant pathogen study, primarily a carbopenam #includes HAP MSRIB patients

[a] Patients with multiple AEs in the same category are counted only once in that category. Patients with AEs in more than 1 category are counted once in each of those categories.

[b] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers and comparator details.

[c] Deaths due to disease progression are not presented here.

[d] Action taken, investigational product (IP) permanently stopped.

<div style=\"page-break-after: always\"></div>

As shown in the table above, the CHMP considered that a higher rate of AEs (69.7% vs. 49.2%) and serious adverse events (SAEs; 12.1% vs.8.7%) was reported in CAZ-AVI treatment arms in the total Bacteraemia subset compared with the Overall safety population. A similar difference was seen for the comparator arm.  However,  the  number  of  AEs,  any  SAEs,  AEs  leading  to  discontinuation  of  IP  were consistently higher in the CAZ-AVI ± MTZ group, only any AEs of severe intensity was higher (6 vs 7 (6.1% vs  7.1%))  in  the  comparator  group.  Thus  overall,  in  the  bacteremia  subset,  the  safety  was numerically less  favourable compared with the comparator. Although this may, as claimed by the MAH, be explained by the difference in the underlying condition of the patients in the Bacteraemia subset and may also be magnified by the smaller denominators, for the CAZ-AVI arm, these differences seem to be driven by the bacteraemic patients with cUTI (both any AEs and SAEs) and NP. The higher rates of AEs in the bacteremia patients treated with CAZ-AVI may also partly be due to the fact that the patients in the Bacteremia subset were older and had more severe renal impairment, compared to the Overall safety population in patients taking CAZ-AVI ± MTZ.

The  Committee  also  noted  the  very  high  frequency of  SAEs  (6 patients,  25%)  and  AEs  with  severe intensity (4 patients, 16.7%) in the comparator arm for the pooled cIAI studies, when the corresponding observed frequencies for CAZ-AVI were the same for the total Bacteraemia subset compared with the Overall safety population. However, due to the small number of patients and events, this result should be interpreted  with  caution.  This  observation  is,  however,  of  no  importance  for  the  Zavicefta  risk assessment.

## Common Adverse Events

The most common adverse events up to the last visit for the Bacteraemia subset are presented below in Table 22.

- The preferred terms (PTs) in the Bacteraemia subset were varied; most PTs only occurred in one patient in either the CAZ-AVI ± MTZ or the comparator group, and no patterns were identified.
- The  most  frequently  occurring  PTs  in  the  Bacteraemia  subset  in  the  CAZ-AVI  ±  MTZ-treated group were Diarrhoea and Nausea; these were the same as the most frequently occurring PTs in the Overall safety population and are known common ADRs with CAZ AVI (Zavicefta EU SmPC 2019).

<div style=\"page-break-after: always\"></div>

Table 22. Most Common (&gt;=2%) Adverse Events up to Last Visit by Decreasing Order (of the Total) of Incidence for CAZ-AVI +/- MTZ and Preferred Term, for Patients with Bacteraemia (Safety Analysis Set) (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                         | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   |
|-------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                         | cIAI [b]                     | cIAI [b]                     | cUTI [b]                     | cUTI [b]                     | NP [b]                       | NP [b]                       | Total                        | Total                        |
| Preferred term          | CAZ- AVI+MIZ (N=27)          | Comparator (N=24)            | CAZ- AVI (N=48)              | Comparator (N=42)            | AVI (N=24)                   | CAZ- Meropenen (N=18)        | CAZ- AVI+/- MTZ (N=99)       | Comparator (N=84)            |
| Patients with any AE    | 15 (55.6)                    | 15 (62.5)                    | 35 (72.9)                    | 22 (52.4)                    | 19 (79.2)                    | 14 (77.8)                    | 69 (69.7)                    | 51 (60.7)                    |
| Diarrhoea               | 0 (0.0)                      | 2 (8.3)                      | 3 (6.3)                      | 1 (2.4)                      | 9 (37.5)                     | 1 (5.6)                      | 12 (12.1)                    | 4 (4.8)                      |
| Nausea                  | 0 (0.0)                      | 1 (4.2)                      | 5 (10.4)                     | 2 (4.8)                      | 4 (16.7)                     | 2 (11.1)                     | 9 (9.1)                      | 5 (6.0)                      |
| Constipation            | 1 (3.7)                      | 1 (4.2)                      | 5 (10.4)                     | 3 (7.1)                      | 1 (4.2)                      | 1 (5.6)                      | 7 (7.1)                      | 5 (6.0)                      |
| Vomiting                | 2 (7.4)                      | 1 (4.2)                      | 3 (6.3)                      | 0 (0.0)                      | 2 (8.3)                      | 1 (5.6)                      | 7 (7.1)                      | 2 (2.4)                      |
| Headache                | 0 (0.0)                      | 1 (4.2)                      | 4 (8.3)                      | 4 (9.5)                      | 1 (4.2)                      | 2 (11.1)                     | 5 (5.1)                      | 7 (8.3)                      |
| Hypertension            | 2 (7.4)                      | 0 (0.0)                      | 3 (6.3)                      | 2 (4.8)                      | 0 (0.0)                      | 0 (0.0)                      | 5 (5.1)                      | 2 (2.4)                      |
| Pyrexia                 | 0 (0.0)                      | 4 (16.7)                     | 5 (10.4)                     | 0 (0.0)                      | 0 (0.0)                      | 1 (5.6)                      | 5 (5.1)                      | 5 (6.0)                      |
| Urinary tract infection | 1 (3.7)                      | 2 (8.3)                      | 2 (4.2)                      | 0 (0.0)                      | 2 (8.3)                      | 2 (11.1)                     | 5 (5.1)                      | 4 (4.8)                      |
| Insommia                | 1 (3.7)                      | 0 (0.0)                      | 3 (6.3)                      | 1 (2.4)                      | 0 (0.0)                      | 1 (5.6)                      | 4 (4.0)                      | 2 (2.4)                      |
| Nephrolithiasis         | 0 (0.0)                      | 0 (0.0)                      | 4 (8.3)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 4 (4.0)                      | 0 (0.0)                      |
| Atrial fibrillation     | 2 (7.4)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 2 (11.1)                     | 3 (3.0)                      | 3 (3.6)                      |
| Cough                   | 0 (0.0)                      | 0 (0.0)                      | 3 (6.3)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 3 (3.0)                      | 0 (0.0)                      |
| Hypoalbuminaemia        | 0 (0.0)                      | 0 (0.0)                      | 1 (2.1)                      | 0 (0.0)                      | 2 (8.3)                      | 0 (0.0)                      | 3 (3.0)                      | 0 (0.0)                      |
| Acute kidney injury     | 1 (3.7)                      | 0 (0.0)                      | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.0)                      | 0 (0.0)                      |
| Back pain               | 1 (3.7)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (2.4)                      | 1 (4.2)                      | 0 (0.0)                      | 2 (2.0)                      | 1 (1.2)                      |

<div style=\"page-break-after: always\"></div>

|                         | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   | Number (%) of patients [a]   |
|-------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                         | cIAI [b]                     | cIAI [b]                     | cUTI [b]                     | cUTI [b]                     | NP [b]                       | NP [b]                       | Total                        | Total                        |
| Preferred term          | CAZ- AVI+MIZ (N=27)          | Comparator (N=24)            | CAZ- AVI (N=48)              | Comparator (N=42)            | CAZ-1 AVI (N=24)             | Meropenem (N=18)             | CAZ- AVI+/- MIZ (N=99)       | Comparator (N=84)            |
| Dizziness               | 1 (3.7)                      | 0 (0.0)                      | 1 (2.1)                      | 1 (2.4)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.0)                      | 1 (1.2)                      |
| Flank pain              | 0 (0.0)                      | 0 (0.0)                      | 2 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.0)                      | 0 (0.0)                      |
| Hypokalaemia            | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (2.4)                      | 2 (8.3)                      | 0 (0.0)                      | 2 (2.0)                      | 1 (1.2)                      |
| Nasopharyngitis         | 0 (0.0)                      | 0 (0.0)                      | 2 (4.2)                      | 2 (4.8)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.0)                      | 2 (2.4)                      |
| Pain in extremity       | 0 (0.0)                      | 0 (0.0)                      | 2 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.0)                      | 0 (0.0)                      |
| Pneumonia               | 2 (7.4)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (2.4)                      | 0 (0.0)                      | 3 (16.7)                     | 2 (2.0)                      | 5 (6.0)                      |
| Rash                    | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (2.4)                      | 2 (8.3)                      | 1 (5.6)                      | 2 (2.0)                      | 2 (2.4)                      |
| Wound infection         | 2 (7.4)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.0)                      | 1 (1.2)                      |
| Anaemia                 | 0 (0.0)                      | 2 (8.3)                      | 0 (0.0)                      | 2 (4.8)                      | 1 (4.2)                      | 1 (5.6)                      | 1 (1.0)                      | 5 (6.0)                      |
| Asthenia                | 0 (0.0)                      | 1 (4.2)                      | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (5.6)                      | 1 (1.0)                      | 2 (2.4)                      |
| Cystitis                | 0 (0.0)                      | 0 (0.0)                      | 1 (2.1)                      | 2 (4.8)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 2 (2.4)                      |
| Oedema peripheral       | 1 (3.7)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (2.4)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 2 (2.4)                      |
| Candiduria              | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (2.4)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.4)                      |
| Depression              | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (11.1)                     | 0 (0.0)                      | 2 (2.4)                      |
| Dyspnoea                | 0 (0.0)                      | 2 (8.3)                      | 0 (0.0)                      | 1 (2.4)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 3 (3.6)                      |
| Infusion site phlebitis | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (4.8)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.4)                      |
| Restlessness            | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (5.6)                      | 0 (0.0)                      | 2 (2.4)                      |

[a] Number (%) of patients who reported at least 1 adverse event (AE) for a preferred term, sorted in decreasing order of frequency in patients treated

with CAZ-AVI+/-MTZ. Includes AEs with an onset date and time on or after the date and time of first dose and up to and including the last visit.

[b] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

Percentages are based on the total number of patients in the treatment group (N).

Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

The  CHMP  considered  that  in  total  69  of  the  99  patients  with  bacteriaemia  treated  with  CAZ-AVI experienced any AE. There are a number of observed AEs reported in the Bacteraemia subset which are not included in the approved Zavicefta SmPC: constipation (observed in 7 patients, 7.1%), hypertension, pyrexia and UTI (5 patients each, 5.1%), insomnia, nephrolithiasis (4 pts each, 4.0%), atrial fibrillation, cough, hypoalbuminaemia (3 pts each, 3.0%), back pain, flank pain, hypokalaemia, nasopharyngitis, pain in extremity, pneumonia and wound infection (2 pts each, 2.0%). In addition, anaemia, asthenia, and pheripheral oedema were reported in 1 CAZ-AVI treated patient each (1.0%). Most of these are common AEs/symptoms with a high background incidence and study drug relatedness can be difficult to assess (see below for assessment of relationship to study drug).

<div style=\"page-break-after: always\"></div>

## Incidence of Adverse Events - Maximum Reported Intensity

Up to last visit, in the Bacteraemia subset most patients who had an AE, reported it with a maximum intensity of mild (Table 23).

Table 23. Adverse Events up to Last Visit by Maximum Reported Intensity for Patients with Bacteraemia - (Safety Analysis Set) ((Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                            | Number (%) of Patients [a]   | Number (%) of Patients [a]   | Number (%) of Patients [a]   | Number (%) of Patients [a]   | Number (%) of Patients [a]   | Number (%) of Patients [a]   | Number (%) of Patients [a]   | Number (%) of Patients [a]   |
|----------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                            | cIAI                         | cIAI                         | cUTI                         | cUTI                         | NP                           | NP                           | Total                        | Total                        |
| Maximum Reported Intensity | CAZ-AVI+ MTZ (N=27)          | Comparator (N=24)            | CAZ-AVI (N=48)               | Comparator (N=42)            | CAZ-AVI (N=24)               | Meropenam (N=18)             | CAZ-AVI± MTZ (N=99)          | Comparator (N=84)            |
| Total                      | 15 (55.6)                    | 15 (62.5)                    | 35 (72.9)                    | 22 (52.4)                    | 19 (79.2)                    | 14 (77.8)                    | 69 (69.7)                    | 51 (60.7)                    |
| Mild                       | 8 (29.6)                     | 9 (37.5)                     | 23 (47.9)                    | 17 (40.5)                    | 10 (41.7)                    | 4 (22.2)                     | 41 (41.4)                    | 30 (35.7)                    |
| Moderate                   | 6 (22.2)                     | 2 (8.3)                      | 10 (20.8)                    | 5 (11.9)                     | 6 (25.0)                     | 8 (44.4)                     | 22 (22.2)                    | 15 (17.9)                    |
| Severe                     | 1 (3.7)                      | 4 (16.7)                     | 2 (4.2)                      | 0 (0.0)                      | 3 (12.5)                     | 2 (11.1)                     | 6 (6.1)                      | 6 (7.1)                      |

[a] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

Only terms with at least one record with one intensity will be reported.

Includes AEs with an onset date and time on or after the date and time of first dose and up to and including the last visit.

Percentages are based on the total number of patients in the treatment group (N).

Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

There was no individual severe PT reported by &gt;1 patient in the Bacteraemia subset. Six (6) patients who received  CAZ-AVI  ±  MTZ  experienced  at  least  1  severe  AE.  These  were  Migraine,  Cardiac  Arrest, Cardio-respiratory arrest, Cardiac failure congestive, Left ventricular failure, Peripheral artery occlusion, Acute kidney injury and Procedural haemorrhage.

There were no patterns of severe AEs. The AEs with severe intensity tended to be those expected to occur in patients with severe infections and, therefore, reflect the underlying infection or associated surgery.

The CHMP noted that AEs with severe intensity were observed in 6 patients treated with CAZ-AVI in bacteraemia subset. No specific patterns of severe AEs could be seen. The Committee agreed that the observed AEs with severe intensity may reflect the underlying infection or associated surgery.

## Incidence of Adverse Events - Relationship to Study Drug

The most common (reported by ≥2 patients in either of the treatment groups) treatment -related adverse events up to last visit for the Bacteraemia  subset were Diarrhoea, Headache and Nausea (Table 24) which are known ADRs included in the Zavicefta Investigator's Brochure (IB) Table 7-3 and Zavicefta EU SmPC 2019 Section 4.8. Most AEs in the Bacteraemia subset were assessed as not related to the study drug.

<div style=\"page-break-after: always\"></div>

Table 24. Most Common (Reported by ≥2 patients) Related Adverse Events up to Last Visit by Decreasing Order (of the Total) of Incidence for CAZ-AVI + /-MTZ and Preferred Team, for Patients with Bacteraemia - (Safety Analysis Set) (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                    | Number(%o)ofpatients   | Number(%o)ofpatients   | Number(%o)ofpatients   | Number(%o)ofpatients   | Number(%o)ofpatients   | Number(%o)ofpatients   | Number(%o)ofpatients   | Number(%o)ofpatients   |
|--------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
|                    | cIAI[a]                | cIAI[a]                | cUTI [a]               | cUTI [a]               | NP [a]                 | NP [a]                 | Total                  | Total                  |
| Preferredterm      | CAZ-AVI+MTZ (N=27)     | Comparator (N=24)      | CAZ-AVI (N=48)         | Comparator (N=42)      | CAZ-AVI (N=24)         | Meropenem (N=18)       | CAZ-AVI+/-MTZ (N=99)   | Comparator (N=84)      |
| Patientswith anyAE | 2 (7.4)                | 3 (12.5)               | 8 (16.7)               | 5 (11.9)               | 8 (33.3)               | 1 (5.6)                | 18 (18.2)              | 9 (10.7)               |
| Diarrhoea          | 0 (0.0)                | 1 (4.2)                | 1 (2.1)                | 1 (2.4)                | 4 (16.7)               | 0 (0.0)                | 5 (5.1)                | 2 (2.4)                |
| Headache           | 0 (0.0)                | 0 (0.0)                | 1 (2.1)                | 3 (7.1)                | 0 (0.0)                | 1 (5.6)                | 1 (1.0)                | 4 (4.8)                |
| Nausea             | 0 (0.0)                | 0 (0.0)                | 1 (2.1)                | 1 (2.4)                | 0 (0.0)                | 1 (5.6)                | 1 (1.0)                | 2 (2.4)                |

[a] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

Number (%) of patients who reported at least 1 adverse event related to study drug, sorted in decreasing order of frequency in patients treated with

CAZ-AVI+/-MTZ.

Includes AEs with an onset date and time on or after the date and time of first dose and up to and including the last visit.

Percentages are based on the total number of patients in the treatment group (N).

Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

The CHMP noted that most AEs in the Bacteraemia subset were assessed as not related to the study drug. Of  the  69  patients  with  bacteriaemia  treated  with  CAZ-AVI  that  experienced  any  AE,  there  were  18 patients who experienced treatment-related AEs; 2 in cIAI, 8 in cUTI  and 8 in NP. No trends regarding AEs related to treatment is apparent and no specific trends are expected, having in mind the low number of patients  in  this  subset;  99  CAZ-AVI  treated  patients  with  bacteraemia compared  to  a  total  of  2024 patients in the five studies.

The most common treatment-related adverse events up to last visit for the Bacteraemia subset were Diarrhoea (5 pts), Headache and Nausea (1 patient each).

## Analysis of Adverse Events by Organ System or Syndrome

Safety  topic  of  interest  (STOI)  for  CAZ-AVI  in  the  Bacteraemia  subset  is  presented  here  and  the corresponding summary of STOI for CAZ-AVI in the Overall safety population is presented in 2016 SCS. The  AE  PTs  and  potentially  clinically  significant  (PCS)  laboratory  results  up  to  the  last  visit  that  are relevant to each STOI were assessed for the Bacteraemia subset. The incidence of 5 STOI (liver disorders, diarrhoea, hypersensitivity/anaphylaxis, haematological disorders and renal disorders) were programmatically assessed based on pre-defined AE PTs (MedDRA Version 19).

Hepatotoxicity and risk of neurological sequelae when the dose is not appropriately reduced in patients with  renal  impairment  are  important  potential  risks  in  the  currently  approved  Zavicefta  EU  Risk Management Plan v2.0.

According to the MAH, no new safety findings were identified on review of these events and the majority of  the  AEs  in  the STOI  were  known ADRs.  See  below  for  a  discussion  of  the  frequency  of  the  AE  of diarrhoea.

The CHMP considered that safety topic of interest (STOI) for CAZ-AVI in the Bacteraemia subset was presented in detail in the documentation submitted by the MAH (detailed presentation of the issues and with regard to separate indications and in total for the overall population, is given in 2016 SCS, as stated

<div style=\"page-break-after: always\"></div>

above). However, there are few events in these areas: li ver disorders, diarrhoea, hypersensitivity/anaphylaxis, haematological disorders, and renal disorders.

Renal disorders were identified as an STOI based on the ceftazidime SmPC in which interstitial nephritis and acute renal failure are recognized ADRs (Fortum SmPC 2016). In the current SmPC for Renal and urinary disorders the following ADRs are listed (frequency uncommon): Blood creatinine increased, Blood urea increased and Acute kidney injury. In addition, Tubulointerstitial nephritis is reported as very rare. In the subset in question, relevant AEs Urinary tract infection is reported in 5 pts, nephrolithiasis in 4 pts, flank pain in 2 pts and acute kidney injury in 2 pts and cystitis in 1 patient treated with CAZ-AVI. As none of these AEs are deemed related to treatment (at least not for 2 or more patients, see comment under 'Incidence of Adverse Events - Relationship to Study Drug'), this issue was not discussed any further by the MAH, which was acceptable to the CHMP. The issue of diarrhoea is discussed below.

## Adverse Drug Reactions for the Bacteraemia  Subset

The frequency of each ADR for the Bacteraemia subset was compared to the frequencies of ADRs for CAZ AVI  in  the  Overall  safety  population. Important  caveats  with  regard  to  this  assessment  are  that  the bacteraemia pooled data subset has a small denominator which is too small to accurately estimate the true frequency and so any ADR occurring in 1 patient has a frequency of 1/99 (&gt;1.0% = common).  The patients who comprise the Bacteraemia subset were included in the original frequency determination for Zavicefta EU SmPC Section 4.8.

ADR frequencies in the Bacteraemia subset were generally in line with the ADR frequencies reported in the Overall safety population and the known safety profile of ceftazidime and no change to the Zavicefta EU SmPC is required.

ADRs observed at a higher frequency in the Bacteraemia subset than in the Overall safety population are presented in Table 25 below.

Diarrhoea is common in the Zavicefta EU SmPC but was very common (12.12%) in the Bacteraemia subset (Table 25). A detailed safety analysis of each individual case was conducted. All the patients in the Bacteraemia subset had non-serious, mild or moderate events of Diarrhoea. Of the 12 patients in the Bacteraemia subset treated with CAZ-AVI ± MTZ who had diarrhoea, 9 were from the REPROVE study with an indication of NP. The frequency of this population was 15.4% in the Overall safety population. The patients  with  the  remaining  indications  had  a  frequency  of  diarrhoea  in  line  with  the  Overall  safety population.  There  were  7  patients  with  diarrhoea  considered  to  be  unrelated  to  CAZ-AVI  by  the investigator and these cases did not have a clear temporal relationship to CAZ-AVI treatment, had prior laxative treatment or resolved even though CAZ-AVI was continued. A slight increase in frequency of diarrhoea (&gt;10%) was seen in the Overall safety population in patients &gt;75 years old, however it was assessed that this was not a significant difference and might have been due to the smaller denominator. As mentioned in section 4.6. Safety in special populations, Bacteraemia subset has a slightly higher age than the Overall safety population. For these reasons, no new safety finding was identified.

This difference in frequency of diarrhoea is not clinically significant and may have been related to the small denominator and the increased age of the patients in  the Bacteraemia subset which made the frequency more aligned with that seen in the Overall safety population in patients &gt;75 years old.

Neutropenia, Lymphocytosis, Blood creatinine increased, and Acute kidney injury were expected to be seen in less than 1 in 100 patients (frequency categories of uncommon, rare and frequency unknown as presented in the current Zavicefta EU SmPC), however the denominator of 99 in the Bacteraemia subset automatically makes any reported ADR &gt;1% (i.e. common). There was no evidence of a difference in

<div style=\"page-break-after: always\"></div>

safety profile (e.g. severity) on assessment of these ADRs. This difference in frequency is not clinically significant and is related to the small denominator.

Table 25. ADRs Occurring at a Higher Frequency in the Bacteraemia Subset than in the Overall Safety Population

| ADR                      | ZaviceftaEUSmPC   | FrequencyintheOverallSafety Population N=2024 (%)   | FrequencyintheBacteraemia Subset N=99 (%)   |
|--------------------------|-------------------|-----------------------------------------------------|---------------------------------------------|
| Neutropenia              | Uncommon          | 16/2024 (0.791)                                     | 1/99 (1.010)                                |
| Lymphocytosis            | Uncommon          | 6/2024 (0.296)                                      | 1/99 (1.010)                                |
| Diarrhoea                | Common            | 150/2024 (7.411)                                    | 12/99 (12.121)                              |
| Bloodcreatinineincreased | Uncommon          | 16/2024 (0.791)                                     | 1/99 (1.010)                                |
| Acutekidneyinjury        | Uncommon          | 12/2024 (0.593)                                     | 2/99 (2.020)                                |

Source: Zavicefta EU SmPC.

As mentioned above, the Committee noted that the presentation of the STOI (elsewhere denoted Adverse Events  of  Special  Interest,  AEoSI)  for  CAZ-AVI  was  minimal.  These  STOI  are,  however,  previously predefined to be liver disorders, diarrhoea, hypersensitivity/anaphylaxis, haematological disorders, and renal disorders.

It is important to bear in mind that caveats with regard to this assessment are that the bacteraemia pooled data subset has a small denominator which is too small to accurately estimate the true frequency and so any ADR occurring in 1 patient has a frequency of 1/99 (&gt;1.0% = common). It is therefore not expected to observe much differences or new safety issues in this application.

Some ADRs (Neutropenia, Lymphocytosis, Blood creatinine increased, and Acute kidney injury) were observed in higher frequencies than expected from previously reported uncommon frequency (less than 1  in  100  patients).  However,  in  this  bacteraemia  pooled  population  these  ADRs  were  observed  in frequency common, all represented with only one patient (out of 99), except Acute kidney injury which were experienced by two patients. Diarrhoea was also reported with a higher frequency than previously reported, but within the same frequency category (common). The increase in the reported frequency is explainable by age, indication and small denominator, and is deemed not clinically significant, which is agreed by the Committee.

With regard to the RMP, at the time of adoption of this Assessment Report, a revision of the currently approved RMP v2.0 was under evaluation in the application for paediatric indications (cIAI and cUTI, procedure  number  EMEA/H/C/004027/II/0015)  and  hence,  amendments  are  requested  within  that variation application. Additionally, the RMP was updated as approved in the procedure EMEA/H/C/004027/II/0008 (Opinion April 2018) to remove the important identified risks Anaphylaxis and other severe Hypersensitivity and Clostridium difficile associated diarrhoea (CDAD) from PART II. Module SVII.

## Serious adverse event/deaths/other significant events

## Deaths

All AEs with a fatal outcome in the Bacteraemia subset were considered unrelated by the Investigator and no new safety findings with regards to CAZ-AVI were observed with regard to the patients who died:

- Six (6) deaths (3 CAZ-AVI ± MTZ; 3 comparator) occurred up to the last visit in patients in the Bacteraemia subset.
- Three (3) patients had death due to disease progression which was not recorded as an AE as the individual studies contained a protocolled exemption of capturing these as AEs because they were part of the study objectives.

<div style=\"page-break-after: always\"></div>

- Three (3) patients had an AE with a fatal outcome (Cardiac arrest and Cardio-respiratory arrest in the CAZ-AVI group and Septic shock in the comparator group) all of which were considered by the Investigator to be unrelated to study treatment.
- All  patients  who  died,  who  had an  available  score at  baseline,  had  an  Acute  Physiology  and Chronic Health Evaluation (APACHE) II score &gt;10. One (1) patient with cUTI, who did not have an APACHE II score recorded, was over 80 years old and had cardiomyopathy as a secondary cause of death.

The Committee noted that there were 3 deaths reported in patients treated with CAZ-AVI and 3 deaths reported in patients in the comparator treatment arm who were all received meropenem. In the CAZ-AVI group  one  of  these  were  due  to  disease  progression  (PD),  the  other  two  cardiac  arrest  and cardio-respiratory. All AEs with a fatal outcome were considered unrelated to study treatment by the Investigator.

## Serious adverse events

A  higher  rate  of  SAEs  was  reported  for  the  Bacteraemia  subset  compared  with  the  Overall  safety population in both treatment groups (Table 21). This may be explained by the difference in the baseline condition of the patients in the Bacteraemia subset, who may be expected to have associated symptoms such as tachycardia, fever or sepsis and may be magnified by the smaller denominator. SAEs up to last visit by decreasing order (of the total) of incidence for CAZ-AVI ± MTZ and by PT, for patients with Bacteremia are presented in Table 27.

<div style=\"page-break-after: always\"></div>

Table  26.  Serious  Adverse  Events  up  to  Last  Visit  by  Decreasing  Order  (of  the  Total)  of Incidence  for  CAZ-AVI  +/-  MTZ  and  by  Preferred  Term,  for  Patients  with  Bacteraemia  (Safety Analysis Set) (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                                          | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   |
|------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                          | cIAI [b]                     | cIAI [b]                     | cUTI[]                       | cUTI[]                       | NP[]                         | NP[]                         | Total                        | Total                        |
| Preferred term                           | CAZ-AVI+MTZ (N=27)           | Comparator (N=24)            | CAZ-AVI (N=48)               | Comparator (N=42)            | CAZ-AVI (N=24)               | Meropenem (N=18)             | CAZ-AVI+/- MTZ (N=99)        | Comparator (N=84)            |
| Patients with any SAE                    | 2 (7.4)                      | 6 (25.0)                     | 6 (12.5)                     | 0 (0.0)                      | 4 (16.7)                     | 2 (11.1)                     | 12 (12.1)                    | 8 (9.5)                      |
| Nephrolithiasis                          | 0 (0.0)                      | 0 (0.0)                      | 2 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 2 (2.0)                      | 0 (0.0)                      |
| Empyema                                  | 1 (3.7)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Sepsis                                   | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 1 (5.6)                      | 1 (1.0)                      | 1 (1.2)                      |
| Chronic hepatitis C                      | 0 (0.0)                      | 0 (0.0)                      | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Anaemia                                  | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Hypoalbuminaemia                         | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Cardiac arrest                           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Cardio-respiratory arrest                | 0 (0.0)                      | 0 (0.0)                      | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Cardiac failure congestive               | 1 (3.7)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Left ventricular failure                 | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Peripheral artery occlusion              | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Hyperventilation                         | 0 (0.0)                      | 0 (0.0)                      | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Localisedintraabdominal fluid collection | 1 (3.7)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Spinal pain                              | 0 (0.0)                      | 0 (0.0)                      | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Acute kidney injury                      | 1 (3.7)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Procedural haemorrhage                   | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Gastrointestinalstomacomplication        | 1 (3.7)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Systemic candida                         | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |
| Pneumonia                                | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |
| Septic shock                             | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (5.6)                      | 0 (0.0)                      | 1 (1.2)                      |
| Atrial fibrillation                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |
| Drug eruption                            | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |
| Pyrexia                                  | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |
| Laceration                               | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |
| Abdominalwounddehiscence                 | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |
| Incision site complication               | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.2)                      |

[a]  Number (%)  of  patients  who  reported  at  least  1  Serious  adverse  event (AE),  sorted  in  decreasing  order  of frequency in patients treated with CAZ-AVI+/-MTZ.

[b] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

Includes SAEs with an onset date and time on or after the date and time of first dose and up to and including the last visit.

Percentages are based on the total number of patients in the treatment group (N).

Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

The  Committee  noted  that  there  were  12  patients  with  bacteraemia  treated  with  CAZ-AVI  who experienced a serious adverse event (SAE), it  was  not  stated  how  many  were  considered treatment-related.

A  higher  rate  of  SAEs  was  reported  for  the  Bacteraemia  subset  compared  with  the  Overall  safety population in both treatment groups; CAZ-AVI vs. comparator: 12.1% vs. 9.5% compared to 8.7% vs. 7.2% in the Overall safety population. The MAH stated that this higher frequency can be explained by the underlying mores severe disease at baseline. This explanation is reasonable and was accepted by the Committee. There were no new safety findings on review of SAEs.

<div style=\"page-break-after: always\"></div>

## Laboratory findings

## Clinical laboratory evaluations

No trends were identified on assessment of potentially clinically significant (PCS) laboratory evaluations as defined in the 2016 SCS. PCS post-baseline haematology and clinical chemistry values, anytime up to last visit, for the Bacteraemia subset are presented in tables (not shown here). Overall, the CAZ-AVI laboratory results for the Bacteraemia subset were in line with  the results seen in the Overall safety population.

## Vital signs, physical examination,  electrocardiogram, and left ventricular ejection fraction

Electrocardiogram (ECG), vital sign or Physical Examination data were not pooled for the Phase 2 and Phase 3 studies.

## Safety in special populations

The intrinsic and extrinsic factors for the Overall safety population are presented in the in the 2016 SCS, and assessed within that procedure.

## Effect of Age

A  larger  proportion  of  the  Bacteraemia  subset  treated  with  CAZ-AVI  ±  MTZ  were  over  65  years  old compared with the Overall safety population treated with CAZ-AVI ± MTZ. The AEs up to last visit in any category by age group, for the Bacteraemia subset are presented below in Table 28.

In the Bacteraemia subset treated with CAZ-AVI ± MTZ, there was a higher incidence of AEs in each age cohort compared to the Overall safety population, in line with what was observed in total. The incidence of AEs also rose with age. In each age cohort, very few patients had AEs with a fatal outcome, SAEs and severe AEs however the incidence tended to rise with increasing age cohort. This was also observed for the  comparator  group  and  reflects  what  was  seen  in  the  Overall  safety  population  where  the  older population has a higher rate of AEs compared with patients &lt;65 years old.

With the caveat that the cohorts were very small to make any firm conclusions, no clinically relevant effect of age on the safety profile in the Bacteraemia subset was identified.

Table 27. Adverse Events up to Last Visit in any Category by Age (Years) Group, for Patients with  Bacteraemia  -  (Safety  Analysis  Set)  (Studies  RECLAIM,  RECLAIM3,  RECAPTURE, REPRISE, REPROVE)

|                                             | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   |
|---------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                             | CAZ-AVI+/-MTZ                      | CAZ-AVI+/-MTZ                      | CAZ-AVI+/-MTZ                      | CAZ-AVI+/-MTZ                      | Comparator                         | Comparator                         | Comparator                         | Comparator                         |
| AEcategory                                  | >=18-45 (N=19)                     | 46-64 (N=33)                       | 65-74 (N=21)                       | 75-90 (N=26)                       | >=18-45 (N=13)                     | 46-64 (N=28)                       | 65-74 (N=25)                       | 75-90 (N=18)                       |
| Any AE                                      | 13 (68.4)                          | 20 (60.6)                          | 15 (71.4)                          | 21 (80.8)                          | 8 (61.5)                           | 15 (53.6)                          | 14 (56.0)                          | 14 (77.8)                          |
| AnyAEwith outcome=death [c]                 | 0 (0.0)                            | 0 (0.0)                            | 0 (0.0)                            | 2 (7.7)                            | 1 (7.7)                            | 0 (0.0)                            | 0 (0.0)                            | 0 (0.0)                            |
| Any SAE                                     | 1 (5.3)                            | 3 (9.1)                            | 2 (9.5)                            | 6 (23.1)                           | 4 (30.8)                           | 0 (0.0)                            | 4 (16.0)                           | 0 (0.0)                            |
| Any AE leading to discontinuation of IP [d] | 1 (5.3)                            | 3 (9.1)                            | 1 (4.8)                            | 1 (3.8)                            | 1 (7.7)                            | 0 (0.0)                            | 2 (8.0)                            | 0 (0.0)                            |
| AnyAEofsevereintensity                      | 1 (5.3)                            | 1 (3.0)                            | 1 (4.8)                            | 3 (11.5)                           | 2 (15.4)                           | 0 (0.0)                            | 4 (16.0)                           | 0 (0.0)                            |

[a] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

[b] Patients with multiple adverse events (AEs) in the same category are counted only once in that category. Patients with AEs in more than 1 category are counted once in each of those categories.

<div style=\"page-break-after: always\"></div>

[c] Deaths due to disease progression are not presented here.

[d] Action taken, investigational product (IP) permanently stopped.

Includes AEs and SAEs with an onset date and time on or after the date and time of first dose and up to and including the last visit.

Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

## Effect of Gender

Most patients (62%) treated with CAZ-AVI ± MTZ were female in the Bacteremia subset, compared to the Overall safety population treated with CAZ-AVI ± MTZ. Nonetheless, there was no clinically meaningful difference in the incidence of AEs in the Bacteraemia subset between genders. Although there was a higher incidence of AEs overall in the Bacteraemia subset compared to the Overall safety population this was also observed for the comparator group and there was no clinically meaningful difference between the Bacteraemia subset and the Overall safety population based on gender.

## Effect of Race

AEs  were  assessed  by  race  and  there  were  no  new  safety  findings.  Similar  to  the  Overall  safety population, most patients in the Bacteraemia subset were White or Asian. Numbers of patients in all other race categories were too small for meaningful comparisons (&lt;10 patients per treatment group).

The incidence of AEs in the Bacteraemia subset up to the last visit was similar between White and Asian patients and treatment groups. Although there was a higher incidence of AEs overall in the Bacteraemia subset compared to the Overall safety population this was also observed for the comparator group and there was no clinically meaningful difference between the Bacteraemia subset and the Overall safety population based on race.

## Effect of Body Mass Index

AEs were assessed by baseline BMI and there were no new safety findings. The incidence of AEs in the Bacteraemia subset up to the last visit was similar across BMI category and treatment groups. There was no clinically meaningful difference between the Bacteraemia subset and the Overall safety population based on baseline BMI.

## Effect of Renal Function

As  mentioned  before,  the  patients  treated  with  CAZ-AVI  ±  MTZ  had  worse  renal  function  in  the Bacteremia subset, compared to the Overall safety population treated with CAZ-AVI ± MTZ (mild renal impairment according to mean and median CrCl in the Bacteremia subset and normal renal function in Overall safety population).  Most CAZ-AVI ± MTZ-treated and comparator patients in the Bacteraemia subset had normal renal function or mild renal impairment (CrCl ≥51 mL/min) (82.8% and 76.2%, respectively). Numbers of patients in the severe renal impairment subgroup were too small (&lt;5 patients) for  meaningful  comparison.  The  number  of  patients  within  each  CrCl  stratum  was  balanced  across treatment groups.

The AEs up to last visit in any category by baseline renal status for the Bacteraemia subset are presented below in Table 29. In the Bacteraemia subset of patients with moderate or severe renal impairment there were  no  new safety  findings.  The  incidence of  AEs  in  these  patients  was similar  between  treatment groups. Although there was a higher incidence of AEs overall in the Bacteraemia subset compared to the Overall safety population, this was also observed for the comparator group and there was no clinically meaningful  difference  between  the  Bacteraemia  subset  and  the  Overall  safety  population  based  on baseline renal status.

<div style=\"page-break-after: always\"></div>

Table  28.  Adverse  Events  up  to  Last  Visit  in  any  Category  by  Baseline  Renal  Status  CrCl (mL/min),  for  Patients  with  Bacteraemia -  (Safety  Analysis  Set)  (Studies  RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                                      | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   | Total [a] Number(%)ofpatients[b]   |
|--------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                      | CAZ-AVI+/-MITZ                     | CAZ-AVI+/-MITZ                     | CAZ-AVI+/-MITZ                     | CAZ-AVI+/-MITZ                     | Comparator                         | Comparator                         | Comparator                         | Comparator                         |
| AEcategory                           | <=30 (N=3)                         | 31-50 (N=14)                       | 51-80 (N=42)                       | >=81 (N=40)                        | <=30 (N=2)                         | 31-50 (N=18)                       | 51-80 (N=41)                       | >=81 (N=23)                        |
| Any AE                               | 2 (66.7)                           | 13 (92.9)                          | 28 (66.7)                          | 26 (65.0)                          | 1 (50.0)                           | 13 (72.2)                          | 22 (53.7)                          | 15 (65.2)                          |
| AnyAEwith outcome=death[c]           | 0 (0.0)                            | 1 (7.1)                            | 1 (2.4)                            | 0 (0.0)                            | 0 (0.0)                            | 0 (0.0)                            | 0 (0.0)                            | 1 (4.3)                            |
| Any SAE                              | 0 (0.0)                            | 3 (21.4)                           | 6 (14.3)                           | 3 (7.5)                            | 0 (0.0)                            | 2 (11.1)                           | 2 (4.9)                            | 4 (17.4)                           |
| AnyAEleadingtodiscontinuationofIP[d] | 0 (0.0)                            | 2 (14.3)                           | 1 (2.4)                            | 3 (7.5)                            | 0 (0.0)                            | 1 (5.6)                            | 1 (2.4)                            | 1 (4.3)                            |
| AnyAEofsevereintensity               | 0 (0.0)                            | 2 (14.3)                           | 2 (4.8)                            | 2 (5.0)                            | 0 (0.0)                            | 2 (11.1)                           | 1 (2.4)                            | 3 (13.0)                           |

[a] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

[b] Patients with multiple adverse events (AEs) in the same category are counted only once in that category.

Patients with AEs in more than 1 category are counted once in each of those categories.

[c] Deaths due to disease progression are not presented here.

[d] Action taken, investigational product (IP) permanently stopped.

Includes AEs and SAEs with an onset date and time on or after the date and time of first dose and up to and including the last visit.

Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

Percentages are based on the total number of patients in the subgroup and treatment group (N).

## Adverse Events by Geographic Region

The number of patients in the Bacteraemia subset that were enrolled by region across treatment groups were balanced and most of the patients in the CAZ-AVI ± MTZ and comparator groups were from Eastern Europe (36.4% and 36.9%, respectively) and Rest of World (44.4% and 42.9%, respectively).

The incidence of AEs in each AE category for CAZ-AVI ± MTZ patients was similar to comparator for each geographic region. There was no clinically meaningful difference between the Bacteraemia subset and the Overall safety population based on region.

The Committee noted that a larger proportion of the Bacteraemia subset treated with CAZ-AVI ± MTZ were over 65 years old compared with the Overall safety population treated with CAZ-AVI ± MTZ. In the Bacteraemia subset treated with CAZ-AVI ± MTZ, there was a higher incidence of AEs in each age cohort compared to the Overall safety population. The incidence of AEs also rose with age. In each age cohort, very few patients had AEs with a fatal outcome, SAEs and severe AEs, however, the incidence tended to rise with increasing age cohort. This was also observed for the comparator group and reflects what was seen in the Overall safety population where the older population has a higher rate of AEs compared with patients &lt;65 years old.

With the caveat that the cohorts were very small to make any firm conclusions, no clinically relevant effect  of  age  on  the  safety  profile  in  the  Bacteraemia  subset  was  identified.  In  addition,  there  was apparently no clinically meaningful difference between the Bacteraemia subset and the Overall safety population based on gender, race, baseline BMI, baseline renal status or region which were the other special populations analysed.

## Safety related to drug-drug interactions and other interactions

Not applicable.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

This section describes discontinuations due to AEs in  the Bacteraemia subset. According to the MAH, CAZ-AVI was well tolerated in this subset of patients and most events leading to discontinuation were non-serious:

- Six (6) patients in the CAZ-AVI ± MTZ group of the Bacteraemia subset had at least 1 AE leading to discontinuation of study treatment.
- No individual PT was reported in more than 1 patient in the Bacteraemia subset. Two (2) patients in  the  CAZ-AVI  ±  MTZ  group  discontinued  due  to  known  ADRs  (Vomiting,  Drug  eruption) (Zavicefta EU SmPC).
- Three (3) AEs in 3 patients that led to discontinuation were SAEs (1 patient in the CAZ-AVI group [Cardio-respiratory arrest] and 2 in the comparator group [Drug eruption, Septic shock])

Adverse events leading to discontinuation of Investigational Product (IP) up to EOT by system organ class (SOC) and PT, for the Bacteraemia subset are presented in Table 30 below.

Table 29. Adverse Events Leading to Discontinuation of IP up to EOT by System Organ Class and Preferred Term, for Patients with Bacteraemia - (Safety Analysis Set) (Studies RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE)

|                                                     |                    |                   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   | Nunber (%) of patients [a]   |
|-----------------------------------------------------|--------------------|-------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                     | cIAI[]             | cIAI[]            | cUTI []                      | cUTI []                      | NP []                        | NP []                        | Total                        | Total                        |
| System organclass/ Preferred term                   | CAZ-AVI+MTZ (N=27) | Comparator (N=24) | CAZ-AVI (N=48)               | Comparator (N=42)            | CAZ-AVI (N=24)               | Meropenem (N=18)             | CAZ-AVI+/- MTZ (N=99)        | Comparator (N=84)            |
| Patients with any AE leading to discontinuationofIP | 2(7.4)             | 1 (4.2)           | 3 (6.3)                      | 0 (0.0)                      | 1 (4.2)                      | 2 (11.1)                     | 6 (6.1)                      | 3 (3.6)                      |
| Infections and infestations                         | 0 (0.0)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1(5.6)                       | 0 (0.0)                      | 1 (1.2)                      |
| Septic shock                                        | 0 (0.0)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1(5.6)                       | 0 (0.0)                      | 1 (1.2)                      |
| Metabolismandnutritiondisorders                     | 0 (0.0)            | 0 (0.0)           | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Hypoproteinaemia                                    | 0 (0.0)            | 0 (0.0)           | 1(2.1)                       | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Cardiac disorders                                   | 0 (0.0)            | 0 (0.0)           | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Cardio-respiratory arrest                           | 0 (0.0)            | 0 (0.0)           | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Respiratory, thoracic and mediastinal disorders     | 0 (0.0)            | 0 (0.0)           | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Pleural effusion                                    | 0 (0.0)            | 0 (0.0)           | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Gastrointestinaldisorders                           | 0 (0.0)            | 0 (0.0)           | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Vomiting                                            | 0 (0.0)            | 0 (0.0)           | 1 (2.1)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Hepatobiliary disorders                             | 0 (0.0)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Cholestasis                                         | 0 (0.0)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 1 (4.2)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Skin and subcutaneous tissue disorders              | 1 (3.7)            | 1 (4.2)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 1 (1.2)                      |
| Drug eruption                                       | 1 (3.7)            | 1 (4.2)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 1(1.2)                       |
| Renal and urinary disorders                         | 0 (0.0)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1(5.6)                       | 0 (0.0)                      | 1(1.2)                       |
| Renal failure                                       | 0 (0.0)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1(5.6)                       | 0 (0.0)                      | 1 (1.2)                      |
| Generaldisordersand administrationsite conditions   | 1 (3.7)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |
| Impaired healing                                    | 1 (3.7)            | 0 (0.0)           | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 0 (0.0)                      | 1 (1.0)                      | 0 (0.0)                      |

[a] Number (%) of patients who reported at least 1 adverse event leading to discontinuation of IP, sorted by system organ class in international order and by preferred term in MedDRA hierarchy.

[b] Refer to listing 4.1.1 for indication specific information including abbreviations, study numbers, and comparator details.

Includes adverse events with an onset date on or after the date of first dose.

Percentages are based on the total number of patients in the treatment group (N).

Medical Dictionary for Regulatory Activities (MedDRA) version 19.0.

IP Investigational product.

<div style=\"page-break-after: always\"></div>

The Committee noted that, overall, 2.6% and 1.7% of patients in the CAZAVI +/- MTZ and comparator treatment groups, respectively, discontinued study drug due to AEs in the Overall safety population (2016 SCS).  In  the  Bacteraemia  subset  these  numbers  were  higher;  6.1%  vs.  3.6%.  The  6  patients  with bacteraemia who discontinued CAZ-AVI due to AEs were all reported as different PTs. Hence, there were no clustering in events leading to discontinuation.

## Post marketing experience

As of 26 April 2019, 46 events in 30 post marketing cases were identified that reported an indication which included at least one PT from the following MedDRA v21.1 Higher Level Terms (HLTs): HLT Sepsis, bacteraemia,  viraemia  and  fungaemia  NEC,  HLT  Endocarditis,  HLT  Vascular  Infections.  These  were considered to reflect either bacteraemia, sepsis or an intravascular bacterial infection.

The  31  indications  in  30  cases  identified  to  be  associated  with  bacteraemia  were:  Sepsis  (12), Bacteraemia (11), Septic shock (3). Abdominal sepsis (2), Endocarditis, Escherichia bacteraemia and Neutropenic sepsis (1 each).

Most cases did not contain sufficient information to fully assess the underlying source of infection:

- Five  (5)  cases  were  assessed  to  be  cIAI:  Abdominal  sepsis  (2),  Abdominal  infection  (2), Peritonitis bacterial (1).
- Five  (5)  cases  were  assessed  to  be  infections  in  patients  with  Gram-negative  infections  with limited  treatment  options:  Bacteraemia  in  a  patient  with  refractory  B-cell  lymphoma,  CNS ventriculitis, Endocarditis, Neutropenic sepsis, Osteomyelitis (1 each).
- Nineteen (19) cases did not provide a source or site of infection:  Bacteraemia (8), Sepsis (8), Septic shock (3), Bacterial infection, Enterobacter infection, Pseudomonas infection (1 each).
- One case reported pneumonia but did not confirm if the patient had HAP. With regards to the events reported in the post-marketing cases:
- On assessment, 9 cases do not describe adverse events, but describe the following: Off label use in  bacteraemia  [PTs  Off  label  use,  Product  use  in  unapproved  indication],  Off  label  use  in Paediatrics [PTs Off label use, Product use issue (5 events)] and prolonged duration of therapy [PT Product use issue (2 events)].
- Seven (7) cases describe progression of the underlying disease or lack of efficacy: PTs Drug ineffective (3), Death (2), Infection and Condition aggravated (1 each).
- Six (6) cases only describe known ADRs without evidence of an increase in severity or frequency: PTs Acute  kidney injury (3), Seizure, Toxic encephalopathy, Epilepsy, Encephalopathy, Hypersensitivity (1 each).  One (1) of these 6 cases also reports an overdose in a patient with renal impairment (PT Product use issue).
- Three  (3)  cases  did  not  contain  sufficient  information  to  perform  a  causal  assessment:  PTs Anaemia, Prothrombin time shortened, Anti factor V antibody positive, Drug interaction (1 each). One (1) of these three cases also reported off label use in paediatrics (Product use issue).
- The remaining 5 cases describe events which were assessed to be due to the patient's underlying medical condition or concomitant treatment: Shock haemorrhagic (2), Metabolic acidosis (2). B-cell  lymphoma  refractory,  Hypernatraemia,  Anuria,  Jaundice,  Hepatitis  cholestatic,  Renal injury, Thrombocytopenia, Bacterial disease carrier, Hypertension (1 each), Of these 5 cases, 3 also include known ADRs without evidence of an increase in severity or frequency (Platelet count

<div style=\"page-break-after: always\"></div>

decreased, Acute kidney injury [2]) and 1 case describes off label use in paediatrics (Product use issue).

No new safety issues have been identified in the population of patients with bacteraemia at baseline or indications indicative of bloodstream infections from post marketing surveillance.

An RMP has not been provided within this application as with regards to this Type II variation there are no changes with respect to the list of safety concerns, no change to the current routine pharmacovigilance activities and routine risk minimisation activities, and no change to the risk-benefit balance of Zavicefta.

The CHMP noted that a search as of 26 April 2019 of AEs in post-marketing cases reporting an indication which  was  considered  to  reflect  either  bacteraemia,  sepsis  or  an  intravascular  bacterial  infection, identified  46  events  in  30  post  marketing  cases.  According  to  the  MAH,  no  new  safety  issues  with Zavicefta treatment were identified from post-marketing surveillance in the population of patients with bacteraemia / bloodstream infections at baseline.

The patients with bacteraemia from the clinical development programme are already included in the current EU-RMP in SIII Clinical trial exposure as this is a subset analysis  of the overall safety data set. The MAH did not  find  any  reason  for  updating  the  RMP  for  this  Type II variation,  which  was  considered acceptable by the CHMP.

The  RMP  will  anyhow  be  updated  as  part  of  procedure  EMEA/H/C/004027/II/0015    (application  for extension of indication to include paediatric patients aged 3 months to less than 18 years for Zavicefta for the treatment of cIAI and cUTI), which was ongoing at the time of adoption of this assessment report.

## 2.5.1. Discussion on clinical safety

With  this  Type  II  variation  procedure,  the  MAH  is  applying  for  an  extension  of  the  indication  for ceftazidime-avibactam (CAZ-AVI), to add the treatment of patients with bacteraemia in association with, or suspected to be  associated with the currently approved  adult indications for complicated intra-abdominal  infection  (cIAI),  complicated  urinary  tract  infection  (cUTI)  and  hospital-acquired pneumonia, including ventilator-associated pneumonia (HAP/VAP).

The clinical development programme for ceftazidime/avibactam included patients with bacteraemia in all 5 of the completed Phase 3 clinical trials that were conducted to support the approved indications of cIAI, cUTI  and  HAP/VAP.  Data  was  derived  from  the  following  clinical  studies:  RECLAIM  (global,  cIAI), RECLAIM3 (Asia, cIAI), RECAPTURE (global, cUTI), REPRISE (global, ceftazidime-resistant pathogens in cIAI &amp; cUTI) and REPROVE (global, HAP/VAP). A post-hoc analysis of efficacy and safety data from the sub-group  of  patients  who  had  bacteraemia  at  baseline  across  these  5 studies  was  performed.  The Bacteraemia safety subset was then assessed against the known safety profile of CAZ-AVI presented and submitted in January 2017 as part of variation EMEA/H/C/004027/II/0002). The known safety profile is based on the overall Phase 2/3 pooled safety analysis population (comprising these five studies plus 2 phase 2 studies), and is referred to as the 'Overall safety population'. These comprise 4050 patients, of which 2024 treated with CAZ-AVI.

The Bacteraemia safety subset comprised 183 patients, of whom 99 received CAZ-AVI ± MTZ and 84 received  comparator  treatment.  The  differences  between  patients  included  in  Bacteremia subset  and Overall safety population when evaluating demographic characteristics may be due to small number of patients included in CAZ-AVI ± MTZ group in Bacteremia subset (n=99). The duration of exposure to CAZ-AVI ± MTZ in the Bacteraemia subset varied from mean of 7.0 days in the cUTI indication, 7.6 days in  cIAI  to  9.3  days  in  pneumonia  (NP/HAP)  indications.  There  was,  however,  a  similar  duration  of exposure to CAZ-AVI ± MTZ with a mean of 7.7 days in the Bacteraemia subset compared to 8.2 days in the Overall safety population.

<div style=\"page-break-after: always\"></div>

There was a higher proportion of patients with moderate to severe renal insufficiency in the Bacteraemia subset treated with CAZ-AVI ± MTZ compared with the Overall safety population.

## Adverse events:

There were many AEs reported in the bacteraemia safety subset treated with CAZ AVI ± MTZ, both known from the safety profile of Zavicefta, and AEs not known with its use. Most AEs in the Bacteraemia subset were assessed as not related to the study drug. In total 69 of the 99 patients with bacteriaemia treated with  CAZ-AVI  experienced  any  AE,  and  of  these  69,  there  were  18  patients  (18%)  who experienced treatment-related AEs. The most common AEs in this population were diarrhoea and nausea (12 and 9 patients, respectively), which are known ADRs of CAZ-AVI. The most common treatment-related adverse events up to last visit for the Bacteraemia subset were diarrhoea (5 pts), headache and nausea (1 patient each). There were 12 patients with bacteraemia treated with CAZ-AVI who experienced a serious adverse event (SAE), it is not stated how many were considered treatment-related. A higher rate of AEs (69.7% vs. 49.2%) and serious adverse events (SAEs; 12.1% vs.8.7%) was reported in the CAZ-AVI treatment arm in the total Bacteraemia subset compared with the Overall safety population. A similar difference was seen in the comparator arm. These higher frequencies seem in general to be driven by the cUTI and the NP population. The MAH claimed that these increases in frequencies can be explained by the difference in the underlying condition of the patients in  the Bacteraemia subset, who were older and had a higher APACHE score at baseline, who may be expected to have symptoms associated with bacteraemia such as tachycardia, fever or sepsis and may  also be magnified by the smaller denominators. This was considered reasonable and accepted by the Committee.

## Deaths and serious adverse events:

## Deaths:

Six  (6)  deaths  (3  CAZ-AVI  ±  MTZ;  3  comparator)  occurred  up  to  the  last  visit  in  patients  in  the Bacteraemia subset. None of the AEs with a fatal outcome was considered related to study treatment by the Investigator.

## Serious adverse events:

The SAEs reported in the Bacteraemia safety subset were in-line with what would be expected for the underlying indications and there were no new safety findings on review of SAEs.

## Discontinuation due to AEs:

Overall, 6.1% (6 patients) and 3.6% (4 patients) of patients in the CAZAVI +/- MTZ and comparator treatment groups, respectively, discontinued study drug due to AEs in bacteraemia subset. No individual PT was reported in more than 1 patient in the Bacteraemia subset.

Considering all the above, the assessment of the safety from the subset of patients with bacteraemia in the pooled adult safety data did not identify new safety issues in patients with bacteraemia.

## Additional expert consultations

Not applicable.

## Assessment of paediatric data on clinical safety

Not applicable. Review of a type II c.I.6a variation application (EMEA/H/C/004027/II/0015), aiming to include  a  new  indication  for  the  use  of  ceftazidime/avibactam  in  the  treatment  of  cIAI  and  cUTI  in

<div style=\"page-break-after: always\"></div>

paediatric patients aged ≥3 months to &lt;18 years, was ongoing at the time of adoption of this assessment report.

## 2.5.2. Conclusions on clinical safety

The safety of CAZ-AVI ± MTZ was evaluated in a subset of patients with bacteraemia at baseline from the Phase  3  pooled  safety  population  from  five  Phase  3  adult  studies  in  cIAI,  cUTI  and  HAP:  RECLAIM, RECLAIM 3, RECAPTURE, REPROVE and REPRISE. The Bacteraemia safety subset comprised 183 patients, of whom 99 received CAZ-AVI ± MTZ and 84 received comparator treatment, was assessed against the known safety profile of CAZ-AVI.

There were many AEs reported in the bacteraemia safety subset treated with CAZ AVI ± MTZ. The most common AEs in this population were diarrhoea and nausea. Most AEs in the Bacteraemia subset were assessed as not related to the study drug. Six patients of  99 patients  with bacteraemia discontinued CAZ-AVI treatment due to AEs. None of the AEs with a fatal outcome were considered related to study treatment by the Investigator. The SAEs reported in the Bacteraemia safety subset were in line with what would be expected for the underlying indications and there were no new safety findings on review of SAEs.

The higher rates of AEs in the bacteremia patients treated with CAZ-AVI may be due to small number of patients  included  in  the  Bacteraemia subset  compared  to  Overall  safety  population,  and  also  due  to underlying medical conditions, patients in the Bacteremia subset being older and had more severe renal impairment, compared to the Overall safety population in patients taking CAZ-AVI ± MTZ.

The safety profile of the Bacteraemia safety subset is in line with the expected safety profile for CAZ-AVI in adults and the established safety profile of ceftazidime alone, or the pattern of AEs expected for the patient population. No new safety issues were identified for CAZ AVI, however,  acknowledging the limited database of patients with bacteraemia.

Approval to include treatment of patients with bacteraemia in association with the currently approved adult indications for cIAI, cUTI and HAP is recommended from a safety point of view.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Update of the Product information

As a consequence of this new indication, sections 4.1 and 4.2 of the SmPC are being updated to reflect the recommendation of approval for including treatment of bacteraemia.

- Section 4.1 (Therapeutic indications):

Zavicefta is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1):

- Complicated intra-abdominal infection (cIAI)
- Complicated urinary tract infection (cUTI), including pyelonephritis
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)

Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.

<div style=\"page-break-after: always\"></div>

Zavicefta is  also indicated for the treatment of infections due to aerobic  Gram-negative organisms in adult patients with limited treatment options (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

The Package Leaflet (PL) is updated accordingly.

Please refer to Attachment 1, which includes all agreed changes to the Product Information.

## 2.6.1. User consultation

No justification for not performing a full user consultation with  target patient groups on  the package leaflet has been submitted by the MAH. However, the changes to the package leaflet are minimal and do not require user consultation with target patient groups.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The proposed extension of indication for Zavicefta is to include treatment of bacteraemia (in association with, or suspected to be associated with, the currently approved indications for cIAI, cUTI and HAP/VAP in adults.

Bacteraemia  due  to Gram-negative  pathogens  is  associated  with  significant  morbidity  and  mortality. Nearly 2 million episodes of bloodstream infection in North America and Europe annually led to ~250,000 deaths and nearly half of community-acquired and one third of healthcare associated cases were caused by Gram-negative bacteria. The aim of the therapy is to cure the infection.

## 3.1.2. Available therapies and unmet medical need

Infections associated with bacteraemia may be severe, require hospitalisation and have the potential to be life-threatening. Bacteraemia due to resistant pathogens is increasing in frequency and associated with  more  adverse  effects.  Prompt  administration  of  effective  antibiotics  is  therefore  critical  for  a favorable outcome. There are no specific treatment guidelines for treatment of bacteraemia as such. The choice of the treatment is dependent of the clinical condition (e.g. site of infection, resistance, pathogens etc.).  Relevant  treatment  options  for  bacteraemia  caused  by  multi-drug  resistant  Gram-negative pathogens (e.g. ESBL producing organisms) are carbapenems. Other options that still may be used in the setting of multi-drug resistant Gram-negative bacteraemia (including carbapenem-resistant pathogens), alone or in combination with other agents, include colistin, tigecycline and fosfomycin.

Infections due to multi-drug resistant Gram-negative bacteria are increasingly common. Few antibiotics with activity against ESBL and carbapenemase producing Gram-negative bacteria are currently available. However, alternative treatment options which are efficacious against multi-drug resistant Gram-negative bacteria would be useful.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The MAH did not conduct any specific studies to support the proposed indication extension. The main evidence  of  efficacy  and  safety  is  based  on  post-hoc  analysis  of  efficacy  and  safety  data  from  the sub-group of patients who had bacteraemia at baseline across the previously assessed 5 Phase 3 studies. These studies ( RECLAIM, RECLAIM3, RECAPTURE, REPRISE, REPROVE ) were conducted to support the  currently  approved  indications  of  cIAI,  cUTI  and  HAP/VAP  in  adults.  Meropenem  was  the  main comparator in the studies concerning cIAI  and HAP/VAP, while doripenem was the main comparator in the cUTI studies.

## 3.2. Favourable effects

For all indications combined, the clinical cure rate at TOC in the Bacteraemia efficacy subset was 87% (47/54) for patients in the CAZ-AVI ± MTZ treatment group vs. 83% (39/47) in the comparator treatment group. Although some differences between Clinical response at EOT and TOC were seen, the presented results  were  largely  comparable;  the  clinical  cure  at  EOT  in  the  Bacteraemia  set  was  92.6%  in  the CAZ-AVI ± MTZ treatment group compared to 93.6% in the comparator group. The corresponding results in the Overall set were generally comparable with the results seen in the Bacteraemia set.

## 3.3. Uncertainties and limitations about favourable effects

For all indications combined, the clinical cure rate at TOC in the Bacteraemia efficacy subset was 87% (47/54) for patients in the CAZ-AVI ± MTZ treatment group vs. 83% (39/47) in the comparator treatment group. Although some differences between Clinical response at EOT and TOC were seen, the presented results  were  largely  comparable;  the  clinical  cure  at  EOT  in  the  Bacteraemia  set  was  92.6%  in  the CAZ-AVI ± MTZ treatment group compared to 93.6% in the comparator group. The corresponding results in the Overall set were generally comparable with the results seen in the Bacteraemia set.

## 3.4. Unfavourable effects

The bacteraemia safety subset comprised 183 patients, of whom 99 received CAZ-AVI ± MTZ and 84 received comparator treatment. In total, 99 CAZ-AVI treated patients with bacteraemia compared to a total of 2024 pts in total in the five studies. The Overall population receiving CAZ-AVI or comparator was 4050 patients.

In total 69 of the 99 patients with bacteriaemia treated with CAZ-AVI experienced any AE, and of these 69, there were 18 patients (18%) who experienced treatment-related AEs. The most common AEs in this population  were  diarrhoea and  nausea  (12  and  9  patients,  respectively),  which  are  known  ADRs  of CAZ-AVI. The most common treatment-related adverse events up to last visit for the bacteraemia subset were diarrhoea (5 pts), headache and nausea (1 patient each). There were 12 patients with bacteraemia treated with CAZ-AVI who experienced a serious adverse event (SAE), it is not stated how many were considered treatment-related.

A  higher  rate  of AEs  (69.7%  vs.  49.2%)  and  serious  adverse events  (SAEs;  12.1%  vs.  8.7%)  was reported in the CAZ-AVI treatment arm in the total bacteraemia subset compared with the overall safety population.

Six  (6)  deaths  (3  CAZ-AVI  ±  MTZ;  3  comparator)  occurred  up  to  the  last  visit  in  patients  in  the bacteraemia subset.

<div style=\"page-break-after: always\"></div>

Six patients of 99 (6.1%) patients with bacteraemia discontinued CAZ-AVI treatment due to AEs, all different PTs.

## 3.5. Uncertainties and limitations about unfavourable effects

The bacteraemia safety subset comprised 183 patients, of whom 99 received CAZ-AVI ± MTZ, and hence, the population of patients with bacteriaemia was rather limited. Very few patients had cIAI and NP, the majority of the patients come from the cUTI studies.

There was a higher proportion of patients with moderate to severe renal insufficiency in the Bacteraemia subset treated with CAZ-AVI ± MTZ compared with the Overall safety population.

The observed increases in AEs and SAEs compared to the Overall population represent an uncertainty.

## 3.6. Benefit-risk assessment and discussion

## 3.6.1. Importance of favourable and unfavourable effects

For ceftazidime, the antibacterial component of this FDC, bacteraemia in association with, or suspected to be associated with, the currently approved indications for cIAI, cUTI and HAP/VAP is already approved through an Article 30 procedure in 2011 (EMEA/H/A-30/001006).

Despite the limitations of data due to the small numbers included in the Bacteraemia subsets, the fact that the randomisation was not stratified by bacteraemia status at baseline in any of the main studies, and that the efficacy analyses were only descriptive; for all indications combined, the clinical cure rate at TOC in the Bacteraemia set was broadly in line with the corresponding results in the Overall set, and the microbiological outcomes were generally in support of the main clinical responses.

Furthermore, the efficacy in the HAP/VAP CAZ-AVI bacteremia subset was comparable to the comparator (i.e., the cure rates at TOC were 66.7% vs. 62.5% in the CAZ-AVI and meropenem groups, respectively). However, the number of patients with bacteraemia included in these HAP/VAP subsets is very limited and hence cure rates should be interpreted with caution. Importantly, a similar shift in the cure rates in HAP/VAP patients from EOT to TOC visit was seen in both the test and comparator groups. Considering the high mortality and serious complications associated with HAP/VAP, this shift could be expected.

For ceftazidime, the antibacterial component of this FDC, bacteraemia in association with, or suspected to be associated with, the currently approved indications for cIAI, cUTI and HAP/VAP is already approved through an Article 30 procedure in 2011 (EMEA/H/A-30/001006). In addition, it has previously been demonstrated  that  there  was  no  concerns  about  tissue  penetration  of  the  beta-lactamase  inhibitor avibactam  to  the  relevant  infection  sites  such  as  ELF.  The  pharmacokinetics  and  the  joint  target attainment for ceftazidime and avibactam appear similar in patients with and without bacteraemia. This supports  that  the  approved  doses  for  certain  site  specific  infections  (including  HAP/VAP)  are  also appropriate for patients with concurrent bacteraemia. Moreover, the formal grounds in terms of being an antibacterial agent used for many years and indicated for use in a broad range of infections as reflected in the Addendum  to the guideline on the evaluation of medicinal products indicated for  treatment of bacterial infections (EMA/CHMP/351889/2013),  are fulfilled.

<div style=\"page-break-after: always\"></div>

The observed increases in AEs and SAEs can be explained by the difference in the underlying condition of the patients in the Bacteraemia subset, who were older and had a higher APACHE score at baseline. None of the AEs with a fatal outcome was considered related to study treatment by the Investigator.

The higher proportion of patients with moderate to severe renal insufficiency in the Bacteraemia subset treated with CAZ-AVI ± MTZ compared with the Overall safety population might have an impact on the safety profile. However, due to assumed dose reductions according to the recommendations in the SmPC, this unbalance is not considered to induce an additional risk.

The safety profile of the Bacteraemia safety subset is in line with the expected safety profile for CAZ-AVI in adults and the established safety profile of ceftazidime alone, or the pattern of AEs expected for the patient  population.  In  total,  acknowledging  the  limited  database  of  patients  with  bacteraemia,  the assessment of safety from the subset of patients with bacteraemia in the pooled adult safety population did not identify new safety issues in patients with bacteraemia.

## 3.6.2. Balance of benefits and risks

The overall B/R of Zavicefta for the treatment of patients with bacteraemia in association with the already approved adult indications for cIAI and cUTI is positive. Taking into account the additional data, provided by the MAH, the risk-benefit balance for the bacteraemia indication covering HAP/VAP is also positive. However, the data specific for the FDC Zavicefta are mainly considered to be supplementary.  It has to be emphasised that the fact that for ceftazidime, the antibacterial component of this FDC, bacteraemia in association with, or suspected to be associated with, the currently approved indications for cIAI, cUTI and HAP/VAP is already approved through an Article 30 procedure in 2011 (EMEA/H/A-30/001006) was of critical importance for reaching a positive conclusion.

## 3.6.3. Additional considerations on the benefit-risk balance

None.

## 3.7. Conclusions

The overall B/R of Zavicefta on the extension of the indications to include bacteraemia in association with the already approved adult indications for cIAI, cUTI and HAP/VAP is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

<div style=\"page-break-after: always\"></div>

Extension of Indication to include bacteraemia (in association with, or suspected to be associated with, the currently approved indications for complicated intra-abdominal infection (cIAI), complicated urinary tract  infection  (cUTI)  and  hospital-acquired  pneumonia,  including  ventilator-associated  pneumonia (HAP/VAP)) for Zavicefta; as a consequence, sections 4.1 and 4.2 of the SmPC are updated in order to add this indication and the posology. Furthermore, the PI is brought in line with the latest QRD template version 10.1.

The Package Leaflet is updated in accordance.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I and IIIB are recommended.